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9SYNOPSIS OF THE THESIS
Due to concern about possible negative effects of systemic chemotherapy on cognitive 
function (i.e. memory and concentration), these functions in cancer patients after such 
treatment have received increasing clinical and public attention. However, in 2005, at the 
onset of the research project leading to this thesis, no neuropsychological studies had been 
published on cognitive function in testicular cancer patients (TCPs) after systemic 
chemotherapy. TCPs in general are young and have a favorable prognosis. Hence, most 
patients have a long life expectancy after their malignancy, and they are expected to resume 
a regular professional and familial life after treatment. Cisplatin, the cornerstone of 
chemotherapy for testicular cancer, has well-known toxic effects on the peripheral nervous 
system. Therefore we considered systematic assessment of cognitive function in TCPs 
treated with chemotherapy to be of considerable importance, both for the patients and for 
future clinical work.
The main aim of this thesis was to explore cognitive function in TCPs. In the period 
from 2006 to 2009 we therefore conducted a prospective study of cognitive function in 
TCPs evaluated and treated at the Norwegian Radium Hospital and the Ullevaal University 
Hospital (now both parts of the Oslo University Hospital). This thesis also includes a 
prospective study on self-reported cognitive complaints in TCPs included in three European 
Organization of Research and Treatment of Cancer Organization (EORTC) / Medical 
Research Council (MRC) treatment studies done during the 1990’ies, before the 
associations between chemotherapy and reduced cognitive function became a public 
concern.
In paper I (the 1990’ies study) self-reported cognitive complaints in TCPs treated 
with chemotherapy or radiotherapy during the 1990’ies are prospectively explored. We 
found no significant difference between the chemotherapy and the radiotherapy group in 
prevalence of cognitive complaints at one-year follow-up. Treatment modality was not 
significantly associated with cognitive complaints at any time point after adjustment for 
QoL domains such as emotional function and fatigue.
Paper II-IV reports results from our prospective study of cognitive function in TCPs, 
conducted at the Oslo University Hospital (“The Oslo-study”). In paper II (the distress 
paper) we explored the level of emotional distress shortly after the diagnosis of TC (at the 
baseline evaluation of our study), and investigated whether current level of distress had any 
impact on the neuropsychological test results at that time-point. About one-fourth of the 
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TCPs had clinically significant distress at baseline. However, we found that the majority of 
neuropsychological test scores (14 out of 18) were not significantly associated with levels of 
emotional distress.
In paper III (the neuropsychological paper) we compared the proportions of TCPs in 
three treatment groups (no chemotherapy, one cycle of chemotherapy, and multiple cycles 
of chemotherapy) with changes in neuropsychological test performance from baseline (pre-
treatment) to one year follow-up. No significant group differences in proportions of TCPs 
with a decline in neuropsychological test performance from baseline to follow-up were
observed. 
In paper IV (the self-report paper) we prospectively explored self-reported cognitive 
complaints in TCPs. Increase of cognitive complaints from baseline to one-year follow-up 
was significantly associated with levels of emotional distress and fatigue and treatment with
chemotherapy, but not with a decline in neuropsychological test performance.
From the findings presented in this thesis we conclude that cisplatin-based 
chemotherapy does not seem to have a negative impact on neuropsychological test 
performance in TCPs at one year follow-up. However, this finding should be confirmed in 
larger prospective studies before definite conclusions can be made. Self-reported cognitive 
complaints were not associated with neuropsychological test performance in our study, but 
were related to current emotional distress and fatigue. For TCPs treated in the 1990’ies, 
chemotherapy was not a significant predictor of post-treatment cognitive complaints after 
adjustment for emotional function and fatigue.
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Abbreviations and definitions
ANCOVA Analysis of covariance
ANOVA Analysis of variance
BEP Bleomycin, Etopside and Cisplatin
CAGE Instrument to assess alcohol problems (acronym)
CHEM group Group of patients treated with chemotherapy
CI Confidence interval
EORTC European Organization for Research and Treatment of Cancer
EPQ Eysenck Personality Questionnaire
FQ Fatigue Questionnaire
HADS Hospital Anxiety and Depression Scale
IES Impact of Event Scale
MRC Medical Research Council
MULTIPLE-CHEMO group Group of patients treated with multiple cycles of 
chemotherapy
NART National Adult Reading Test
NO-CHEMO group Group of patients who have received no chemotherapy
NRH Norwegian Radium Hospital
ONE-CHEMO group Group of patients treated with one cycle of chemotherapy
OR Odds ratio
PANAS Positive and Negative Affect Scale
RPLND Retroperitoneal lymph node dissection
SCIN Scale for Chemotherapy-Induced Neurotoxicity
RAD group Group of patients treated with radiotherapy
SD Standard deviation
SRB model Standardized regression-based model
TC Testicular cancer
TCP Testicular cancer patient
QLQ-C30 Quality of Life Questionnaire C30
QoL Quality of life
UUS Ullevål University Hospital
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1. BACKGROUND
1.1. Oncological aspects of testicular cancer
1.1.1. Incidence and etiology
Testicular cancer (TC) is the most common malignancy in males aged between 15 and 40 
years in the Western countries. During the past 50 years the incidence of TC has been rising 
steadily with a doubling of the incidence-rate during this period (Richiardi et al. 2004). 
Today, Norway and Denmark have the highest incidences of TC worldwide (Bray et al. 
2006; Richiardi et al. 2004). In Norway, the age-adjusted incidence-rate of TC in Norway 
was 12.3 per 100.000 person-years in 2008, and 296 Norwegian males were diagnosed with 
TC in that year (Cancer Registry of Norway, 2009).
Research indicates that both genetic and environmental factors acting on the 
primordial gonocytes (germ cells) during foetal life may be involved in the etiology and 
pathogenesis of testicular tumors (Krausz and Looijenga, 2008; McGlynn and Cook, 2009). 
There is an increased risk of TC in brothers and sons of affected males supporting an 
eventual genetic factor (Heimdal et al. 1996; Krausz and Looijenga, 2008), however a 
major gene associated with TC has not been identified so far. 
Peri-natal environmental factors are suspected to influence the development of TC 
(McGlynn and Cook, 2009). In particular, exposure of the male foetus to endocrine-
disrupting chemicals (i.e. chemicals with a hormone-like effect used in industrial and 
household products) have been proposed as a possible risk factor. Post-natal environmental 
factors such as testicular trauma and factors in work life have also been considered 
(McGlynn and Cook, 2009). Overall, the etiology and pathogenesis of TC seem to be multi-
factorial, and the exact mechanisms involved are far from clear (Krausz and Looijenga, 
2008; McGlynn and Cook, 2009). Skakkebæk and colleagues have proposed that TC may be 
a part of a testicular dysgenesis syndrome, in which conditions like cryptorchidism (non-
descended testis), impaired spermatogenesis, hypospadias (birth defect of urethra) and TC 
are risk factors for each other, and share a common biology of early dysgenesis in the foetal 
testis (Wohlfahrt-Veje et al. 2009).
1.1.2. Tumor staging and treatment principles
If TC is suspected (lump or changes in a testicle), the diagnosis is usually verified by 
unilateral orchidectomy (surgical removing of the affected testicle) and a subsequent 
histologic examination of the tumour. Ninety-eight percent of TCs are malignant germ cell 
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tumours with a histological diagnosis of seminoma (50-60%) or non-seminoma (40-50%) 
(Horwich et al. 2006). The incidence of seminoma peaks at 35 years of age, while the 
incidence of non-seminoma peaks ten years earlier (McGlynn and Cook, 2009). 
After the orchidectomy, further medical examinations are performed to evaluate the 
stage of the disease and the eventual need for chemotherapy or radiotherapy. These 
examinations usually include analyses of biochemical markers (human chorionic 
gonadotropin, -foetoprotein and lactate dehydogenase) and radiologic examinations of the 
chest, abdomen and pelvis in order to detect metastases. Scanning of the brain is performed 
only if there are clinical signs of brain metastases or in high-risk patients (Horwich et al. 
2006).
In Norway, the Royal Marsden Index (Peckham, 1988) is used for clinical staging of 
TC at the time of diagnosis. TC stage I indicates non-metastatic disease, whereas stage II, 
III and IV indicate metatstatic disease at increasing levels of severity. For seminoma, 
approximately 80% of patients have clinical stage I at the time of diagnosis, while for non-
seminoma around 50% have stage I at that time (Oldenburg et al. 2008b).
Risk-adapted post-orchidectomy treatment of TC is planned based on histology, 
stage and biochemical markers (Horwich et al. 2006), and the current treatment strategies 
for TC in Norway are as follows: Seminoma stage I is managed with surveillance (no 
additional treatment but frequent follow-up examinations), or treated with one dose of 
carboplatin chemotherapy. Traditionally, radiotherapy was used in stage I seminoma, 
however this is not practice today. Seminoma stage II-IV is treated with radiotherapy (only 
stage II), or more commonly with cisplatin-based (bleomycin, etoposide and cisplatin –
BEP) chemotherapy.
Non-seminoma stage I is managed with surveillance (low risk) or with one or two 
BEP-cycles (high risk). Non-seminoma stage II-IV is treated with 3 or 4 BEP-cycles and 
additional chemotherapy if needed. Surgical removing of retroperitoneal lymph nodes 
(Retroperitoneal lymph node dissection - RPLND) are performed in patients with metastatic 
non-seminoma if retroperitoneal lymph node masses persist after end of chemotherapy.
1.1.3. Prognosis of TC
After cisplatin was introduced in treatment during the 1980-ies, the prognosis of TC has 
improved quite significantly compared to earlier on, and the overall age-adjusted five years 
survival rate of TC in the European countries has reached 97% (Verdecchia et al. 2007). 
Non-metastatic (stage I) TC has a five years survival rate of almost 99% (Horwich et al. 
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2006). For metastatic TC three prognostic groups have been defined by the International 
Germ Cell Cancer Collaborative Group (International Germ Cell Cancer Collaborative 
Group, 1997), and the 5 years survival rate ranges from 48% (poor prognosis group) to 91% 
(good prognosis group). Relapse of TC is usually diagnosed within the first year after 
primary treatment, and occurs rarely more than two years later (Oldenburg et al. 2006b).
1.1.4. Short- and long-term health and morbidity after TC
Due to the high cure rate, long-term adverse effects of the disease and/or the treatment have 
received considerable clinical attention (Fossa et al. 2009; Travis et al. 2010). Adverse 
effects after cancer can be divided into short-term effects (<1 year post-diagnosis), medium-
term (1-4 years post-diagnosis) and long-term ones (	
-diagnosis). In this thesis, 
long-term TC survivors are defined as testicular cancer patients (TCPs) alive and tumour-
free 
-diagnosis. In 2008 about 5,700 Norwegian men lived with a prior diagnosis of 
TC, and around 4,400 (77%) of these men were long-term TC survivors (Cancer Registry of 
Norway, 2009).
Only a few studies on acute emotional distress related to the orchidectomy and the 
TC-diagnosis have been published. As expected, TCPs frequently report emotional distress 
shortly after the diagnosis (Fossa et al. 2003; Trask et al. 2003; Tuinman et al. 2007; van 
Basten et al. 1996). 
Physical health problems during the first year after diagnosis are mostly related to 
acute side-effects of surgery, radiotherapy or chemotherapy (Fossa et al. 2009). Acute 
toxicity of the BEP chemotherapy may affect the gastrointestinal (nausea), the 
hematological (anemia/infections), the renal (nephrotoxicity), or the neurological 
(peripheral neurotoxicity) organ systems (Brydoy et al. 2009). Nausea and fatigue are 
reported as acute side-effects of abdominal radiotherapy in TCPs (Fossa et al. 2009).
Patients with non-metastatic disease receiving surveillance only have no somatic 
side-effects other treatments, but must cope with the psychological distress associated with 
having TC and frequent follow-up examinations (Jones and Payne, 2000). Long-term TC 
survivors have demonstrated increased levels of anxiety and fatigue compared to normative 
male population samples (Dahl et al. 2005; Orre et al. 2008) and fear of cancer recurrence
is not uncommon among TC survivors (Skaali et al. 2009). In contrast, long-term health
related quality of life (QoL) (Mykletun et al. 2005; Vidrine et al. 2010) have not been 
found different to the normative population. Also, the work ability of long-term TC 
survivors has been found similar as in the general population (Gudbergsson et al. 2008).
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Studies have shown that about 20% of TCPs have clinical or sub-clinical 
hypogonadism (low levels of testosterone) already at diagnosis, while some TCPs develop 
hypogonadism after treatment (Fossa et al. 2009; Travis et al. 2010). Post-treatment 
endocrine hypogonadism is usually related to a decrease of testosterone production after 
removal of the diseased testicle, and occurs until a compensatory increase of the production 
is achieved by the non-affected testicle (Eberhard et al. 2008). If hypogonadism persists, 
medical substitution with testosterone may be a therapeutic option.
As to sexual function after TC, research findings have been ambiguous. Wiechno et 
al (Wiechno et al. 2007) reported that survivors with abnormal hormone levels had more 
sexual complaints compared with survivors with normal hormone levels. However, in a 
study by Dahl et al (Dahl et al. 2007) no difference in overall sexual satisfaction between 
long-term TC-survivors and a normative sample was found.
Knowledge about long-term toxic effects after cisplatin-based (BEP) chemotherapy
in TCPs are emerging (Horwich et al. 2006). Reduced fertility due to gonadal toxicity, 
long-term cardiovascular morbidity and persistent peripheral neurotoxic symptoms are 
major side effects (Fossa et al. 2009). The neurotoxic effects of the chemotherapeutic 
agents used in treatment of TC are discussed in detail below. Second cancers are rare but 
represent serious late effects after radiotherapy and chemotherapy for TC (Fossa et al. 
2009; Travis et al. 2010).
1.1.5. Neurotoxicity of cytotoxic agents used in treatment of TC
Cisplatin is a platinum compound with cytotoxic and antitumor effects, mostly exerting its 
effect by producing cross-links on the DNA (Wang and Lippard, 2005). Cisplatin has a
well-known neurotoxic effect, mostly affecting the peripheral nervous system. Among TCPs 
treated with cisplatin, 10-30% develop persisting peripheral neuropathy (numbness / 
reduced sensation in fingers or toes) due to the accumulation of cisplatin in the dorsal root 
ganglia and/or to axonal damage of the sensory peripheral nerves (Fossa et al. 2009). 
Further, about 20% of long-term TC survivors treated with cisplatin complain about hearing 
loss or tinnitus (Brydoy et al. 2009). Such ototoxic symptoms are most probably due to 
cisplatin-induced damage of the outer hair cells of the inner ear. Genetic polymorphisms 
involved in the metabolism of cisplatin and possibly protective of ototoxicity have been 
described (Oldenburg et al. 2008a).
Cisplatin is supposed to have poor penetration of an intact blood-brain barrier (in 
patients without brain metastases), and low penetration of systemically administrated 
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cisplatin has been shown in an animal study (Jacobs et al. 2005). However, reports of post-
mortem histo-pathological damage in the central nervous system (CNS) after cisplatin 
infusion have been published (Troy et al. 2000). Further, there exist case reports of cerebral 
symptoms (seizures, encephalopathy and visual disturbances) in patients after systemically 
administrated cisplatin (Hartmann and Lipp, 2003; Troy et al. 2000). Hence, systemically 
administrated cisplatin could possibly have a direct toxic effect on the CNS in some cases. 
Carboplatin is a platinum compound resembling cisplatin, but is less effective on 
tumor cells. In routine treatment of TC, carboplatin is used only as adjuvant treatment for 
seminoma stage I patients. Carboplatin has less nephrotoxic and neurotoxic effects 
compared to cisplatin (Hartmann and Lipp, 2003). Bleomycin and etopside have little or no 
neurotoxic effects (Dahl O et al. 2009). 
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1.2. Cognitive function in adult cancer patients
1.2.1. Cognitive function
Cognitive function refers to the mental activities of information processing in the brain, and 
involves functions like perception, memory, thinking, reasoning and expression. In 
everyday language cognitive function is usually referred to as concentration and memory. 
Information processing in the brain is based on complex neural activity involving 
schematically four “classes” of cognitive functions (Lezak et al. 2004). Processing starts 
with the perception of incoming sensory stimulus (receptive functions), followed by storage 
and retrieval of information (learning and memory), then reaching a “higher level” of 
processing involving functions like abstraction, reasoning, planning and executive 
functions1 (thinking), and finally the level by which information or thoughts are 
communicated or acted upon (expressive functions). These four “classes” of cognitive 
functions are visualized in the following model of information processing (Figure 1), 
modified from Vanderploeg (Vanderploeg, 2000). In this figure, the different “classes” of 
cognitive functions are marked with different colors: receptive functions (green), learning
and memory functions (blue), thinking (orange) and expressive functions (yellow).
Stimulus Response
Memory:
working memory, 
learning, recall
Level of
processing The brain
Tertiary
association
areas
Secondary
association
areas 
Primary 
areas
Executive 
functions
Alertness - Attention - Activation
Sensory
Perception
Language/
spatiality
Abstract
thinking
Problem-
solving
Problem-
solving
Planning
Pre-motoric
sequencing
Complex
actions
Simple
actions
Time axis
High
Low
Figure 1. Schematic model of cognitive information processing, modified from 
Vanderploeg (Vanderploeg, 2000)
1 executive functions refer to “higher order” mental functions such as rule acquisition, initiating 
appropriate actions and inhibiting inappropriate actions
19
As visualized in Figure 1, cognitive information processing from stimulus to 
response (via memory and thinking) represents mental activities at different levels of 
complexity in the brain. By cognitive dysfunction we usually mean disturbances at any level 
of information processing. Basic mental functions such as alertness /attention /activation are 
the “gateway” for all subsequent information processing. If these basic functions are 
disturbed, for example in a person who is preoccupied by anxiety or fatigue, further 
information processing such as learning and memory may be disturbed. Dysfunctions at the 
highest level of processing, involving abstraction, reasoning, planning and executive 
functions, can reduce an individual’s ability to function in complex settings (multi-tasking), 
even though the more basic functions such as learning and memory seem to be intact 
(Vanderploeg, 2000).
Earlier models of cognitive information processing were based on the assumption 
that different cognitive functions were located in discrete anatomical areas of the brain. In 
contrast, current models emphasize that cognitive functions are based on activity in complex 
neural circuits involving large parts of the brain, comprising both cortical and sub-cortical 
structures (Vanderploeg, 2000). However, some basic anatomic localization of cognitive 
functions is recognized, for example that the left cerebral hemisphere predominantly 
processes verbal information, whereas the right one mostly processes visuo-spatial 
information. Complex “higher order” cognitive functions such as abstraction, logical 
thinking, planning and executive functions are based on neuronal circuits in the prefrontal 
cortex in conjunction with sub-cortical structures (fronto-subcortical circuits).
1.2.2. Assessment of cognitive function
Neuropsychological testing represents the gold standard for assessment of an individual’s 
cognitive function (Lezak et al. 2004; Reitan and Wolfson, 1993; Vanderploeg, 2000). A 
neuropsychological test battery consists of a set of tasks designed to measure different 
aspects of cognitive function, i.e. different cognitive domains. The neuropsychological tasks 
are administrated in a standardized manner by trained personnel. Comprehensive 
neuropsychological test batteries usually include evaluation of the following cognitive 
domains (Lezak et al. 2004):
 Attention / concentration / working memory
 Verbal and visual learning and memory
 Speed of information processing
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 Executive functions including verbal fluency
 Motor function
These cognitive domains do not represent totally separate functional constructs however, 
and many neuropsychological tests require involvement of several cognitive domains. 
Examples of neuropsychological tests are to memorize a word list, to draw a line alternating 
between ascending and letters numbers as fast as possible, or to copy a construction using as 
few moves as possible. In addition to traditional “paper and pencil” neuropsychological 
tests, also newer computer-based neuropsychological tests have been developed (Levaux et 
al. 2007; Sahakian and Owen, 1992). Computerized tests may be particularly useful for 
evaluation of attention and speed of information processing.
Age, level of basic education, and level of intellectual capacity (IQ) are factors that 
have an impact on neuropsychological test performance. Normative data for 
neuropsychological tests are regularly customized for gender and age, and preferably also 
for level of education and intellectual capacity. Hence, neuropsychological test results can 
usually be controlled for these variables. High levels of education and intellectual capacity 
have been suggested as protective factors to reduced cognitive function after brain trauma, 
explained by a larger “cognitive reserve” (Stern, 2009). 
The neuropsychological test method is generally sensitive for detecting reduced 
cognitive function; however, the method is not specific concerning the cause of cognitive 
reduction (Vanderploeg, 2000). In the case of non-focal (diffuse) cognitive reduction, the 
same pattern of reduced test performance can be observed with different neurological 
etiologies. Neuropsychological test performance can also be reduced secondary to emotional 
distress, fatigue or low motivation for testing, and controlling for these variables may be 
difficult (Vardy and Tannock, 2007).
A general problem with neuropsychological testing is the low ecological validity of 
many tests, referring to the fact that the tests do not adequately mirror task performances of 
everyday life, but rather assess performances in a standardized test situation (Lezak et al. 
2004; Spooner and Pachana, 2006). Currently, work is going on to develop new 
neuropsychological tests which better represent the cognitive challenges of everyday life, 
thereby increasing the ecological validity. There are also some problems when 
neuropsychological testing is performed in a sample of individuals with good cognitive 
capacity. Many traditional neuropsychological tests were developed to detect major 
cognitive deficits rather than subtle changes in cognitive function, hence ceiling effects of 
test performance may occur. Finally, “higher order” cognitive functions such as planning, 
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multi-tasking and executive functions are per definition difficult to evaluate by standardized 
testing, since such functions describe how the person cope with “non-standardized” 
cognitive demands. However, executive tests do measure some aspects of these functions.
In addition to neuropsychological testing, cognitive function can also be studied by 
functional brain scanning [e.g. functional MRI or positron emission tomography (PET)], 
which implies that the test person is performing a cognitive task while the brain activity is 
registered. Such cognitive imaging techniques are an emerging field, however beyond the 
scope of this thesis, and will therefore not be presented further. Neurophysiologic 
registration of brain activity during cognitive tasks [e.g. event-related potentials (ERP)] also 
represents an opportunity for assessment that will not be covered further here.
1.2.3. Cognitive function in cancer patients
Malignant disease affecting the CNS and/or cancer treatment with direct involvement of the 
CNS may have a detrimental effect on brain functioning including cognitive function. This 
has been well documented (Correa, 2010; Platta et al. 2010; Ricard et al. 2009), and is not 
a theme of this thesis.
Complaints about reduced concentration and memory are, however, frequent also in 
cancer patients with no obvious CNS involvement of the tumor or treatment (Kohli S et al. 
2007). During the last decade there has therefore been an increasing attention and research 
on cognitive functioning among patients with non-CNS cancers (Vardy et al. 2008; Vardy 
and Tannock, 2007), particularly so after treatment for breast cancer (Shilling and Jenkins, 
2007; Vardy and Tannock, 2007; Vodermaier, 2009).
Patients and oncologists are concerned that systemic chemotherapy may have a 
negative effect on cognitive function, and reduced cognitive function in (breast) cancer 
patients after chemotherapy has popularly been called “chemo brain” or “chemo fog”. 
However, based on systematic research so far, significant associations between systemic 
chemotherapy and reduced cognitive function in cancer patients are still only partially 
documented. 
At the onset of the studies of this thesis, no neuropsychological study exploring 
cognitive function in TCPs after systemic chemotherapy had been published.
1.2.4. History of “chemo brain”
One of the first reports of to mention cognitive dysfunction in relation to chemotherapy was 
published in 1974 (Weiss et al. 1974a; Weiss et al. 1974b). A few small scale 
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neuropsychological studies (Cull et al. 1996; Meyers et al. 1995; Oxman and Silberfarb, 
1980; Silberfarb et al. 1980; Wieneke M and Dienst E, 1995) evaluating cognitive function 
in patients after chemotherapy for non-CNS solid tumors (lymphoma, lung cancer, breast 
cancer or mixed cancers) were published in the subsequent 20 years, including a Norwegian 
study by Kaasa et al on lung cancer patients (Kaasa et al. 1988). Conflicting results 
concerning reduced cognitive function after chemotherapy were presented.
Neuropsychological studies with larger sample sizes conducted in breast cancer 
patients have been published during the last 15 years. Among them, the earlier cross-
sectional studies (Ahles et al. 2002; Brezden et al. 2000; Castellon et al. 2004; Schagen et 
al. 1999; Tchen et al. 2003; van Dam et al. 1998) all demonstrated that a subgroup of the 
breast cancer patients showed reduced cognitive function after chemotherapy. In contrast, 
newer prospective studies in breast cancer patients, including a pre-treatment assessment 
(Bender et al. 2006; Debess et al. 2010; Jenkins et al. 2006; Mehlsen et al. 2008; Quesnel
et al. 2009; Schagen et al. 2006; Stewart et al. 2008; Tager et al. 2009; Wefel et al. 
2004b; Wefel et al. 2010), have reported more divergent findings regarding significant 
associations between systemic chemotherapy and reduced cognitive function. 
1.2.5. Hypothetical mechanisms for reduced cognitive function after non-CNS malignancies
In addition to a possible direct effect of systemic chemotherapy on the brain, several other 
factors could hypothetically affect short- and/or long-term cognitive function in patients 
with non-CNS malignancies. These factors (including systemic chemotherapy) are shown in 
Figure 2 and presented in some detail below.
Systemic chemotherapy
It is generally assumed that only a few cytotoxic agents (e.g. 5-fluoruracil, methotrexate and 
ifophosphamide) cross an intact blood-brain barrier, while most cytotoxic agents do not 
(Ahles and Saykin, 2007). However, sporadic reports about encephalopathic and cerebellar 
symptoms after systemic chemotherapy with commonly used cytotoxic agents have been 
published (Troy et al. 2000; Verstappen et al. 2003). Hypothetically, patients may be 
genetically more or less susceptible for cytotoxic agents crossing the blood-brain barrier 
(Ahles and Saykin, 2007). In the brain, the cytotoxic agents may exert a direct toxic effect 
by damage of neurons or their supportive cells, or interfere with the level or function of 
neurotransmitters.
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In a preclinical study by Noble and colleagues (Dietrich et al. 2006), cytotoxic 
agents (carmustine or cisplatin) administered systemically in mice were associated with an 
increased cell death and decreased cell division in the hippocampus and the corpus callosum 
regions of the brains, several weeks after the drug administration. In a later study by the 
same research group (Han et al. 2008), altered transcriptional regulation in 
oligodendrocytes and damage to myelin was found in adult mice brains 56 days after the 
administration of 5-fluoruracil in clinically relevant doses. This later study may indicate a 
particular toxic effect of cytotoxic agents on the myelin in the CNS, eventually resulting in 
axonal damage of neuronal networks (“white matter”).
In a recent clinical study by de Ruiter et al (de Ruiter et al. 2010) using functional 
MRI, brain activation during an executive (planning) task and a memory task was registered 
in 16 breast cancer patients treated with high dose chemotherapy 10 years earlier 
(chemotherapy group) and in 15 controls (breast cancer patients not treated with 
chemotherapy). The chemotherapy group showed significantly lower activation in parts of 
the prefrontal cortex (dorsolateral prefrontal cortex) during the executive task and in parts of 
the hippocampus (parahippocampal gyrus) during the memory task compared to the control 
group, indicating functional changes in the brain associated with chemotherapy. Further, the 
chemotherapy group showed a general lower activation of parts of the parietal cortex (lateral 
posterior parietal cortex) during both the executive and the memory tasks compared to the 
Figure 2. Overview of factors that hypothetically could impact on cognitive 
function in cancer patients with non-CNS malignancies (direct or indirect effects)
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control group, indicating a disturbance in attentional processing among the patients treated 
with chemotherapy.
In addition to a direct toxic effect, several indirect mechanisms by which cytotoxic 
agents could affect the brain have been proposed (Vardy et al. 2008). Cytokines are 
released during chemotherapy, and some cytokines could have direct or indirect negative 
effects on brain cells. Further, some cytotoxic agents may cause endothelial disruption, and 
brain cells could be affected indirectly due to vascular damage leading to insufficient 
oxygenation. Toxic effects to the bone marrow resulting in anemia and low oxygen levels 
could also be a contributing factor. Cytotoxic agents may also have a damaging effect on 
gonadal function and hormone production, thereby indirectly causing hypogonadism (low 
levels of sex hormones) in both sexes and premature menopause in women. Hormone 
receptors are widely distributed in the brain (Luine, 2008; Ulubaev et al. 2009), and 
changes in circulating hormone levels could have an impact on cognitive function.
Hormonal changes
In addition to the indirect hormonal effects of chemotherapy described above, some 
malignancies (such as ovarial cancer and TC) directly involve the gonads and may therefore 
interfere with hormone production. Also, anti-hormonal treatment is commonly used in the 
treatment of for example breast cancer (anti-estrogens) and prostate cancer (testosterone 
blockade).
Paraneoplastic phenomena
These are induced by the malignancy itself and involve inflammation processes with the 
release of cytokines that could have an effect on brain function (as described above) (Foster 
and Caplan, 2009).
Cytokines
In addition to the release of cytokines in response to the malignancy or its treatment, some 
cytokines are used directly as therapeutic agents in treatment of certain malignancies 
(immunotherapy) (Fry and Lankester, 2010). Such agents could possibly have an adverse 
effects on cognitive function.
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Supportive agents
Among these are anti-emetics, corticosteroids, analgesics and anxiolytics/hypnotics that are 
commonly used during or after treatment of malignancies. These agents may have adverse 
effects on cognitive function.
Radiotherapy 
Radiotherapy may hypothetically have an indirect effect on cognitive function via secondary 
vascular effects (endothelial damage) (Jurado et al. 2008) affecting the brain cells, or via 
radiotherapy-induced fatigue which is common after such treatment for malignancies 
(Wang, 2008).
Surgery and anesthesia
Particularly in older cancer patients there is a risk of post-operative cognitive dysfunction 
due to the anesthetic agents or to insufficient cerebral oxygenation.
Genetic susceptibility
Individual variability in genetic predisposition (genetic polymorphisms) for cognitive 
dysfunction (e.g. apolipoprotein E), or for an increased permeability of cytotoxic agents 
over the blood-brain barrier may lead to an increased risk for cancer-related cognitive 
dysfunction in some patients (Ahles and Saykin, 2007).
Fatigue
Clinically significant fatigue of long duration is common during and after malignancies and 
includes both physical and mental symptoms (Wang, 2008). Mental fatigue is characterized 
by subjective cognitive symptoms such as concentration problems, word finding problems 
and memory problems.
Emotional distress
Symptoms of reduced concentration and memory function are prevalent in individuals with 
anxiety disorders and/or depressive disorders. Such cognitive symptoms may also be a 
consequence of cancer-related emotional distress. Dysregulation of the glucocorticoid 
hormones pathway (cortisol) are observed in patients with major depression, and altered 
cortisol metabolism may eventually be a contributing factor in distress-related cognitive 
dysfunction (Sierksma et al. 2010).
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1.2.6. Neuropsychological functioning in breast cancer patients
Since nearly all research studies on cognitive function after treatment of non-CNS 
malignancies so far have been performed in breast cancer patients, a summary of the 
findings in this patient group is given. As referred above (Section 1.2.4), the majority of the 
early cross-sectional neuropsychological studies in such patients demonstrated that more 
patients exposed to chemotherapy had reduced cognitive function compared to controls (no 
chemotherapy) or published norm data (Ahles et al. 2002; Brezden et al. 2000; Castellon et 
al. 2004; Schagen et al. 1999; Tchen et al. 2003; van Dam et al. 1998; Wieneke M and 
Dienst E, 1995). However, the proportions of patients showing reduced cognitive function 
after chemotherapy ranged widely, from 17% to 75% across the studies (Correa and Ahles, 
2008). Cognitive domains possibly affected by chemotherapy included attention/working 
memory, processing speed, and verbal and visual memory (Correa and Ahles, 2008) (Vardy 
and Tannock, 2007). Notably, two more recent cross-sectional studies (Donovan et al. 
2005; Scherwath et al. 2006) did not find group differences in neuropsychological 
performance between breast cancer patients exposed or non-exposed to chemotherapy.
Newer prospective neuropsychological studies in breast cancer patients, with the 
inclusion of a pre-chemotherapy evaluation, have shown variable findings concerning the 
relation between chemotherapy and cognitive function. Interestingly, some of these studies 
reported that a subgroup of the patients showed reduced neuropsychological performance in 
several cognitive domains (verbal memory and reaction time) at pre-treatment (before 
chemotherapy) compared to healthy controls or published age-adjusted norm data (Ahles et 
al. 2008; Wefel et al. 2004a; Wefel et al. 2010). The authors explain these findings by 
paraneoplastic phenomena which may trigger release of inflammatory cytokines affecting 
cognitive function. Another explanation could be that the neuropsychological performance 
is reduced due to high levels of emotional distress shortly after the cancer diagnosis. 
Alternatively the study samples studied could lack representativeness in relation to relevant 
populations as to level of cognitive capacity due to selection biases.
As to post-treatment cognitive function, several prospective studies have 
documented that a subset of breast cancer patients exposed to chemotherapy had decline in 
neuropsychological test performance from baseline (pre-treatment) to short-term follow-up
(1-6 months post-treatment) (Quesnel et al. 2009; Schagen et al. 2006; Shilling et al. 
2005; Stewart et al. 2008). Among the cognitive domains affected were attention and 
verbal memory. However, other prospective studies with short-term follow-up assessments 
did not find an overall decline in cognitive function from pre- to post-chemotherapy (Debess
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et al. 2010; Hermelink et al. 2007; Mehlsen et al. 2008; Tager et al. 2009), hence 
discrepant results have been reported.
Notably, most prospective studies with longer follow-up intervals (12-18 months 
after chemotherapy) found that neuropsychological performance was unchanged or had 
improved compared to pre-treatment levels (Collins et al. 2009; Jenkins et al. 2006). These 
results suggest that a possible negative effect of chemotherapy on cognitive function is 
resolved over time. However, in a recent prospective study by Wefel et al (Wefel et al. 
2010), a subgroup of breast cancer patients exhibited decline in neuropsychological 
performance from pre-chemotherapy to 12-months follow-up; again conflicting findings 
have been observed.
The majority of breast cancer patients also receive hormonal therapy (anti-estrogens) 
and/or experience hormonal changes due to chemotherapy-induced menopause. The level of 
estrogens may possibly influence on cognitive functioning (Maki and Dumas, 2009), and 
hormonal therapy after breast cancer is associated with reduced cognitive function in some 
patients (Schilder et al. 2010). Castellon et al found that breast cancer patients who were 
exposed to both chemotherapy and hormonal therapy were more likely to show reduced 
cognitive function compared to patients treated with chemotherapy only (Castellon et al. 
2004).
Based on these findings there is an ongoing debate whether any reduced cognitive 
function after treatment for breast cancer should be attributed mainly to chemotherapy or to 
hormonal changes (Vodermaier, 2009). Finally, radiotherapy is regularly given for breast 
cancer and may hypothetically have an indirectly negative effect on cognitive functioning 
due to related fatigue.
No consistent patterns of affected cognitive domains have been described after 
chemotherapy in breast cancer patients. Cognitive reductions are generally mild and non-
focal (diffuse), and seem particularly to involve attention, processing speed and memory. 
Such cognitive reductions are mostly consistent with fronto-subcortical abnormalities, 
involving neural circuits between prefrontal cortex and subcortical structures (Vardy et al. 
2008). Patients with fronto-subcortical abnormalities are characterized by slow mental 
processing with difficulties concerning attention, encoding and retrieval of information 
(Bonelli and Cummings, 2008). 
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1.2.7. Neuropsychological functioning in other cancer groups including males
Hardly any neuropsychological studies of cognitive function in other malignancies than 
breast cancer have been published. This implies that cognitive function rarely has been 
explored in male cancer patients. Exceptions are studies of cognitive function in patients 
treated for prostate cancer. However, the agenda in these studies were to explore if 
medically induced castration was associated with cognitive dysfunction (Nelson et al. 
2008), and chemotherapy-related cognitive function was not an issue. Recently, however, 
two cross-sectional neuropsychological studies in TCPs were published (Pedersen et al. 
2009; Schagen et al. 2008) and they are described fully in Section 1.3.
Hormonal factors may be related to the post-treatment cognitive dysfunction 
described in cancer patients, with possible differences across the genders. Future studies 
involving both male and female cancer patients could possibly illuminate any cognitive 
side-effects of systemic chemotherapy.
1.2.8. Methodological issues in neuropsychological studies of cancer-related cognitive 
function
Methodological issues concerning the neuropsychological studies reported above are 
covered here. First, the majority of studies has relatively small sample sizes, and thereby 
will only report significance for big differences due to type II statistical errors. Studies 
reporting no significant differences may therefore show significant differences in larger 
samples. Further, most of the early studies were cross-sectional without pre-treatment 
baseline data; hence individual changes in cognitive function over time could not be 
assessed.
This state of affairs called for prospective studies which are now gradually emerging, 
but until now such studies of patients with other malignancies than breast cancer are few. As 
stated in the preceding section, it is difficult distinguish between cognitive effects of 
chemotherapy and hormonal changes in breast cancer patients. Prospective 
neuropsychological studies have their own limitations, however, since pre-treatment 
evaluation is performed shortly after the cancer diagnosis when the patients may experience 
high levels of emotional distress due to their recent diagnosis. Increased level of emotional 
distress might have an impact on neuropsychological test performance (Vardy et al. 2008).
The neuropsychological test batteries used for assessing cognitive function have 
varied across studies, both in the numbers and selections of tests. Also, time points for the 
assessments vary considerably between studies. Lastly, various definitions of reduced or 
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decline in cognitive function have been used across studies (Shilling et al. 2006) (Vardy et 
al. 2007).
In sum, based on neuropsychological studies conducted so far, the relation between 
systemic chemotherapy and cognitive function is still mostly unsettled.
1.2.9. Self-reported cognitive function
The basis for the neuropsychological research described above has been cancer patients’ 
complaints about impaired memory and concentration during and after treatment (Clegg, 
2009). Hence, assessment of self-reported (“subjective”) cognitive function is important in 
this field, as a supplement to the more “objective” neuropsychological test studies. Self-
reported cognitive problems are often referred to as cognitive complaints (this term will be 
used in this thesis), in contrast to cognitive dysfunction as measured by neuropsychological 
tests. 
Cognitive complaints in cancer patients can be assessed by interviews, by specific 
cognitive questionnaires such as the Functional Assessment of Cancer Therapy-cognitive 
function (FACT-COG) questionnaire (Lai et al. 2009; Vardy et al. 2006), or by QoL 
questionnaires which include items on cognitive function. For example, the EORTC Quality 
of Life Questionnaire (QLQ)-C30 (Aaronson et al. 1993) includes two items on memory 
and concentration.
Several of the neuropsychological studies in breast cancer patients mentioned in 
Section 1.2.6. also included assessment of cognitive complaints (Hermelink et al. 2010; 
Mehnert et al. 2007; Shilling and Jenkins, 2007). In these studies more than half of the 
patients had some post-treatment cognitive complaints, however such complaints were not 
restricted to patients exposed to chemotherapy. A recent systematic review on cognitive 
complaints in breast cancer patients (Pullens et al. 2009) reported that the prevalence of 
post-treatment cognitive complaints ranged widely across studies, from 21% to 90% of the 
patients.
Noteworthy, a low correlation between self-reported cognitive complaints and 
cognitive dysfunction found by neuropsychological testing has been repeatedly documented 
in breast cancer patients (Hermelink et al. 2010; Mehnert et al. 2007; Shilling and Jenkins, 
2007). This discrepancy was already described in a small study of lymphoma patients from 
1996 (Cull et al. 1996). Low correlations between self-reported and test-assessed cognitive 
function have been found also in other medical conditions associated with subtle cognitive 
dysfunction (Vardy and Tannock, 2007).
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In contrast, cognitive complaints in breast cancer patients are reported to be 
significantly associated with symptoms of emotional distress and fatigue (Hermelink et al. 
2010; Jenkins et al. 2006; Mehnert et al. 2007), and such complaints may actually reflect 
emotional status more than neurocognitive dysfunction. However, there are some data from 
non-cancer populations suggesting that self-reported cognitive complaints may be 
associated with brain-imaging parameters, in spite of normal neuropsychological test 
performance. In a study by Saykin et al (Saykin et al. 2006), 40 healthy older adults with 
cognitive complaints and normal neuropsychological test performance were examined with 
structural brain MRI. The results were compared with brain MRI’s from a group of adults 
with mild dementia (amnestic mild cognitive impairment). The group with cognitive 
complaints showed grey matter abnormality in the temporal lobes of the brain comparable to 
the group with mild dementia, suggesting that neuropsychological testing was not sensitive 
to detect subtle cognitive impairment among these persons with cognitive complaints.
In 2007, Kohli et al. published a prospective study on self-reported memory and 
concentration complaints among 595 cancer patients with various malignancies (34% male 
patients) and treated with chemotherapy and/or radiotherapy (Kohli S et al. 2007). The 
patients filled in questionnaires at pre-treatment (T1), within 2 weeks after end of therapy 
(T2), and then at 6 months post-treatment (T3). Memory and concentration complaints were 
reported by nearly half of the study sample at baseline (T1) and these rates had significantly 
increased at T2 (shortly after end of treatment). At 6-months follow-up (T3) the rates of 
complaints were lower than at T2 but had not returned to baseline levels. Patients exposed 
to chemotherapy had significantly higher prevalence of concentration and memory 
complaints at T2 and T3 compared with patients treated with radiotherapy only. Compared 
to females, the male patients had significantly lower prevalence of cognitive complaints 
both at T2 and T3.
During the last decade there has been an increasing public attention about “chemo 
brain” or “chemo fog” in the media and on the Internet. Hence expectation bias (see Section 
6.1.3) may be a problem in current studies of subjective cognitive complaints among 
patients treated with chemotherapy. In a study by Schagen and colleagues (Schagen et al. 
2009), breast cancer patients with pre-existing knowledge about chemotherapy-related
cognitive problems reported significantly more cognitive complaints compared with patients 
without such knowledge. In another study on cognitive complaints in breast cancer patients 
(Shilling and Jenkins, 2007), the authors stated: “self-report [of cognitive complaints] may 
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be high, simply because we asked patients to take part in a study investigating the potential 
effects of treatment on their memory”.
1.3. Neuropsychological functioning and cognitive complaints in TCPs
Before the onset of the studies comprising this thesis, only one published study had 
described aspects of cognitive function in TCPs. In a prospective QoL study published in 
2003, Fossa et al (Fossa et al. 2003) described subjective cognitive complaints (memory 
and concentration problems) as assessed by the EORTC QLQ-C30 questionnaire (Aaronson
et al. 1993) in 666 TCPs treated with 3 or 4 BEP cycles. Nineteen percent of the TCPs had 
an increase of cognitive complaints from baseline (pre-treatment) to 2 years follow-up. This 
study gave the impetus for planning of the prospective study of cognitive function in TCPs 
presented in this thesis, including both neuropsychological and self-report evaluations.
Two cross-sectional studies of cognitive function in TCPs including 
neuropsychological evaluation were published during our period of data collection (see 
Section 3.2). In 2008, Schagen et al (Schagen et al. 2008) presented study of 
neuropsychological functioning and cognitive complaints in 182 TCPs at a mean follow-up
time of 3 years post-treatment. Their sample consisted of 70 TCPs treated with 4 cycles of 
BEP-chemotherapy after orchidectomy (chemotherapy group), 57 TCPs treated with 
abdominal radiotherapy (20-30 Gy) after orchidectomy (radiotherapy group), and 55 TCPs 
treated with orchidectomy only (surveillance group). These TCPs were tested once with a 
neuropsychological battery consisting of 10 tests (24 sub-test measures) at a minimum of 6 
months after end of treatment. Concerning mean raw neuropsychological scores, no 
significant differences were observed across the three treatment groups.
The authors also performed individual analyses using the following approach: The 
raw neuropsychological scores were converted to z-scores using the surveillance group as 
the reference group. If a patient scored 		

a test then he was considered as impaired on that test. Based on the fifth-percentile of the 
surveillance group a person was classified as showing reduced neuropsychological 
performance if he had deviant scores on at least 3 of the 24 test measures (corresponding to 
12.5% of the test measures). Significantly higher proportions of patients in the 
chemotherapy and the radiotherapy groups had reduced neuropsychological performance 
(14% and 18% respectively) compared to the surveillance group (6%). No significant 
difference in proportions with reduced performance was observed between the 
chemotherapy and the radiotherapy group. However, after adjustment for age and level of 
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intellectual functioning, the chemotherapy group had significantly higher risk for showing 
reduced neuropsychological performance compared to the surveillance group (OR 4.6, 95% 
CI 1.1 – 19.7, p=0.04), but not if compared to the combined radiotherapy and surveillance 
group (OR 0.8, 95% CI 0.3 – 2.4, p=0.70).
The TCPs were also interviewed about cognitive problems, and the responses were 
rated on 5-point scales ranging from 1 (never) to 5 (always). A score of 3 or more defined
the category of having cognitive complaint. Further, the patients were asked to indicate the 
extent they were bothered by eventual cognitive problems, also this question rated on a 5-
point scale ranging from 1 (not) to 5 (extremely), and with a score of 3 or more defining as 
being bothered by the problems. Thirty-two percent of both the chemotherapy and the 
radiotherapy groups reported cognitive complaints, while for the surveillance groups the 
corresponding percentage was 27. Hence no significant between-groups differences in 
prevalence of cognitive complaints were observed. Approximately half of all TCPs with 
cognitive complaints indicated that they were bothered by these problems. Further, the study 
found no significant association between cognitive complaints and reduced 
neuropsychological performance. As previously reported in breast cancer patients, cognitive 
complaints in the TCPs were significantly associated with symptoms of fatigue and 
emotional distress, while being classified as cognitively impaired on neuropsychological 
tests did not show significant associations with these variables (Schagen et al. 2008).
Schagen et al concluded that regarding the possible effects of BEP chemotherapy on 
neuropsychological functioning in TCPs, their results were inconclusive and further 
research, in particular prospective studies, were needed. The strengths of the study by 
Schagen et al was a high inclusion rate (89%) and well powered group samples of TCPs that 
had received three different treatment modalities. The surveillance group served as an ideal 
control group and the authors report that the mean neuropsychological scores in the 
surveillance group were in line with published norm data. Complete data on 
neuropsychological test performance and self-reported cognitive complaints were obtained. 
However, a limitation was cross-sectional design with lack of pre-treatment assessment; 
hence individual change over time in neuropsychological test performance or cognitive 
complaints could not be assessed.
In 2009, Pedersen and colleagues (Pedersen et al. 2009) published a cross-sectional 
study on neuropsychological functioning in 72 TCPs at a mean of 4 years after end of 
treatment. In their study, 36 TCPs had received chemotherapy (3 or 4 BEP-cycles) after 
orchidectomy (chemotherapy group) and 36 patients had not received chemotherapy (23 
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TCPs had orchidectomy only and 13 received radiotherapy; no chemotherapy group). These 
patients were tested with a neuropsychological test battery of 21 test measures. Cognitive 
complaints were not assessed.
In line with Schagen et al, these authors did not find any differences in mean raw 
neuropsychological test scores between the treatment groups. Pedersen et al used the same 
method as Schagen et al for the classification of individually reduced neuropsychological 
performance. However, based on the fifth percentile of this control group (the no 
chemotherapy group), patients were defined as showing reduced neuropsychological 
performance if they had test scores the no chemotherapy group 
on at least 4 of the 21 test measures (corresponding to 19% of the test measures). Six 
percent of patients in the chemotherapy group and 8% of patients in the no chemotherapy 
group were classified with reduced neuropsychological performance, and this difference 
was not statistically different. The authors concluded that BEP-chemotherapy did not have a 
long-term negative effect on cognitive function in TCPs.
Limitations of this study are a rather small sample size with a risk for type II 
statistical error, and that the control-group consisted of TCPs who had received either 
surveillance or radiotherapy. As mentioned in Section 1.2.5, radiotherapy could 
hypothetically affect cognitive function indirectly through fatigue. The inclusion rate of the 
study is not given. Finally, this study also lacks pre-treatment neuropsychological 
evaluation.
1.4. Implications of cancer-related cognitive problems
Reduced cognitive function after cancer may have considerable consequences for patients’ 
QoL and daily functioning. In Norway about 50% of cancer patients are older than 70 years 
(Cancer Registry of Norway, 2009). Cancer-related cognitive problems may eventually 
aggravate existing age-related cognitive reduction in such patients. For younger patients, 
cognitive problems may interfere with educational and occupational tasks. Studies in breast 
cancer patients have documented that perceived cognitive problems had substantial negative 
impact on the patients’ professional life (Boykoff et al. 2009; Downie et al. 2006; Oberst
et al. 2010).
Knowledge about cognitive problems after cancer is important for health care 
workers, both as to inform the patients about potential side-effects before treatment, but also 
for securing adequate interventions if such problems should arise. In a pilot study, cognitive
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rehabilitation techniques were shown to be effective in alleviating treatment-related 
cognitive problems in breast cancer patients (Ferguson et al. 2007a).
To facilitate for further information and research on cancer-related cognitive 
problems, an international working group of clinicians and researchers [the International 
Cancer and Cognition Task Force (ICCTF)] was established in 2006 (ref 
http://www.icctf.com/ retrieved August 21, 2010) (Vardy et al. 2008).
1.5. Status on the relation between systemic chemotherapy and cognitive function at 
the onset of this thesis
When the studies of this thesis were planned in 2005, the QoL-study by Fosså et al (Fossa et 
al. 2003) was the only published study that included aspects of cognitive function in TCPs.
Among breast cancer patients, several cross-sectional neuropsychological studies had been 
published at that time, and most of these reported that systemic chemotherapy seemed to 
have a negative impact on cognitive function in subgroups of patients. Until 2005, only one 
small-scale prospective neuropsychological study in breast cancer patients had been 
published (Wefel et al. 2004b). Results from this study also indicated negative cognitive 
effects of chemotherapy in a subgroup of the patients.
Reviews and meta-analyses of cognitive function after systemic chemotherapy 
conducted until 2006 (Anderson-Hanley et al. 2003; Falleti et al. 2005; Jansen et al. 2005; 
Minisini et al. 2004; Stewart et al. 2006; Tannock et al. 2004) found evidence for the 
conclusion that systemic chemotherapy exerted a small to moderate negative effect on 
neuropsychological test performance in a subgroup of breast cancer patients. However, the 
majority of studies included in these reviews had cross-sectional designs and comprised 
only breast cancer patients.
More studies on cognitive function also in other groups of cancer patients were 
requested, in particular prospective studies including a pre-treatment assessment (Tannock
et al. 2004). Further, recommendations were given to consider the use of computer-based 
neuropsychological tests, since such tests possibly were more sensitive to subtle changes in 
cognitive processing speed than traditional tests (Tannock et al. 2004). The intriguing 
findings of low correlations between subjective cognitive complaints and cognitive 
dysfunction (as assessed with neuropsychological tests) in breast cancer patients also 
warranted further exploration. Studies of treatment and patient-related variables associated 
with cognitive complaints or cognitive dysfunction were requested, in order to elucidate 
possible etiological and pathogenetic mechanisms.
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Due to the excellent cure rate of TC, in part established by highly effective 
chemotherapy, TCPs have a long life-expectancy after their disease and are expected to 
resume their regular professional and familial life after treatment. Based on the findings by 
Fosså et al (Fossa et al. 2003) further exploration of cognitive adverse effects of BEP-
chemotherapy in TCPs seemed necessary, since such adverse effects could have serious 
consequences for QoL as well as for future career and employment of TC survivors.
On this background, we found it timely and of clinical importance to initiate a 
prospective study of cognitive function in TCPs with the assessment of both 
neuropscyhological and self-reported function, and with the aim to study eventual 
differences in cognitive function from baseline (pre-treatment) to 12 months follow-up in 
various treatment groups. In addition, due to the general knowledge of “chemo brain”, we 
decided to prospectively compare cognitive complaints in TCPs treated with or without 
chemotherapy during the 1990-ies, when that concept was virtually unknown to the public.
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2. THIS THESIS
2.1. Research setting
During the last twenty years much research on different aspects of TC has been conducted at 
the Norwegian Radium Hospital (NRH) under the leadership of professor Sophie D. Fosså 
at the National Resource Center for Long-term Effects after Cancer. Based on previous 
findings by Fosså et al on cognitive complaints after TC treatment (Fossa et al. 2003), it 
was a natural next step for the research group to initiate further studies of cognitive function 
in TCPs. Collaboration with chief psychologist Stein Andersson at the Neuropsychological 
laboratory at Department of Neuropsychiatry and Psychosomatic Medicine at Rikshospitalet 
was established for implementation of this research. When the studies of this thesis were 
planned in 2005, both the NRH and the Ullevaal University Hospital (UUS) were 
responsible for the treatment of TC in the Southern and Eastern parts of Norway. 
Cooperation with the oncological department of UUS, represented by uro-oncologist Carl
W. Langberg, was initiated in order to recruit TCPs from both hospitals. Systematic 
neuropsychological assessment of cancer patients was a new procedure at both hospitals.
The research fellow and principal investigator on the studies of this thesis (Tone
Skaali) is a medical doctor trained in psychiatry. She has clinical experience from 
consultation/liaison psychiatry at the Department of Oncology, Oslo University Hospital 
(NRH).
2.2. Aims of the studies
Based on the Background section and the research setting described above, the following 
studies were initiated, with the aims described here. 
Paper I. A prospective study of cognitive complaints in TCPs treated in the pre “chemo 
brain” era (The 1990’ies study) 
Background: During the last decade there has been an increasing attention among 
patients and oncologists on whether systemic chemotherapy has cognitive side-effects. After 
this concern has become public, there is a risk of expectation bias in current studies of self-
reported cognitive complaints (Schagen et al. 2009). We therefore decided to explore 
cognitive complaints in TCPs treated during the 1990’ies, prior to today’s increased 
awareness of this adverse effect. Our study sample were TCPs enrolled in three EORTC / 
MRC treatment studies during the 1990-ies who had had completed the EORTC QLQ-C30 
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before and after treatment with chemotherapy or radiotherapy. The QLQ-C30 includes two 
items on cognitive function (memory and concentration). 
Purpose: To examine if TCPs treated with chemotherapy (CHEM group) had more 
cognitive complaints during the first year after the diagnosis compared with TCPs treated 
with radiotherapy (RAD group), and to explore variables associated with such cognitive 
complaints. 
Aims: 1) To study the prevalence of self-reported cognitive complaints and its 
changes from before treatment (baseline) to 3 and 12-month follow-up among TCPs treated 
with either chemotherapy or radiotherapy, and to identify variables associated with such 
cognitive complaints; and 2) To identify self-reported QoL dimensions before treatment that 
were predictive for cognitive complaints at 12-month follow-up.
Hypotheses: Based on previous studies of cognitive complaints in breast cancer 
patients and a mixed cancer sample (Kohli S et al. 2007), we hypothesized that 1) The 
CHEM group had higher prevalence of cognitive complaints at 3 and 12 months follow-up
compared to the RAD group, and that post-treatment cognitive complaints were 
significantly associated with treatment modality, current fatigue and emotional function. 2) 
Emotional function and fatigue symptoms before treatment were predictors for cognitive 
complaints at 12 month follow-up.
Paper II. Is psychological distress in men recently diagnosed with testicular cancer 
associated with their neuropsychological test performance? (The distress paper)
Background: Prospective neuropsychological studies of cancer patients, including a 
pre-treatment assessment, have been requested in the field. We therefore initiated a 
prospective neuropsychological study in TCPs. However, such studies imply that the 
baseline neuropsychological assessment is performed shortly after the patients have got their 
cancer diagnosis, when the patients may experience high levels of emotional distress due to 
this negative life event. The level of distress could hypothetically have an impact on 
neuropsychological test performance, but research-based knowledge on such distress in 
TCPs at that time point was lacking at the onset of our study. At follow-up evaluation one 
year after end of treatment, we expected the level of emotional distress to be lower 
compared to baseline, since treatment was finished and a good prognosis was regularly 
expected. If current distress has an impact on neuropsychological test performance, then
change in distress-levels from baseline to follow-up assessments could confound the 
interpretation of changes in neuropsychological test results between the two time-points.
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Purpose: To explore the level of cancer-related emotional distress in TCPs shortly 
after the cancer diagnosis, and to study if level of emotional distress had an impact on 
neuropsychological test performance at this time point (at baseline).
Aims: To study the following aspects: 1) What proportion of the recently diagnosed 
TCPs reports clinically significant cancer-related distress? 2) Which variables are 
significantly associated with increased level of cancer-related distress? 3) (Main aim) Does 
the current level of emotional distress significantly affect the results on any of the 
neuropsychological tests at the baseline evaluation? 
Hypotheses: 1) A considerable proportion of TCPs has clinically significant distress 
shortly after the diagnosis; 2) The level of cancer-related distress at baseline is associated 
with both patient-related variables and with stage of TC; 3) The current level of emotional 
distress is significantly associated with some of the neuropsychological test scores.
Paper III. A prospective study of neuropsychological functioning in testicular cancer 
patients (The neuropsychological paper)
Background: Based on cross-sectional studies, ambiguous findings concerning the 
effect of cisplatin-based chemotherapy on neuropsychological test performance in TCPs 
have been reported. Prospective neuropsychological studies in TCPs, with the inclusion of a 
pre-treatment evaluation, were requested in order to elucidate an eventual causal 
relationship.
Purpose: To prospectively study neuropsychological test performance in TCPs 
treated with or without chemotherapy.
Aims: 1) To compare changes from baseline to one year follow-up of 
neuropsychological test performance in TCPs exposed to three different treatment 
modalities: no chemotherapy, one cycle of chemotherapy, and multiple cycles of 
chemotherapy; 2) To study variables associated with a decline in neuropsychological test 
performance from baseline to one-year follow-up.
Hypotheses: 1) A significantly larger proportion of TCPs treated with multiple 
cycles of chemotherapy exhibit a decline in neuropsychological test performance compared 
to TCPs treated with no or only one cycle of chemotherapy; 2) A decline in 
neuropsychological test performance from baseline to one year follow-up is significantly 
associated with chemotherapy.
40
Paper IV. Self-reported cognitive problems in testicular cancer patients: Relation to 
neuropsychological performance, fatigue and mental distress (The self-report paper)
Background: In studies of breast cancer patients, low correlations between reduced 
neuropsychological performance and self-reported cognitive complaints have been
observed. In a cross-sectional study of cognitive complaints in TCPs (Schagen et al. 2008), 
approximately 1/3 of all patients had such complaints at a mean of three years after end of 
treatment. In this study, cognitive complaints were associated with emotional distress and 
fatigue, but not with treatment modality or with neuropsychological test performance. The 
relation between cognitive complaints, neuropsychological test performance, fatigue and 
emotional distress had not been studied prospectively in TCPs.
Purpose: To assess the proportion of TCPs who report an increase of cognitive 
complaints from baseline to one-year follow-up and to explore variables associated with 
such an increase.
Aims: 1) To compare the proportions of TCPs with an increase of self-reported 
cognitive problems from baseline to one-year follow-up among patients treated with no 
chemotherapy, one cycle of chemotherapy and multiple cycles of chemotherapy; and 2) To 
study variables associated with an increase of self-reported cognitive problems from 
baseline to one-year follow-up.
Hypotheses: 1) A larger proportion of TCPs treated with multiple cycles report 
increase of cognitive problems from baseline to one year follow-up compared with TCPs 
treated with no or with one cycle of chemotherapy. 2) An increase of self-reported cognitive 
problems from baseline to one year follow-up is significantly associated with treatment with 
chemotherapy and emotional distress and fatigue at follow-up, but not with a decline in 
neuropsychological test performance.
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3. STUDY SAMPLES AND PROCEDURES
3.1. Paper I: The 1990’ies study (TCPs enrolled in three EORTC / MRC trials)
In paper I, we wanted to prospectively compare cognitive complaints during the first year 
after diagnosis in TCPs treated with or without chemotherapy in the 1990’ies, before 
“chemo brain” was publicly known, in order to reduce possible expectation bias.
Patients relevant for this study were identified from the electronic records of three 
randomized treatment-studies of testicular cancer (TC) organized by the EORTC / MRC 
during the 1990-ies (Figure 3). The chemotherapy group consisted of TCPs with metastatic 
disease included in trial 30941/TE20 (de Wit et al. 2001) which evaluated treatment with 
four different schedules of bleomycin, etoposide and cisplatin (BEP) chemotherapy (3 or 4 
cycles given over 5 or 3 days). From the TE20 trial we had access to the data on 791 
patients from several countries. This is the same study in which Fossa et al studied QoL in 
2003 (Fossa et al. 2003).
The radiotherapy group (the controls in relation to chemotherapy) consisted of 
irradiated non-metastatic seminoma patients included in trial 30942 /TE18 (Jones et al. 
2005) and trial 30982 /TE19 (Oliver et al. 2005). The TE18 study compared the effects of 
20 Grey versus 30 Grey abdominal radiotherapy, while the TE19 study evaluated 
radiotherapy (20 or 30 Grey) versus a single-dose of carboplatin chemotherapy. From the 
TE18/TE19 studies we only had access to the data on the 126 Norwegian patients.
According to the study protocols, the QLQ-C30 and a TC-module were to be 
completed by the patients at pre-treatment (baseline), approximately 3 months and 12 
months after baseline. In the TE20 study the 3-month assessment was done shortly after end 
of chemotherapy. 
The time windows for accepted questionnaires in our study were established as 
follows: The data files on the Norwegian radiotherapy patients in the TE18/TE19 trials 
were provided to us by the MRC Clinical Trial Unit. For these files, the time-windows for 
accepted questionnaires had been defined by the MRC, and were: baseline: 0-28 days before 
treatment start, 3-months: 9-18 weeks after baseline, and 12-months: 9-15 months after 
baseline. For the TE20 trial (the chemotherapy patients) the situation was different as our 
research group had access to data on all TCPs included in that trial. We chose to define 
accepted time-windows in the TE20 trial according to those used in the TE18/TE19 trials, 
with some modifications due to the slight uncertainty related of the date of chemotherapy 
start. Our defined time-windows for accepted questionnaires in the TE20 trial were: 
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baseline: +/-30 days from randomization, 3-months: 9-20 weeks after baseline, and 12-
months: 9-18 months after baseline. Only patients who delivered questionnaires in accepted 
time-windows and who had filled in both cognitive items of the QLQ-C30 at all three time 
points were included in our study. Further, we only included TCPs in the age between 15 
and 59 years old. The study sample therefore consisted of 347 TCPs: 276 TCPs treated with 
chemotherapy (CHEM group) and 71 TCPs treated with radiotherapy (RAD group) (Figure 
3).
Norwegian testicular 
cancer patients
TE18: N=81    TE19: N=45
Total N = 126
Valid data at baseline, 
3 and 12 months 
N = 276 Final sample of patients 
<60 years with
valid data at baseline,
3 and 12 months
Chemotherapy: N = 276
Radiotherapy: N = 71
Total: N = 347
Chemotherapy group Radiotherapy group
TE20 study TE18 study TE19 study radiotherapy arm
Valid data at baseline and 
12 months
N = 417
Patients in TE20 trial
N = 812
N = 625 N = 885
Valid data at baseline and 
age <60 years
N = 636
Testicular cancer patients
N = 791
Extragonadal germ cell 
malignancy, N=21
Valid data at baseline and
age <60 years
N = 115 
Valid data at baseline 
and 12 months
N = 96
Valid data at baseline, 
3 and 12 months 
N = 71
Valid data
at baseline and
age <60 years
N = 751 
Figure 3. Study sample in paper I
Valid data: Patients who delivered questionnaire in defined time-window and had 
filled in both cognitive items (#20 and #25) of the EORTC QLQ-C30
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3.2. Paper II-IV: The Oslo-study
In 2006 we initiated a prospective study of cognitive function in TCPs evaluated at two 
university hospitals (the NRH and the UUS) in Oslo. This study was the basis for paper II-
IV and is referred to as “the Oslo-study” in this thesis. The main purpose of the Oslo-study 
was to investigate if cisplatin-based chemotherapy had a negative impact on cognitive 
function in TCPs. Baseline evaluations in the study were to be completed before the start of 
any adjuvant treatment with chemotherapy (or radiotherapy), and follow-up evaluation were 
scheduled 12-months after end of treatment / start of surveillance period. All evaluations 
consisted of an interview, neuropsychological testing and some questionnaires (Appendix 
A-D). For this study we wanted to include newly diagnosed TCPs who had not yet started 
any adjuvant treatment after orchidectomy.
In Norway, TCPs are usually orchidectomized and receive their cancer diagnosis at 
their local hospital. The patients are then referred to a university hospital for staging and 
evaluation of further treatment. Until ultimo 2009, newly diagnosed TCPs in South-Eastern 
Norway (2,600.000 individuals) were referred for evaluation at the NRH or at the UUS.
The inclusion procedure for the Oslo-study was as follows: TCPs aged 18 to 60 
years referred to the above mentioned hospitals in the period August 2006 (NRH) / January 
2007 (UUS) to September 2008 (both hospitals) were screened by the responsible clinician 
for eligibility in the study. The exclusion criteria were: 1) Severe mental disorders like 
psychoses or substance dependence disorders; 2) Degenerative brain disease or previous 
severe brain trauma; 3) Brain metastases or severe somatic dysfunction; or 4) Lacking 
proficiency of Norwegian language. 
Eligible patients were informed about the study by a written information letter and 
by oral presentation from a medical doctor or nurse at the clinic. Some patients gave their 
decision about participation in the study directly to the doctor/nurse, while others gave their 
decision to the principal investigator (Tone Skaali) after she contacted them and asked for 
their decision concerning participation.
Among 202 eligible TCPs, 135 accepted to join the study and filled in baseline 
questionnaires; however, due to administrative reasons, only 131 of these TCPs were 
interviewed and 129 TCPs (64% of the 202 eligible patients) were tested with a 
neuropsychological battery (Figure 4). Among the 73 eligible TCPs not included or tested at 
baseline, approximately 45 patients declined to participate while the rest were not included 
due to administrative reasons.
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At follow-up examination at a median of 12 months after end of chemotherapy / start 
of the surveillance period, 122 tumour-free TCPs (95% of the 129 with complete baseline 
evaluation) were re-evaluated (Figure 4). Seven TCPs with complete baseline evaluation 
were lost to follow-up: three patients declined re-evaluation, one patient had moved abroad 
and three patients were excluded due to development of mental disorders or somatic 
diseases. 
Among the 122 TCPs re-evaluated at follow-up, 31 TCPs had received no 
chemotherapy (30 TCPs had surveillance and 1 had radiotherapy; NO CHEMO group), 38 
TCPs had received one cycle of chemotherapy (34 TCPs had one course of carboplatin and 
4 had one cycle of BEP; ONE CHEMO group) and 53 TCPs had received two or more 
(B)EP-cycles (MULTIPLE CHEMO group). Among the patients in the MULTIPLE 
CHEMO group, 17 TCPs had received 2 cycles of BEP or EP (etoposide and cisplatin), 33 
had received 3 or 4 BEP-cycles, and 3 had received 4 BEP-cycles plus additional 
chemotherapy. Seven of the 122 TCPs evaluated at follow-up were initially assigned for 
surveillance, but developed a relapse during the follow-up period and were therefore treated 
with chemotherapy instead. Fore these patients, the follow-up evaluation was done 
approximately 12 months after end of chemotherapy.
Not included
N = 67
Patients included, and filled 
in baseline questionnaires 
N = 135
Patients with complete
follow-up evaluation
N = 122
Lost to follow-up
N = 7
Patients eligible for the study 
N = 202
Patients with complete 
baseline evaluation
N = 129
No neuropsychological 
testing at baseline
N = 6
Paper II
Paper III and IV
ONE-CHEMO
group
n = 38
NO-CHEMO 
group
n = 31
MULTIPLE-CHEMO 
group
n = 53
Figure 4. Study sample in the Oslo-study (paper II, III and IV)
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4. METHODS
4.1. Questionnaires
European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life 
Questionnaire (QLQ)-C30 (Paper I) 
The EORTC QLQ-C30 is a widely used questionnaire for assessing health-related quality of 
life in cancer patients (Aaronson et al. 1993; Sprangers et al. 1993). The development of 
this questionnaire by the EORTC dates back to 1986, and the QLQ-C30 was validated by 
Aaronson and colleagues in 1993 (Aaronson et al. 1993). The QLQ-C30 has shown 
satisfactory internal consistency (Hjermstad et al. 1998) and good test-retest reliability 
(Hjermstad et al. 1995). Several versions of the QLQ-C30 exist, and currently version 3.0 is 
standard. In our study, comprising patients included in three randomized studies during the 
1990-ies, version QLQ-C33 and version 2.0 were used.
The QLQ-C30 assesses five functional domains: physical function, emotional 
function, social function, role function and cognitive function, as well as global QoL, and 
nine symptom scales including fatigue, pain and insomnia. By established algorithms 
(Aaronson et al. 1993) the QLQ-C30 items were transformed to function scales with scores 
from 0 (worst) to 100 (best), and fatigue, pain and insomnia from 0 (no symptoms) to 100 
(worst symptoms). The cognitive outcome measures (cognitive complaints) from the QLQ-
C30 are described in detail below (Section 4.4).
As explanatory variables in paper I we selected the functions and symptoms from 
QLQ-C30 which from a clinician’s point of view were most likely to be associated with 
cognitive complaints: emotional function, role function, social function, fatigue, and 
insomnia. Pain was excluded due to high correlation with fatigue. Considering the mean 
scores in a Norwegian population sample (Hjermstad et al. 1998), we defined the cut-off 
for good function at a score of  		!

absent by scores "#$#present as scores >16.67.
TC-module (paper I)
A TC-module developed by Fossa and colleagues (Fossa et al. 1996; Fossa et al. 2003) 
evaluate specific physical chemotherapy-related symptoms and emotional and sexual 
symptoms frequently reported by TCPs. From the TC-module we used the items covering 
peripheral neuropathy, Raynaud’s phenomenon and reduced hearing/tinnitus, summarized 
as neurotoxic symptoms, and transformed to a score from 0 (no symptoms) to 100 (worst 
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symptoms) (Aaronson et al. 1993; Fossa et al. 2003). The transformed score was then 
dichotomized into neurotoxicity symptoms absent (score"#$#%	present (score >16.67).
Impact of Event Scale (paper II, III and IV)
The Impact of Event Scale (IES) (Horowitz et al. 1979; Sundin and Horowitz, 2002) 
assesses the psychological response to a trauma which in our study was getting TC. The IES 
evaluates symptoms of intrusion (7 items) and avoidance (8 items) within the past week. 
Each item is rated from 0 (not at all) to 5 (often), with higher scores denoting more 
emotional distress. The Norwegian version of the IES has shown satisfactory psychometric 
properties (Eid et al. 2009), and the IES has been validated to measure cancer-related 
distress (Thewes et al. 2001). An IES-total score of >26 was used as a cut-off for clinically 
significant cancer-related distress in the Oslo-study (Tuinman et al. 2007).
Hospital Anxiety and Depression Scale (paper II)
The Hospital Anxiety and Depression scale (HADS) (Zigmond and Snaith, 1983) measures 
symptoms of anxiety and depression during the past week, and consists of two subscales: 
anxiety (HADS-A; 7 items) and depression (HADS-D; 7 items), summed up as HADS total 
score. Each item is scored from 0 (minimally present) to 3 (maximally present) and the 
subscale scores range from 0 to 21 with higher scores representing more symptoms. The 
psychometric properties of the HADS have been found good both in somatic patients and in 
the general population (Bjelland et al. 2002).
Positive and Negative Affect Scale, state version (paper II)
The Positive and Negative Affect Schedule (PANAS) state version (Watson et al. 1988) 
measures current affects, and contains 20 mood-descriptive adjectives; 10 on positive 
affects (PA) and 10 on negative affects (NA). Ratings are on 5-point Likert scales ranging 
from 1 (“not at all/very little”) to 5 (“very much”). Higher sum-scores indicate increasing 
level of current affect. The PANAS has shown good validity and reliability in the general 
adult population (Crawford and Henry, 2004).
Eysenck Personality Questionnaire, neuroticism scale (paper II, III and IV)
Neuroticism is a basic personality trait and represents the tendency to be nervous and to 
experience negative emotions. In our study neuroticism was rated at baseline with 6 items 
from an 18-items version of the Eysenck Personality Questionnaire (EPQ) (Eysenck, 1975; 
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Tambs K, 2004). Each item is rated as yes (1) or no (0), and the sum-score for neuroticism 
ranges from 0 (low) to 6 (high). The EPQ has showed satisfactory psychometric properties 
in a Norwegian twin sample (Eysenck and Tambs K, 1990).
CAGE questionnaire (paper II, III and IV)
Possibly hazardous alcohol-use was assessed at baseline in our study with a 4-items version 
of the CAGE questionnaire (Ewing, 1984), a well-validated screening measure for alcohol 
problems (Dhalla and Kopec, 2007). Each item is rated as yes (1) or no (0), and the sum-
score ranges from 0 (low) to 4 (high). As recommended, a sum-score of 
possibly hazardous alcohol in our study; however, the clinical value of this cut-off value has 
been debated (Aertgeerts et al. 2004).
Scale for Chemotherapy-Induced Neurotoxicity (paper III and IV)
Scale for Chemotherapy-Induced Neurotoxicity (SCIN) was derived from the TC-module
(Fossa et al. 2003) described previously, and was validated by Oldenburg and colleagues in 
2006 (Oldenburg et al. 2006a). The SCIN assesses symptoms of peripheral neuropathy 
(paresthesias in hands or feet), Raynauds phenomenon (white fingers or cold feet) and 
ototoxicity (tinnitus or hearing loss) on 4-point scales from 1 (no symptoms) to 4 (much 
symptoms). In the Oslo-study, the item-scores of SCIN were dichotomized into “symptoms” 
(score 3 or 4) vs. “no symptoms” (score 1 or 2).
Fatigue Questionnaire (paper III and IV)
The Fatigue Questionnaire (FQ) vas developed and validated by Chalder and colleagues in 
1993 (Chalder et al. 1993). The FQ provides scores for 7 physical and 4 mental fatigue 
items that are summed up as total fatigue. Each item is rated from 0 (less) to 3 (much more), 
hence total fatigue score ranges from 0 (low) to 33 (high). The FQ has shown good 
psychometric properties in the general population (Loge et al. 1998; Pawlikowska et al. 
1994).
In our study we defined that an increase of fatigue symptoms from baseline to 
follow-up was present if the total fatigue score at follow-up was &
	
baseline score. This represents approximately 10% change on the total fatigue scale.
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4.2. Semi-structured interviews
4.2.1. Background data (paper II, III and IV)
In a semi-structured interview at baseline, data on socio-demography, previous somatic and 
mental health, current medication, smoking and sleeping habits were collected. Further, the
perceived satisfaction by the patient concerning information about TC at the local hospital 
was recorded by the interviewer as “satisfied” or “not satisfied”. The patients were also 
classified by the interviewer as being generally well informed about TC or not.
At interviews at follow-up, data on current socio-demograhy, medication and 
somatic and mental health after the TC-diagnosis were collected. All interviews at baseline 
and follow-up were performed by Tone Skaali. The baseline and follow-up interview 
manuals are presented in Appendix B.
4.2.2. Cognitive complaints (Paper IV)
In the semi-structured interviews at baseline and follow-up, TCPs were also asked to 
describe their general concentration and memory function with the response alternatives 
very good, good, not so good, or poor (see Appendix B). The responses to both 
concentration and memory function were then dichotomized into “no complaints” (very 
good/good) and “complaints” (not so good/poor). A change of category in the dichotomized 
function-scores from baseline to follow-up was noted. If a patient changed category from no
complaints to complaints in either the dichotomized concentration and/or the memory score, 
then he was defined as reporting an increase of cognitive complaints from baseline to 
follow-up.
4.3. Neuropsychological evaluation
4.3.1. Measure of estimated intellectual functioning (paper II, III and IV)
An estimate of intellectual functioning was measured at baseline of our study by the 
Norwegian version of the National Adult Reading Test (NART) (Nelson and Willison, 
1991; Vaskinn and Sundet, 2001). The scores from this oral reading test are highly
correlated with standard IQ-scores from the Wechsler Adult Intelligence Scale (WAIS) 
(Nelson and Willison, 1991), and this has been shown also a Norwegian sample of healthy 
adults (Sundet K and Vaskinn A, 2008). The NART-scores range from 0 to 50, and a lower 
score indicates better intellectual functioning.
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4.3.2. Neuropsychological test battery (paper II, III and IV)
A neuropsychological test battery comprising of both computer-based and traditional 
neuropsychological tests was set up for our study in collaboration with Stein Andersson, an 
experienced neuropsychologist. The computer tests were selected from the Cambridge 
Neuropsychological Test Automated Battery (CANTAB) (Cambridge Cognition, 2005; 
Sahakian and Owen, 1992), which mostly comprises visuo-spatial tasks. Traditional tests 
were used to assess verbal and motor tasks. The battery was designed to assess five major 
cognitive domains listed in Section 1.2.2. The neuropsychological tests covering these 
domains are presented below, with specification if a computer or a traditional test. The tests 
were performed in a pre-defined order, with a few exceptions due to administrative reasons.
Attention, concentration and working memory: The Spatial Working Memory test 
(computer) (Cambridge Cognition, 2005) assessed visuo-spatial working memory, while the 
Choice Reaction Time test (computer) (Cambridge Cognition, 2005) measured speed of 
choice response.
Learning and memory: The Hopkins Verbal Learning Test-Revised (traditional)
(Brandt and Benedict, 2001) was used to assess verbal learning and memory, while the 
Paired Associates Learning test (computer) (Cambridge Cognition, 2005) assessed visual 
learning and memory.
Speed of information processing: The Trail Making Test part A (traditional)
(Reitan and Wolfson, 1993) and the Color-Word Interference Test part 1 and 2 (traditional)
(Delis et al.  2000) were used to measure psychomotor speed. 
Executive functions: The Color-Word Interference Test part 3 and 4 (traditional)
(Delis et al. 2000) were used to assess response inhibition and shifting and the Trail 
Making Test B (traditional) (Reitan and Wolfson, 1993) assessed set-shifting ability. Verbal 
fluency was tested with the Word fluency (FAS) test (traditional) (Ruff et al. 1996). 
Two supplementary computer tests of executive functions were included in the 
battery at baseline if time allowed for it and the patients were motivated. They were the 
Stockings of Cambridge test (Cambridge Cognition, 2005) which assessed spatial planning 
and motor control and the Intra-Extra Dimensional Set Shift test (Cambridge Cognition, 
2005) which evaluated rule acquisition and set-shifting. If any of the supplementary tests 
were completed at baseline then the patient completed the same tests at follow-up.
Motor function: The Grooved Pegboard test (traditional) (Reitan and Wolfson, 
1993) was used to assess visual-motor coordination and speed, using both dominant and 
non-dominant hand. 
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The basic neuropsychological test battery comprised 8 tests which yielded 15 sub-
test measures. The two supplementary executive tests gave an additional three sub-test 
measures. Hence, the total test battery comprising all 10 tests gave a total of 18 sub-test 
measures. All neuropsychological tests and sub-test measures reported are listed in 
Appendix C. 
4.4. Definitions of main outcome measures
4.4.1. Cognitive complaints (Paper I: The 1990’ies study)
Cognitive complaints were assessed by responses to the two cognitive questions of the 
QLQ-C30: “Have you had difficulty in concentrating on things, like reading a newspaper or 
watching television?” (item #20) and “Have you had difficulty remembering things?” (item 
#25). There were four response-alternatives: “not at all”(1), “a little”(2), “quite a bit”(3) and 
“very much”(4), and the time frame were the past week. We defined three separate outcome 
measures: the scores of item #20 (concentration), the scores of item #25 (memory) and the 
cognitive function (CF) scores defined according to the QLQ-C30 (Aaronson et al. 1993) as 
a combination of the memory and concentration scores transformed to a scale from 0 
(worst) to 100 (best), with intervals of 16.67 points.
A representative sample of Norwegian men aged 20 to 59 years had mean CF scores 
between 86.5 and 91.6 according to 10 year age groups (Hjermstad et al. 1998). On this 
background and due to skewed distributions of scores, the three outcome variables of 
cognitive complaints were defined as follows: concentration and memory problems absent
(“not at all”) or present (“a little”/”quite a bit”/”very much”), and CF problems absent
(score 100) or present (score '&$&&%$
4.4.2. Strength of associations between distress and neuropsychological test results (Paper 
II: The distress paper)
The main purpose of paper II was to explore the associations between current levels of 
emotional distress and the neuropsychological test scores at the baseline evaluation. Hence 
the strength of associations (standardized beta values and p-values) between the IES-total 
score / the HADS-total score / the PANAS negative score and each of the 18 
neuropsychological test scores were the main “outcome measures” in this study.
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4.4.3. Changes in neuropsychological test performance (Paper III: The neuropsychological 
paper) 
In paper III exploring eventual changes in neuropsychological functioning in TCPs from 
baseline to follow-up in our study, both group and individual analyses were performed. For 
the group analyses, the outcome measures were the differences (between baseline and 
follow-up) in neuropsychological raw-scores for each of the 18 test measures.
As to the individual analyses, we classified each patient as showing decline or no 
decline in neuropsychological test performance from baseline to follow-up. This categorical 
variable was the main outcome variable for the individual analyses. The method for 
classification of individual decline in neuropsychological test performance is presented 
below under statistical procedures in Section 4.6.3.
4.4.4. Increase of cognitive complaints (Paper IV: The self-report paper)
Based the responses at the baseline and follow-up interviews concerning the patients’ self-
rating of memory and concentration function, we constructed a categorical variable defining 
an increase versus no increase of cognitive complaints from baseline to follow-up. This 
categorical variable represented the main outcome variable in paper IV. The procedure for 
categorization of this variable has been described previously in Section 4.2.2.
4.5. Data management
4.5.1. Paper I
The selected data (see selection procedure in Section 3.1) was merged into one data file for 
the statistical analyses. No imputation of missing data was performed, neither for the 
outcome (cognitive complaints) or the explanatory variables.
4.5.2. Paper II-IV
Interview-data and neuropsychological test results were manually entered into data files. 
Completed questionnaires were scanned, and added to the data files. Data files were 
carefully checked for coding errors and prepared for the analyses. No imputation of missing 
data was performed. 
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4.6. Statistical procedures 
4.6.1. General
Different versions of the statistical software program SPSS (Statistical Package for the 
Social Sciences), after 2009 changed to PASW Statistics (Predictive Analytics SoftWare),
were used for the statistical analyses (SPSS Inc, Chicago IL). All statistical tests were two-
sided, and p-values p<0.05 were considered as statistical significant except in paper I where 
the significance level was set at p<0.01 due to multiple testing.
Descriptive statistics and group comparisons were performed with parametric or 
non-parametric tests as appropriate. For continuous variables Students t-test or Mann-
Whitney Wilcoxon test were used if two groups were compared, and analysis of variance 
(ANOVA) or Kruskall Wallis test were used if three groups were compared. For categorical 
variables Pearson’s chi-square test or Fisher’s exact test were used. Correlations were 
assessed with Pearson’s correlation coefficient (parametric data) or Spearman’s coefficient 
rho (non-parametric data). Internal consistency was described by Cronbach’s coefficient
alpha.
4.6.2. Paper I (The 1990’ies study)
Changes over time and inter-group differences (CHEM vs. RAD group) in the proportions 
of patients with cognitive complaints (concentration problems, memory problems and CF-
problems) were analyzed with 2x2 contingency tables and Fisher’s exact test.
At each time-point, bivariate and multivariate logistic regression analyses examined 
the associations between cognitive complaints (dependent variable) and independent 
variables (treatment group [RAD group as reference] and the self-reported QoL 
function/symptoms). The strength of the associations were expressed as odds ratios (ORs) 
with 95% confidence intervals (95% CI). Age was not entered as independent variable in the 
multivariate analyses since it did not show significant bivariate associations with any of the 
outcome variables at any time point.
With bivariate and multivariate logistic regression analyses we then explored if any 
of the pre-treatment QoL variables were predictors of cognitive complaints at 12 months. 
4.6.2. Paper II (The distress paper)
Univariate and multivariate linear regression analyses explored the association between the 
IES-total score (dependent variable) and relevant independent variables. Independent 
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variables were entered in a multivariate linear regression analysis if they showed p-values 
<0.10 in the bivariate ones.
Stepwise multivariate linear regression analyses were performed to explore the 
association between current distress-scores and neuropsychological test-results. In these 
analyses the score of the IES-total, the HADS-total or the PANAS-NA was independent 
variable, and each of the 18 neuropsychological test-scores was dependent variables. Some 
of the neuropsychological test scores were logarithmic or square-root transformed in order 
to achieve a better model fit. From these stepwise analyses, the p-values are reported, both 
crude and after adjustment for NART, level of education and age.
4.6.3. Paper III (The neuropsychological paper)
Group analyses: Raw-scores on the neuropsychological test-measures at baseline 
and follow-up were compared across treatment groups with the Kruskall-Wallis test. 
Changes in raw-scores (follow-up score subtracted from baseline score) were compared 
with analyses of covariance (ANCOVAs) with age at baseline and follow-up time as 
covariates.
Individual analyses: From prospective studies of breast cancer patients, only a 
subset of the patients (if any) showed decline in neuropsychological test performance from 
baseline to follow-up. Hence, group analyses comparing the mean group change-scores may 
obscure individual changes in test performance. To account for such individual changes, 
individual analyses assessing the change in test performance from baseline to follow-up in 
each person have been recommended in this field (Vardy et al. 2007). 
Several statistical methods for the assessment of individual change have been 
proposed (Vardy et al. 2007) including the reliable change index (RCI) and the 
standardized regression-based (SRB) models. The SRB-model has the advantage of 
allowing adjustment of the neuropsychological test results for relevant covariates, and may 
possibly be more sensitive for individual change than the RCI (Ouimet et al. 2009). We 
therefore chose the SRB-model for assessing individual change in test performance in our 
study.
The SRB-model utilizes the baseline and follow-up scores of a control group (in our 
study the NO-CHEMO group) to derive regression equations that predict an individual’s 
follow-up score on a test-measure, based on this person’s baseline-score and some selected 
covariates. Due to limited group sizes, only age and estimated intellectual functioning 
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(NART score) were used as covariates in our study. Again, some of the neuropsychological 
test scores were logarithmic or square-root transformed to achieve better model fit.
Applying the SRB-model a predicted follow-up score on each test-measure for each 
individual was obtained. An individual z-score of change was then obtained for each test-
measure by subtracting the person’s actual follow-up score from the predicted score, and 
dividing the difference by the standard error of estimate (derived from the control group). 
The obtained z-score of change represents the standardized magnitude and direction of the 
difference between the expected and actual follow-up score. In our study, a z-score of 
change outside ±1.64 SD was defined as a reliable decline or improvement from baseline to 
follow-up on the reported test-measure.
No established cut-off values exist in the literature concerning the proportion of 
declined or improved test-measures needed in order to define a relevant individual change
in neuropsychological performance over time. Based on prospective studies conducted in 
breast cancer patients (Jenkins et al. 2006; Stewart et al. 2008), we defined that individual
decline had occurred with reliable decline on "()	-measures, and individual 
improvement correspondingly. To examine the consequences of our chosen proportions, we 
also assessed individual changes using 15 % as a cut-off. Finally, we explored the 
relationship between the proportion of test-measures with decline and improvement for each 
individual. If the proportion of test-measures with decline was "()		
proportion of measures with improvement, the individual was defined as showing overall 
decline in neuropsychological test performance. 
The proportions of patients with individual decline, improvement and overall decline
with the various definitions described above were compared across the treatment groups.
Finally, we assessed cognitive domain z-scores of change by averaging the z-scores 
of change for all test-measures of a given cognitive domain in each individual (the test-
measures representing each cognitive domain are presented in Appendix C). These cognitive 
domain z-scores of change were compared across the three treatment group by analyses of 
variance (ANOVAs).
4.6.4. Paper IV (The self-report paper)
Pearson’s chi-square test was used to explore differences across the three treatment groups 
in proportions of TCPs with an increase of cognitive complaints from baseline to follow-up.
Descriptive statistics were used for the characterization of TCPs with an increase of 
cognitive complaints.
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4.7. Ethical considerations
4.7.1. Paper I
The EORTC / MRC trials were approved by the local research ethical committees of each 
participating center. All patients provided written informed consent. 
4.7.2. Paper II-IV
The Oslo-study was approved by the Ethical Committee of the Southern Health Region of
Norway (ref. S-05362) and the National Data Inspectorate. All patients delivered a written 
informed consent. 
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5. RESULTS
5.1. Main findings of Paper I (The 1990’ies study) 
5.1.1. Characteristics of the sample 
Attrition analyses showed no significant differences in age or in proportions of patients with 
concentration or memory problems before treatment between the examined sample of 347 
TCPs fulfilling the selection criteria and the 404 TCPs with valid baseline data but excluded 
due to missing data at 3 or 12 months. However, a larger proportion of the excluded patients 
had non-seminoma compared to the included patients (70% vs. 61%, p=0.005).
Among the 347 included TCPs, the mean age of patients at baseline was 
significantly lower in the CHEM group (33.0 years ±8.8) compared to the RAD group (38.2 
years ±8.0). At 3 month follow-up, the CHEM group had significantly higher proportions 
with reduced function on emotional function, social function, role function and higher 
proportions of patients with fatigue and neurotoxic symptoms compared to the RAD group. 
None of these functions or symptoms showed significant inter-group differences at baseline 
(before treatment) or at 12 month follow-up except that the CHEM group had significantly 
more neurotoxic symptoms at 12 months compared to the RAD group.
5.1.2. Changes in cognitive complaints over time, intergroup differences and variables 
associated cognitive complaints (Aim 1)
At baseline, in the CHEM group 23% had concentration problems, 23% had memory 
problems, and 37% had CF-problems. The corresponding proportions in the RAD group 
were 21%, 20% and 27%. At 3 months, the proportions of patients with concentration 
problems were 39% (CHEM group) / 20% (RAD group), memory problems 38% / 31% and 
CF-problems 52% / 34%. At 12 months the equivalent proportions were: 15% / 15%, 29% / 
28 % and 33% / 33%.
These proportions implied that significantly more patients in the CHEM group had 
concentrations problems and CF-problems at 3 months compared to baseline and at 12 
months. Further, the proportions of patients with concentration problems and CF-problems
were significantly higher in the CHEM than in the RAD group at 3 months. This contrasts 
with the findings at baseline and 12 month, where no significant intergroup differences in 
prevalence of concentration problems and CF-problems were observed. For memory 
problems, no significant changes over time were found for any of the treatment groups and 
no significant inter-group differences were observed at any time point.
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In bivariate analyses, belonging to the CHEM rather than the RAD group was 
significantly associated with concentration problems and CF-problems at 3-months (OR 2.6 
and 2.1 respectively), while this was not the case at baseline or 12 months. However, in 
multivariate analyses with adjustment for relevant QoL domains no significant associations 
were observed between treatment type and cognitive complaints at any time point. In these 
multivariate analyses we found that current fatigue was significantly associated with 
cognitive complaints in six out of the nine analyses (3 outcome measures x 3 time points). 
Correspondingly, insomnia and reduced social function were significantly associated with 
cognitive complaints in four analyses, and reduced emotional function in three analyses. 
Reduced role function and neurotoxic symptoms showed no significant associations with 
cognitive complaints at any time point.
5.1.3. Pre-treatment variables associated with cognitive complaints at 12 months (Aim 2)
In bivariate analyses exploring the relation between pre-treatment QoL functions and 
symptoms and cognitive complaints at 12 months, reduced emotional and social functions, 
as well as more fatigue and neurotoxic symptoms before treatment were significantly 
associated with concentration problems at 12 month follow-up. For memory problems no
significant predictors before treatment were identified, and for CF-problems only reduced 
emotional function was significant in bivariate analyses. In multivariate logistic regression 
analyses none of the pre-treatment variables significantly predicted the presence of 
cognitive complaints at 12 month follow-up.
5.2. Paper II-IV - The Oslo-study: Description of the sample
In the Oslo-study, attrition analyses showed no significant differences between 129 included 
and the 73 non-included TCPs concerning age or stage of TC at diagnosis, whereas a 
significantly larger proportion of the included patients had non-seminoma compared to the 
non-included (49% vs. 29%, p=0.005).
Among the 122 TCPs re-evaluated at follow-up, 89 (73%) were tested with one or 
two of the supplementary tests. The distribution of the 122 TCPs in the three treatment 
groups were as follows: NO-CHEMO group (N=31), ONE-CHEMO group (N=38) and 
MULTIPLE-CHEMO group (N=53).
As expected, a significantly larger proportion of TCPs in the MULTIPLE-CHEMO 
group had metastatic disease and non-seminoma compared to the NO and the ONE-
CHEMO groups. Age at baseline was significantly higher in the ONE-CHEMO group 
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(median 35 years) compared to the NO-CHEMO (median 32 years) and the MULTIPLE-
CHEMO group (median 30 years). No statistically significant group differences were found 
for follow-up time, NART-score, level of education or other demographic variables.
The two chemotherapy groups had statistically significantly higher total-fatigue 
scores than the NO-CHEMO group both at baseline and follow-up (mean total-fatigue 
scores: NO-CHEMO group 12.2 (baseline) / 11.4 (follow-up); ONE-CHEMO group 14.8 / 
14.0; and MULTIPLE-CHEMO group 13.8 / 14.3), while no significant group differences 
were observed concerning level of emotional distress (IES score) at baseline or at follow-up.
The presence of self-reported peripheral neurotoxic symptoms did not differ significantly 
across treatment groups at baseline, while at follow-up a significantly larger proportion in 
the MULTIPLE-CHEMO group had Raynaud-like symptoms compared to the two other 
groups (NO-CHEMO group 3%; ONE-CHEMO group 13%; MULTIPLE-CHEMO group 
48 %).
5.3. Main findings of Paper II (The distress paper)
5.3.1. Cancer-related distress (Aims 1 and 2)
Clinically significant cancer-related distress, defined by an IES-total score >26, was 
observed in 24% (95%CI 17%-31%) of the sample at baseline. 
None of the demographic, cancer-related variables, or the perceived level of 
information about TC were significantly associated with level of cancer-related distress 
(IES-total score) in bivariate linear regression analyses. In contrast, daily smoking, 
hazardous alcohol use, previous mental problems, sleeping problems and higher level of 
neuroticism displayed significant bivariate associations. In multivariate regression analysis, 
higher level of neuroticism, daily smoking and hazardous alcohol-use remained significantly 
associated with the level of cancer-related distress.
5.3.2. Associations between current emotional distress and neuropsychological test-results 
(Aim 3 - main study aim)
The 18 baseline neuropsychological sub-test scores (Appendix C) were tested for 
associations with the baseline sum-scores of the IES-total, the HADS-total, and the 
PANAS-Negative Affects (NA) emotional distress scales. After adjusting for NART score, 
education level and age, four out of the 18 test scores were significantly associated with at 
least one of the three distress scale scores: The total errors on Spatial Working Memory test 
was significantly associated with the scores of the HADS-total and the PANAS-NA; the 
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latency time on Choice Reaction Time test was significantly associated with the scores of 
the IES-total and the PANAS-NA; and the time used on Color-Word Interference test part 1 
and 3 were significantly associated with the IES-total score. All significant associations 
were inversely correlated, which implies that higher distress scores were associated with 
lower achievements on these tests.
The remaining 14 neuropsychological sub-test scores were not significantly 
associated with any of the distress scale scores after adjustment for NART, education level 
and age.
5.4. Main findings of Paper III (The neuropsychological paper)
5.4.1. Changes in neuropsychological test performance from baseline to follow-up (Aim 1)
Group analyses: There were no significant group differences on raw-scores at 
baseline or follow-up on any of the 18 test-measures, except that the NO-CHEMO group 
had significantly fewer errors on the Spatial Working Memory test at baseline compared 
with the two other groups. No significant group differences were found for change in raw-
scores from baseline to follow-up (adjusted for age and follow-up time) for any of the 18
neuropsychological measures.
Individual analyses: Applying the SRB-analyses, we found that the proportions of 
TCPs that exhibited reliable decline on any of the 18 test-measures ranged from 0% to 23% 
while the proportions of patients that exhibited reliable improvement ranged from 0% to 
39%. 
Using the pre-defined definitions of individual change in neuropsychological test 
performance, no statistically significant group differences in proportions of TCPs with 
individual decline on "()-measures or overall decline were observed. 
However, significantly larger proportions of TCPs in the ONE- and the MULTIPLE-
CHEMO groups showed improvement on "()
	*+-CHEMO 
group.
Employing a 15% cut-off did not significantly change these results, except that no 
significant difference between the NO- and the ONE-CHEMO groups in proportions of 
TCPs with improvement was found.
Finally, we found no significant differences across the three groups concerning 
cognitive domain z-scores of change for any of the five cognitive domains studied.
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5.4.2. Variables associated with a decline in neuropsychological test performance (Aim 2)
Decline in neuropsychological test performance (decline on "()
neuropsychological test-measures) was not significantly associated with any of the 
demographic variables (age, education or NART score) or the cancer-related variables 
(treatment with chemotherapy, metastatic disease or follow-up time), and neither with the 
scores (or change-scores) of emotional distress or fatigue. In contrast, decline in 
neuropsychological test performance was significantly associated with worsening of 
ototoxic symptoms (tinnitus/hearing loss), while no such association was found for 
worsening of peripheral neuropathy or Raynaud-like symptoms.
5.5. Main findings of Paper IV (The self-report paper)
5.5.1. Proportions of TCPs with an increase of cognitive complaints from baseline to 
follow-up (Aim 1)
Twenty-five TCPs (20%) had an increase of cognitive complaints from baseline to follow-
up. There was a significant (p=0.02) difference across the three treatment groups in 
proportions of TCPs with an increase of cognitive complaints: larger proportions in the 
ONE-CHEMO group (29%) and the MULTIPLE-CHEMO group (25%) had an increase of 
complaints compared to the NO-CHEMO group. However, no significant difference 
appeared between the ONE and the MULTIPLE-CHEMO group. 
5.5.2. Variables associated with an increase of cognitive complaints (Aim 2)
Among the 25 TCPs with an increase of cognitive complaints from baseline to follow-up, a 
significantly larger proportion of patients had received chemotherapy (96% vs.69%), had 
worsening of fatigue score (50% vs.22%) and of Raynaud-like symptoms (42% vs.16%), 
had lower level of education (68% vs.44%) and reported mental problems before TC (48% 
vs.19%) compared to those without an increase of cognitive complaints. Further, TCPs with 
an increase of cognitive complaints had significantly higher follow-up scores of emotional 
distress (median IES-total score 15.5 vs.10) and fatigue (median total-fatigue score 16 
vs.11) compared to those with no such increase of complaints.
No statistically significant association was found between an increase of cognitive 
complaints and a decline in neuropsychological test performance from baseline to follow-up
(p=0.82).
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6. DISCUSSION
6.1 Methodological considerations 
6.1.1. Study design considerations
Clinical studies may have cross-sectional or prospective (longitudinal) designs. In cross-
sectional studies, patients are evaluated at one time-point and changes over time cannot be 
assessed. No causal conclusions can be drawn from cross-sectional studies, only 
associations between the variables. In prospective (longitudinal) studies, a group of 
individuals (cohort) who are similar in many ways (e.g. by having TC), but differ by certain 
characteristics (e.g. by receiving surveillance or various number of cycles with 
chemotherapy) are followed over time, and an outcome measure and its changes can be 
studied over time (such as the development of side-effects like cognitive complaints). 
Prospectively designed studies are well suited to identify possible predictors for an outcome.
In this thesis paper II is a cross-sectional study, while paper I, III and IV concern 
prospective ones for the following reasons: In general, large inter-individual variations in 
neuropsychological test performance are expected, and eventual negative cognitive effects 
of cancer treatment may affect only a subgroup of individuals. Based on these 
considerations prospective studies, including a pre-treatment evaluation with the patient 
serving as his/her own control, have been considered as the optimal design (Tannock et al. 
2004). We therefore chose this design in the two studies of this thesis. However, the 
1990’ies study (paper I) was “retrospective” in the sense that the data had already been 
collected in previous EORTC-trials, but we used these prospectively collected data to assess 
a secondary outcome (cognitive complaints) not focused on in the primary studies. Our aim 
in that paper was to study if exposure to chemotherapy was followed by significantly more 
cognitive complaints compared to radiotherapy.
The Oslo-study (paper II-IV) was clearly a prospective cohort study, where we 
followed a defined cohort over time in order to explore if there was a causal relationship 
between chemotherapy and changes in cognitive function. Such a design was obvious, since 
our main aim was to study if exposure to chemotherapy was followed by reduction in 
neuropsychological test results and increase in cognitive complaints compared to contrast 
groups.
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6.1.2. Statistical power considerations
In clinical studies, an adequate sample size is needed so that group differences of relevant 
size can be discovered with confidence. This methodological demand is usually called 
“adequate statistical power” of the study. If the groups compared are (too) small, only big 
differences can become significant, and there is a risk that study is under-powered (type II 
statistical errors). In type I errors the sample sizes are so big that clinically meaningless 
differences become statistically significant. In the Oslo-study, a risk of type II errors 
(relevant in paper III and IV) will be discussed further in Section 6.1.4.
6.1.3. Bias considerations
Systematic error in the design or the conduct of a study is called bias. Biases may occur due 
to flaws in the methods of selection of study participants, or in the procedures for gathering 
relevant data. As a consequence, the observed study results of the sample will tend to differ 
from the true results of the population (Szklo N and Nieto FJ, 2004). Bias (systematic error) 
should be distinguished from random variability which is the fact that when something is 
studied in a sample drawn from the population of interest; the sample estimates may differ 
from the true parameters in the population (Szklo N and Nieto FJ, 2004). Biases possibly 
relevant for the studies of this thesis are presented below.
Selection bias may occur if the included study sample is not representative of the 
population approached. Attrition analyses are usually performed to explore if the included 
and non-included samples differ significantly, hence exploring the external validity of the 
studied sample. However, regularly only limited information about patients not included in 
the study can be retrieved for ethical reasons. Attrition analyses can therefore usually be 
performed only on available “register data”, such as stage of disease, histology and age. 
In the Oslo-study, attrition analyses showed no significant differences between 
included and the non-included TCPs concerning age or stage of TC at baseline. In contrast, 
significantly larger proportion of included patients had non-seminoma compared to those 
not included, indicating a possible selection bias. However, among the included TCPs the 
proportions of patients with non-seminoma vs. seminoma were 49% and 51% respectively, 
and this is in line with the distributions found in population-based large samples of TCPs 
(Horwich et al. 2006). As the main study aim was to explore individual changes in 
cognitive function in TCPs treated with different modalities, we hardly believe that a 
difference in histology between included and non-included patients represents a serious 
concern to the validity of the study.
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In prospective studies, selection bias may also occur if patients with specific 
characteristics withdraw from the study, e.g. if cancer patients with advanced disease more
often are lost to follow-up than patients with localized disease. In the Oslo-study only seven 
patients (5%) of the patients were lost to follow-up. However, four out of these seven 
patients had received multiple cycles of chemotherapy, so withdrawal was not equally 
distributed between the three treatment groups.
Information bias involves errors that may occur if the methods (measures) for data 
assessment are inappropriate, leading to erroneous information or data. For example, in 
neuropsychological testing it is important that test instructions are given in a standardized 
manner, as was done in the Oslo-study. However, since the same person (Tone Skaali) 
conducted both the testing and the interviews, expectation bias (see below) on her part in 
the interviews could possibly have been a problem. A standardized interview manual 
(Appendix B) and coding of the responses was used, however, and this probably reduced the 
risk for such bias.
All measures used in a study should show appropriate psychometric properties – i.e. 
being reliable (precise) and valid (capturing the true information about a concept) – in order 
to avoid measurement bias. In the Oslo-study, possible ceiling effects on the 
neuropsychological tests could have threatened the validity of the neuropsychological test 
results. However, most of the test results from our study had relatively broad distributions in 
the range of scores, indicating that ceiling effects rarely occurred.
Other types of information bias are expectation bias [when the patient reports (or the 
observer classify) data toward the expected or wished outcome] or memory bias (when the 
patients selectively recall past events). In the Oslo-study, both expectation and memory 
biases could theoretically be operating during self-report of cognitive complaints in the 
interviews (paper IV). A main aim of the 1990’ies study (paper I) was to prevent 
expectation bias concerning cognitive complains caused by public knowledge of such 
effects (“chemo brain”) after chemotherapy. The self-report data were collected before 
“chemo brain” was publicly known, and cognitive function was not a focus of the original 
studies.
6.1.4. Study samples
In the 1990-ies study (paper I), we aimed to prospectively compare cognitive complaints 
during the 12 months after diagnosis between TCPs treated and not treated with 
chemotherapy. Since we did not have access to data from TCPs who had received 
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surveillance only, TCPs treated with radiotherapy was used as the control group. This is a 
limitation of the study, since radiotherapy hypothetically could affect cognitive function; 
however due to anatomy we hardly believe that abdominal radiotherapy could have a 
substantial long-term negative effect on cognitive function in TCPs. Secondly, we included 
only TCPs <60 years old at baseline who had delivered questionnaires in the accepted time-
windows and had filled in both cognitive items at all three time-points. In order to study 
changes over time in cognitive complaints in a relevant study sample (not including men 
with cognitive decline due to age) during the 12-months study period, this selection 
procedure was necessary. However, by this selection procedure the study sample included 
only 46% of the patients with valid baseline data. We considered imputation of missing 
concentration and memory scores in the EORTC QLQ-C30, but with only two cognitive 
items, we regarded imputation as contraindicated. The high “attrition” rate is a limitation of 
paper I. With the smallest group size of 71 patients, the 1990-ies study was powered to 
detect group differences of moderate and large effect sizes (estimated Cohens d 
($,'%-.	
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In the Oslo-study (paper II-IV), 202 patients with TC were admitted to the two 
participating hospitals during the sampling period. Among them, 129 were recruited and 
examined at baseline (64%) and 122 re-examined at follow-up (95% of those examined at 
baseline). A practical challenge was that all baseline evaluations of this study had to be done 
during or after the medical evaluation at the NRH/UUS, but before the start of any 
chemotherapy. This time-window was quite short in many cases, and some patients were 
lost for inclusion due to time constraints.
Some selection bias may have occurred without our intent. Possibly some of the 
most well-functioning and “busiest” patients, with no time to spare for our study, declined 
to participate. Also, some of the most distressed patients may possibly have declined study 
participation, as they felt they had enough just dealing with their current stressful life 
situation. Also, TCPs with very advanced disease needing immediate treatment with 
chemotherapy were not eligible for inclusion.
This study introduced cognitive dysfunction as a “new” eventual adverse effect of 
chemotherapy to the TCPs, and we were worried if this would induce concerns in some of 
the patients. However, we took the outmost care by cautiously presenting the study aims to 
the patients. Anyhow, some patients may have been provoked or scared by the cognitive 
testing part, and therefore declined to participate. Altogether, we regard an inclusion rate of 
64% to be fairly good, taken into account that the study was quite effort-demanding and 
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time-consuming for the patients included. A considerable strength of the study is the high 
follow-up rate (95%).
As to the sample size, and the power to detect group differences, we admit that our 
sample sizes were mostly small, with a define risk for type II statistical error. However, for 
the sampling practical matters were a constraint, since the recruitment of patients and the 
baseline and follow-up testing had to be done within a three year PhD-period. 
As our study had consecutive design, and since many TCPs in Norway receive only 
one course of chemotherapy, a division into three treatment groups was natural in relation to 
our study aims. However, by comparing three instead of two groups, more included patients 
were needed in order to obtain adequate power for the statistical analyses. With a follow-up
sample size of 122 patients divided on three groups, we were able to detect group 
differences of medium and large of effect size (estimated Cohen’s d ($#%-.	
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and Myors B, 2004). Our study was therefore not powered to detect small differences in 
effect size, and a certain risk of type II error is acknowledged in paper III and IV. However, 
group differences with small effect sizes may not necessarily be clinically significant in 
relation to cognitive function.
6.1.5. Time points for the evaluations 
In the 1990’ies study (paper I), evaluations at pre-treatment, at short term, and at longer 
term follow-up were of interest. In the QoL-study by Fosså et al (Fossa et al. 2003), hardly 
any changes in function and symptom scores were observed from 12 and 24 months follow-
up. Due to this finding and the considerable attrition between the 12 and 24 month 
evaluations in the EORTC-studies, we chose 12-months as the time point for longer term 
follow-up in order to keep the sample size as large as possible.
In the Oslo-study (paper II-IV), practical reasons hindered a 3-month evaluation, as 
the research fellow (Tone Skaali) performed all evaluations both at baseline and follow-up.
From a clinical perspective we were mostly interested in any longer term effects of 
chemotherapy on cognitive function. We therefore decided that follow-up evaluations were 
to be performed 12 months after end of chemotherapy or start of the surveillance period. 
However, this implicated that the test-retest interval differed between patients treated with 
chemotherapy and with surveillance. Anyhow, we chose this time-point for follow-up,
however, due to correspondence with the regular 12-month follow-up visits for the TCPs. 
Many of our patients lived far from the Clinics, and we assumed that if the follow-up
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examination in our study was done the same day as their visit, compliance would be 
benefited. The high follow-up rate indicates that this was a reasonable procedure.
6.1.6. The measures used
In the 1990’ies study (paper I) we used pre-collected data, and both the outcome variable 
(cognitive complaints) and the explanatory variables were assessed with the EORTC QLQ-
C30 and TC-module used in these studies. The QLQ-C30 has two items on cognitive 
function (concentration and memory) that can be combined to “cognitive function”. Of 
course, to use an instrument with just two items provided only a rough measure of cognitive
complaints. However, the QLQ-C30 is in common use in oncology, and the instrument has 
well-documented psychometric properties (Aaronson et al. 1993).
As to the Oslo-study (paper II-IV), some considerations regarding the measures used will 
be presented.
Neuropsychological test methods (outcome variable): We chose a combination of 
traditional “paper and pen” and computer-based tests. The traditional tests are regularly used 
by Norwegian neuropsychologists, and they are regarded as valid and reliable instruments. 
The computer tests were, however, new to our research group but were included since they 
may be more sensitive to small cognitive changes compared to traditional tests, and since 
computer-based tests were recommended in the field (Tannock et al. 2004). 
After study start, we realized that the total test battery with 10 tests (including 18 
test-measures) was too time-consuming and demanding for the TCPs at the baseline 
evaluation. We therefore decided that two time-consuming computerized tests of executive 
functions were done as optional, both since we had several executive tests, and since these 
computer-based tests were the least commonly used ones. Ideally, we should have 
performed a feasibility study of the test battery before study start, in order to establish a 
realistic and adequate size. However, time constraints did not allow for this.
A general problem of the neuropsychological studies previously presented in this 
thesis is the variation in the selection and the number of tests used. This critique may be 
raised to our study as well, since we included some computer-based tests not commonly 
used. The International Cancer and Cognition Task Force (ICCTF) group has initiated work 
to develop a standardized neuropsychological test-battery to be used in future studies of 
cognitive function in cancer patients (Vardy et al. 2008). This initiative will allow for better 
opportunities for comparison across studies, and will facilitate meta-analyses.
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Evaluation of cognitive complaints (outcome variable): Cognitive complaints were 
assessed by interviews of the patients only, as no reports from partners or close other was 
obtained. As mentioned previously, expectation or memory bias could have been a problem 
in the self-evaluation. Further, the research fellow (Tone Skaali) performed both the 
interviews and neuropsychological testing, and expectation bias on her part could 
hypothetically have arisen as described in Section 6.1.3. However, from the patients’ point 
of view, to be evaluated by the same professional probably was a positive factor. Finally, 
inclusion of a validated questionnaire assessing broader aspects of self-assessed cognitive 
functioning could have been beneficial for our study. However, such questionnaires are 
quite comprehensive and time consuming, and no such instrument was included.
Questionnaires (explanatory variables): Questionnaires well-known in our research 
group and with good psychometric properties were chosen to assess clinically relevant 
explanatory variables such as emotional distress, fatigue, neuroticism, alcohol-use and 
symptoms of peripheral neurotoxicity.
The IES was our measure for the assessment of cancer-related emotional distress. 
However, several cut-off values for clinical significant distress on the IES-total score with a 
possible range from 0-75 exist in the literature. We used a cut-off score of 26, since this 
score had been used in a previous study on emotional distress in TCPs (Tuinman et al. 
2007). In paper II we also included the distress-scale scores of the HADS and the PANAS-
NA, in order to explore the associations between several distress-scale scores and 
neuropsychological test results. The correlation coefficients between the three distress scale 
scores ranged from 0.63-0.67 (explaining 40-45% of the common variance between the 
measures), indicating that these measures captured partly different dimensions of distress.
Finally, it could have been of value if the EORTC QLQ-C30 questionnaire had been 
included in the Oslo-study, since that questionnaire was used in the QoL-study that made 
basis for our study (Fossa et al. 2003) and in paper I. However, due to time constraints we 
had to limit the number of questionnaires and this questionnaire was not included.
6.1.7. Statistical issues
6.1.7.1. General
Confounder effects are factors that influence the relationship between the independent and 
the dependent variables. As mentioned in the Introduction, Section 1.2.2, level of emotional 
distress may possibly be confounder when interpreting neuropsychological test results in 
relation to treatment groups.
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In the Oslo-study we were concerned if high levels of emotional distress shortly after 
the TC-diagnosis would confound the neuropsychological test results at baseline, and this 
concern was the basis for the study in paper II. As mentioned in the Results, Section 5.3.2 
on paper II, this influence was limited to four out of 18 test measures. Consequently we 
concluded that the neuropsychological test battery was relatively robust for the influence of 
current level of emotional distress.
6.1.7.2. Paper I (The 1990’ies study)
In order to assess the prevalence of cognitive complaints in the TCPs we dichotomized the 
QLQ-C30 cognitive function scores. The cognitive complaints variables concentration
(range 1-4), memory (range 1-4) and summary cognitive function scores (range 0-100) were 
all significantly skewed; the cognitive function scores had a median value of 100 at all time-
points. We therefore considered “not at all” to be reference and other scores to be problems.
This decision implied that a score of “a little” difficulty on concentration and memory, as 
well as a score of 83.33 on a scale from 100 (best) to 0 (worst) were to be considered as 
cognitive complaints. Our definitions thus implied that any deviance from perfect score on 
the three complaint variables implied complaint present. By this strict definition, we may 
have overestimated the prevalence of cognitive complaints of practical relevance among the 
TCPs.
6.1.7.3. Paper II (The distress paper)
We performed multiple analyses exploring the associations between three distress-scores 
and 18 neuropsychological test-scores with a significance level set at 0.05. This implies that 
one out of 20 significant findings may have occurred by chance alone, and our results 
should therefore be interpreted with caution. The reason for our choice was that we 
preferred false positive associations rather than false negatives, since this was an 
exploratory and hypothesis generating study on the influence of distress on 
neuropsychological test results.
6.1.7.4. Paper III (The neuropsychological paper)
For the group analyses we regarded that raw test-scores were the most relevant parameters 
to analyze, since we did not have published norms for some of the computer tests, and since 
our control group was relatively small for deriving standardized scores.
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As to the individual analyses, we chose the SRB-method since it implied an 
opportunity to adjust for relevant covariates. Since age differed significantly across the 
treatment groups, such adjustments were important. In general, when performing such 
individual analyses, the test performance of a control group is used for the prediction of 
individual achievement in other groups of patients. Hence, the control group should be 
representative for the population studied. In our study the control group was relatively 
small, and there was a certain risk that this has influenced on the results, making the results 
less reliable. Also, since current distress possibly may be a confounder as to the 
neuropsychological test results, a group size permitting the inclusion of additional co-
variates such as levels of distress was preferable.
We defined that a z-score of change outside ±1.64 SD represented a reliable change 
on the individual test-scores from baseline to follow-up, as proposed by Ouimet et al 
(Ouimet et al. 2009). However, a more strict cut-off (z-scores of change outside ±1.96 SD)
has been used in some studies (Stewart et al. 2008).
As to individual analyses, it is a problem that no established definitions of 
meaningful individual changes over time in neuropsychological test performance exist in 
the literature. Several studies, inclusive those by Jenkins et al. (Jenkins et al. 2006) and 
Stewart et al. (Stewart et al. 2008) have defined decline/improvement as present when 
reliable change appeared on two or more test-measures. However, in these studies the total 
number of measures varied from 14 to 23, so such a definition implies variable proportions 
of the total number of test-measures applied (15% and 8%, respectively). Since our sample 
of TCPs had completed different numbers of tests, we had to define individual decline and 
improvement in performance by proportions of tests, and not by absolute numbers. To 
compensate for the uncertainty inherent in our defined proportional cut-off levels, we 
analyzed the data using two different cut-off levels (10% and 15%). Finally, all these 
analyses were performed on both the total and the basic test battery.
6.1.7.5. Paper IV (The self-report paper)
Dichotomizing the responses from self-reported concentration and memory and then 
constructing an overall change-score (increase vs. no increase of cognitive complaints from 
baseline to follow-up) reduced the variability of the data. However, such a categorization
was necessary in order to achieve adequate group sizes for the statistical comparisons 
between TCPs with and without such an increase. A multivariate analysis exploring the 
strength of association between background variables and an increase of cognitive 
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complaints could have been preferable in this study. However, the small group size of TCPs 
with an increase of complaints (n=25) precluded such an analysis. Hence, only descriptive 
(bivariate) analyses were performed.
6.2. Discussion of the specific results
6.2.1. Paper I (The 1990’ies study)
In paper I, prospectively exploring cognitive complaints in TCPs treated with chemotherapy 
(CHEM group) or radiotherapy (RAD group) in the 1990-ies, we only partly confirmed our 
hypotheses (stated in Section 2.2). We did find that compared to the RAD group, the CHEM 
group had significantly higher prevalence of concentration problems and cognitive function 
(CF) problems at 3 months, while no significant group difference was found for memory 
problems at this time point. However, contrary to our first hypothesis, no intergroup 
differences in prevalence of any of the three cognitive complaints measures were found at 
12 months. In multivariate analyses with adjustment for self-reported QoL functions and 
symptoms, treatment modality was not significantly associated with cognitive complaints at 
any time point, while more current fatigue, presence of insomnia, as well as reduced 
emotional and social function were significantly associated with cognitive complaints at 
least two out of three time points, thus confirming parts of our first hypothesis. As to our 
second hypothesis we found that poorer emotional function and increased level of fatigue 
before treatment were significantly associated with cognitive complaints (concentration or 
CF-problems) at 12 months in bivariate analysis, while these associations were not 
significant in multivariate analyses.
Our results are partly in line with the findings in the mixed cancer sample studied by 
Kohli et al (Kohli S et al. 2007) confirming an increase in prevalence of cognitive 
complaints from baseline to short-term follow-up among chemotherapy patients not 
observed in the radiotherapy group. However, in our study, this increased rate had returned 
to baseline levels at longer-term follow-up while this was not the case in Kohli et al study. 
However, Kohli et al had shorter follow-up time compared to ours (6 months vs. 12 months 
in our study), and this may explain the divergent longer-term results.
One-third of our TCPs in both the CHEM and the RAD group had cognitive 
complaints (CF-problems) at 12 month follow-up and this prevalence is in agreement with 
the findings by Schagen et al (Schagen et al. 2008). We do not know how this prevalence 
corresponds with the prevalence of cognitive complaints in age-matched men in the general 
population. However, the mean CF-scores of the TCPs in our study were at the same level 
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as the CF-scores of Norwegian men aged 30-39 in the general population (Fossa et al. 
2007), indicating no large difference in self-reported cognitive complaints between TCPs 
one year after the cancer diagnosis and young men in the general population. The 
prevalence of long-term cognitive complaints found in TCPs has overall been lower than the 
corresponding prevalence observed in breast cancer patients (Jenkins et al. 2006; Shilling 
and Jenkins, 2007) and in Kohli et al’s mixed cancer sample (Kohli S et al. 2007). 
However, since different instruments for the assessment of cognitive complaints have been 
used across these studies, such comparisons must be interpreted with caution.
In our study we confirmed the association between cognitive complaints and 
increased fatigue / lower emotional function (i.e. increased anxiety/depression) observed in 
other groups of cancer patients (Cull et al. 1996; Hermelink et al. 2010) and also reported 
by Schagen et al in their cross-sectional study of TCPs (Schagen et al. 2008). In the 
multivariate analyses of our study, increased current fatigue was significantly associated 
with cognitive complaints at all time points. Mental fatigue and cognitive complaints may 
represent similar constructs since both phenomena include symptoms of reduced 
concentration and memory (Hermelink et al. 2010).
There may be a risk of expectation bias in today’s studies of self-reported cognitive 
complaints after chemotherapy (Schagen et al. 2009). Among the TCPs treated during the 
1990’ies we expect that no such bias was present. Hence, we conclude from this study that 
chemotherapy does not seem to exert a longer-term negative effect on cognitive complaints 
in TCPs.
6.2.2. Paper II (The distress paper)
In this study we found that 24% (95 CI 17%-31%) of the TCPs had clinically significant 
distress by our definitions at baseline, shortly after receiving the cancer diagnosis. This 
prevalence is in line with the findings in two small-scale studies on post-diagnosis 
emotional distress in TCPs (Trask et al. 2003; Tuinman et al. 2007). The majority of 
recently diagnosed TCPs seem to adapt relatively quickly to the situation, probably since a 
good prognosis is to be expected. However, we must consider a possible selection bias in 
our study sample, since some of the most distressed patients may have declined to 
participate in the study. Also, patients with very advanced disease when diagnosed were 
excluded from study participation due to medical reasons.
Surprisingly, and contrary to our second hypothesis, none of the cancer-related 
variables were significantly associated with the levels of emotional distress. Based on
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studies from other cancer groups (Gurevich et al. 2002), we hypothesized that patients with 
metastatic disease would be more concerned than those with non-metastatic disease, but this 
expectation was not confirmed. Explanations for this finding may be the good prognosis 
expected even in metastatic disease, or that patients had not perceived the stage of their 
disease at the baseline evaluation of our study. Since we found that high level of 
neuroticism, current smoking and high alcohol-use were significantly associated with an 
increased distress-level, personality and lifestyle seemed more relevant for the level of 
distress than the cancer-related variables. This finding confirms the results from a study of 
long-term TC survivors (Fleer et al. 2006), which reported that patient-related variables 
rather than cancer-related variables were associated with levels of cancer related distress. 
Our study indicates that some patients may be vulnerable to increased levels of 
distress shortly after the TC-diagnosis without regard to the stage of disease, and such 
vulnerability warrants clinical attention. Future prospective studies could explore the 
relation between level of post-diagnosis distress and long-term emotional functioning in 
TCPs.
As to the main focus of this study, we found that the scores on four of the 18 
neuropsychological test measures were significantly associated with at least one of the three 
distress scores at baseline, thus partly confirming our third hypothesis. These four test-
scores represent cognitive domains of working memory/attention/concentration, speed of 
information processing, and executive functions. Interestingly, these cognitive domains 
partly overlap with the cognitive domains possibly affected after treatment for breast cancer 
(Vardy et al. 2008). Reduced attention due to current emotional distress may partly explain 
a reduced cognitive performance, as visualized in Figure 1 (Section 1.2.1)
However, with multiple testing using 0.05 as the significance level, some of the 
significant associations between the distress- and the test-scores found in this study may be 
due to chance alone. Importantly, the majority of the neuropsychological test measures used 
in our study (14 out of 18 measures) were not significantly associated with current distress-
levels. We therefore conclude that the neuropsychological test battery was relatively 
resistant to any confounding effect of distress, and that neuropsychological testing of TCPs 
may be undertaken shortly after the diagnosis with valid results.
6.2.3. Paper III (The neuropsychological paper)
In this prospective study of neuropsychological functioning in TCPs, we found no 
statistically significant group differences regarding decline in neuropsychological test 
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performance from baseline to a median of one-year follow-up. This was shown both in the 
group analyses as well as in the individual ones. Hence, the hypothesis that TCPs with 
multiple chemotherapy cycles more often would show decline in test performance compared 
with those treated with no or only one cycle was not confirmed. 
We performed analyses using two different proportional cut-off levels on both the 
basic and the total test-battery. All these analyses gave the same result of no significant 
group differences concerning proportions of TCPs with decline of test performances. We 
therefore conclude that today’s standard chemotherapy for TC does not seem to have a 
negative impact on neuropsychological functioning in the patients at one-year follow-up. 
This result confirms the cross-sectional findings by Pedersen et al (Pedersen et al. 2009).
Our study had some limitations. The study sample was relatively small, with the 
control group consisting of 31 patients only. Hence, our results need confirming in larger 
prospective studies before definite conclusions can be made. Further, positive results on test 
performance may have appeared if testing were done closer to the termination of 
chemotherapy, since chemotherapy possibly may have transient negative effects on 
cognitive function. However, long-term functioning is considered to be more important for 
the patients than any transient short-term dysfunction.
When using the 10% cut-off on the data from the total test battery, 42 of our TCPs 
showed individual decline in neuropsychological test performance (with a non-significant 
difference in proportions across the treatment groups). This should, however, not be 
interpreted as if one-third of the sample actually declined in neuropsychological 
functioning, but is most probably related to a liberal definition of decline and to the natural 
variation in neuropsychological test performance in general. When we applied the 15% 
cutoff, only 17 TCPs (14% of the sample) were classified with individual decline. Lastly, 
with our definition of overall decline (which takes into account the relation between 
declined and improved test scores), 18 TCPs (15%) were classified as showing decline.
Counter intuitively, significantly more TCPs in both chemotherapy-groups compared 
to the no-chemotherapy group had individual improvement on test performance from 
baseline to follow-up. However, we hardly believe that chemotherapy has a positive effect 
on cognitive function. Several explanations might be given for this finding. Some of the 
TCPs assigned for chemotherapy may have experienced relatively high levels of emotional 
distress at baseline due to metastatic disease, and the increased distress-level could have 
affected their neuropsychological test performance in a negative way (ref paper II). At 
follow-up, these patients were probably less distressed, and they, therefore, performed better 
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on the tests. Another explanation could be that some TCPs treated with chemotherapy were 
highly motivated to perform at their very best at the follow-up evaluation, due to fear of 
“chemo brain”. Anyhow, the improvement effect is probably not of large clinical 
importance, since we did not detect any significant group differences on the test raw-scores 
neither at baseline (except one score), at follow-up, or for the change-scores.
As to our second study aim, we wanted to explore if any patient-related or disease-
related variables were significantly associated with a decline in neuropsychological test 
performance from baseline to follow-up. In particular, we hypothesized that chemotherapy 
could be a risk factor for such decline, but this hypothesis was not confirmed. None of the 
demographic, cancer-related or emotional distress / fatigue variables (except increase of 
ototoxic symptoms) showed significantly association with a decline in test performance. 
This is in line with results from breast cancer patients (Jenkins et al. 2006). We had no ‘a 
priori’ hypothesis of an association between ototoxic symptoms and decline in 
neuropsychological performance, and this association may possibly be significant by chance
due to multiple testing.
In future prospective neuropsychological studies in TCPs, assessment of cognitive 
function at 5 or 10 year follow-up intervals might also be valuable, since adverse effect of 
cancer treatment may have a long latency before they become clinically apparent (Fossa et 
al. 2009). A working hypothesis of our research group is that chemotherapy may induce 
premature aging of the different organs. Hence, it could be of interest to explore age-related 
cognitive decline in long-term TC survivors treated with or without chemotherapy. 
However, age was not a significant predictor of decline in neuropsychological test 
performance in our sample of TCPs.
A problem with neuropsychological testing in general is that the testing does not 
measure the effort needed to solve the tasks. Such effort, however, can be assessed in part 
by functional neuro-imaging of the brain. In a small functional MRI-study by Ferguson and 
colleagues, a pair of monozygotic twins (two females aged 60, one had completed 
chemotherapy for breast cancer 22 months earlier) performed a working memory task 
during brain imaging. The sisters performed almost identical on the memory task, however 
more brain activation was noted during task performance in the twin who had received 
chemotherapy compared to other twin, indicating that a larger effort was needed to solve the 
task (Ferguson et al. 2007b). Functional neuro-imaging could possibly have added valuable 
information in our study of TCPs; however such assessment was too comprehensive in our 
research setting. 
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6.2.4. Paper IV (The self-report paper)
In this study, prospectively exploring cognitive complaints in the TCPs included in the 
Oslo-study, we hypothesized that a higher proportion of TCPs in the MULTIPLE-CHEMO 
group would report an increase of cognitive complaints from baseline to follow-up
compared to the NO-CHEMO and the ONE-CHEMO groups. This hypothesis was only 
partially confirmed, as significantly more patients in both chemotherapy groups had an 
increase of cognitive complaints compared to the NO-CHEMO group, and since no 
significant difference appeared between the two chemotherapy groups. This result is in 
contrast to the neuropsychological findings in paper III, and indicates that chemotherapy 
may have a negative impact on self-reported cognitive complaints, in line with findings 
among breast cancer patients (Shilling and Jenkins, 2007). That patients treated with 
chemotherapy to some extent had been primed about this eventual side-effect when entering 
the study, implying expectation bias as an alternative explanation of the findings.
Our second hypothesis was confirmed, as we found that an increase of self-reported 
cognitive complaints from baseline to follow-up was significantly associated with follow-up
scores of increased emotional distress and fatigue, but not with a decline in 
neuropsychological test performance. These results confirm findings from other studies 
(Hermelink et al. 2010; Schagen et al. 2008), and they indicate that cognitive complaints in 
TCPs may represent emotional rather than neurocognitive response. Chronic fatigue is 
common in TCPs (Orre et al. 2008), and the symptoms of mental fatigue and cognitive 
complaints seem to be highly correlated (Cull et al. 1996; Hermelink et al. 2010).
The discrepancy observed between “subjective” and “objective” decline in cognitive 
function could be explained in several ways. Low ecological validity of neuropsychological 
tests and the standardized test situation imply that cognitive performance in stressful 
situations of daily life, requiring good multitasking capacity, were not adequately evaluated 
by our test battery. Further, the validity of self-reported cognitive complaints was threatened 
by expectation or memory bias. Interestingly, studies on elderly in the general population 
have demonstrated a significant association between self-reported cognitive complaints and 
neuroimaging findings in the absence of reduced neuropsychological test performance 
(Haley et al. 2009; Saykin et al. 2006). Cognitive complaints may, in some cases, represent 
subtle cognitive reduction not (yet) identified by neuropsychological testing.
Cognitive complaints in TCPs seem to have a multi-factorial etiology, in which 
emotional distress, fatigue, hormonal factors (Fossa et al. 2009; Nord et al. 2003) and 
treatment modalities might play a role. The majority of the TCPs included in our study, 
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however, had no cognitive complaints at one-year follow-up, indicating that cognitive 
complaints are not very prevalent in TCPs. However, for the minority of patients 
experiencing such cognitive problems, adequate clinical assessment of eventual 
precipitating or maintaining factors such as current emotional distress, fatigue or 
hypogonadism should be evaluated. Adequate interventions should eventually be 
undertaken in order to alleviate such symptoms.
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7. CONCLUSIONS
7.1. Summary of results related to the study aims
7.1.1. Paper I (The 1990-ies study)
Aim 1: Among TCPs treated with chemotherapy during the 1990’ies, there was a 
significantly increase in prevalence of cognitive complaints from baseline to 3 month 
follow-up. At 12 month follow-up these rates had returned to baseline levels. For TCPs 
treated with radiotherapy no significant changes over time in prevalence of cognitive 
complaints were observed. In multivariate analyses with adjustments for self-reported QoL 
function and symptoms, treatment modality [chemotherapy vs. radiotherapy (reference)] 
was not significantly associated with the presence of cognitive complaints neither at any 
time point. In these analyses, current fatigue, insomnia, reduced emotional function and 
reduced social function were significantly associated with cognitive complaints at several 
time points.
Aim 2: In bivariate analyses, several pre-treatment QoL function / symptom scores were 
significantly associated with concentration problems at 12 months, however in multivariate 
analyses none of these associations remained statistically significant.
7.1.2. Paper II (The distress paper)
Aim 1: About one-fourth (24%) of the included TCPs in the Oslo-study had clinical 
significant cancer-related distress at the baseline evaluation, shortly after their TC-
diagnosis. 
Aim 2: Cancer-related distress at baseline was significantly associated with patient-related 
variables such as high level of neuroticism, smoking and high alcohol-use, but not with the 
stage of TC.
Aim 3 (Main study aim): The majority of the neuropsychological test-scores (14 out of 18 
test measures) at baseline were not significantly associated with current distress scale scores 
at that time point.
7.1.3. Paper III (The neuropsychological paper)
Aim 1: No significant group differences between the NO-CHEMO, the ONE-CHEMO, and 
the MULTIPLE-CHEMO groups in proportions of TCPs with a decline in 
neuropsychological test performance from baseline to one-year follow-up were observed. 
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Aim 2: Decline in neuropsychological test performance from baseline to follow-up was not 
associated with treatment with chemotherapy or with any of the other patient or cancer-
related variables, except for an increase of subjective ototoxic symptoms (tinnitus and 
reduced hearing).
7.1.4. Paper IV (The self-report study)
Aim 1: Significantly higher proportions of TCPs in the ONE-CHEMO and the MULTIPLE-
CHEMO groups had an increase of subjective cognitive complaints from baseline to one-
year follow-up compared to the NO-CHEMO group.
Aim 2: Increase of cognitive complaints from baseline to follow-up in the Oslo-study was 
significantly associated with symptoms of emotional distress and fatigue at follow-up and 
treatment with chemotherapy, but not with a decline in neuropsychological test 
performance. 
In both paper I and IV cognitive complaints were found significantly associated with 
levels of emotional distress and fatigue, and both papers displayed bivariate associations 
between chemotherapy and post-treatment cognitive complaints. However in paper I, the 
association between chemotherapy and cognitive complaints did not remain significant after 
adjustment in multivariate analysis.
7.2. Conclusions and clinical implications of the study results
 About one-fourth of TCPs experience high levels of emotional distress shortly after their 
diagnosis of TC, and their level of such distress is not necessarily associated with the 
stage of the disease at diagnosis. Some TCPs may be vulnerable to emotional distress 
after a TC-diagnosis, and this should be kept in mind by clinicians. 
 Neuropsychological testing can be performed in a valid way in TCPs shortly after their 
diagnosis, although some test measures (of attention and working memory) may be 
negatively influenced by high levels of emotional distress in some individuals.
 Current standard treatment with chemotherapy for TC does not seem to have a negative 
impact on neuropsychological functioning in patients at one-year follow-up. There is a 
risk of type II statistical error due to our sample sizes, and this result should be 
investigated further in future prospective studies with larger samples than ours.
 The association between cognitive complaints and chemotherapy in TCPs seem 
uncertain and may be explained by confounding variables such as emotional distress and 
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fatigue. There is a certain risk of expectation bias in current studies of cognitive 
complaints after chemotherapy.
 Cognitive complaints in TCPs probably have a multi-factorial etiology and seem to be
related to current emotional distress and fatigue rather than to objectively reduced
neurocognitive functioning. Clinical interventions for reducing emotional distress and 
fatigue may eventually help reducing self-experienced cognitive complaints in TCPs.
 The low correlation between cognitive complaints and neuropsychological test 
parameters in TCPs seem to document that both these issues should be included in 
studies of cancer-related cognitive function.
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8. FUTURE CONSIDERATIONS AND RESEARCH QUESTIONS
 Prospective studies with large samples of TCPs assessing cognitive complaints by 
validated cognitive questionnaires and with the inclusion of a standardized 
neuropsychological test battery are needed to further elaborate the association between 
cisplatin-based chemotherapy and cognitive function in TCPs.
 In such studies the recruitment of TCPs should be offered special consideration, since 
the Oslo-study probably missed the patients with the best and the worst coping with 
their recent diagnosis of TC.
 In future prospective studies, one should consider long-term follow-up evaluation at 5 
and 10 years post-treatment, since any adverse effects of chemotherapy may have long 
latency before they become clinically apparent.
 Future studies of cognitive function in cancer patients including functional neuro-
imaging of the brain can possibly add valuable information to the field, and may also be 
relevant in TCPs.
 Since a small proportion of TCPs develop hypogonadism, and since cognitive function 
possibly may be affected by hormone levels, cognitive complaints and 
neuropsychological functioning in relation to testosterone level in TCPs could be 
explored in future studies.
 There is a continuous search for the minimal though effective dose of chemotherapy in 
TCPs. In randomized controlled treatment studies, instruments covering cognitive 
complaints and brief neuropsychological testing should be included, since eventual 
reduced cognitive function may have serious consequences for these mostly young 
patients.
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APPENDIX A: Order of assessments in evaluations of the Oslo-study 
Baseline and follow-up evaluations (90-120 min, all performed by Tone Skaali)
1) Information about the evaluation, informal talking
2) Semi-structured interview
3) Neuropsychological testing
4) Collection of questionnaires filled in by the patients before the evaluation
5) Patient evaluation of study participation 
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APPENDIX B: Semi-structured interviews in the Oslo-study
Baseline interview 
Demography
Date of birth
Place of living
Civil status
Fathered children
Completed years of education  10-12 13-15 
Current occupation working student not working
Health and lifestyle
Somatic health problems during childhood, adolescence, adulthood?
Mental health problems during adulthood?
Sleeping problems?
Smoking / alcohol / drugs?
Severe health problems last year before the diagnosis of TC?
Current medications?
Cognitive complaints
In general, how is your concentration?
Very good Good Not so good Poor
In general, how is your memory function?
Very good Good Not so good Poor
Have you experienced any long-term cognitive problems before the TC-diagnosis? If yes, 
when did these problems start and what were they like?
Please indicate with a number on a scale from 0 to 10 if any cognitive problems affect your 
habitual daily functioning (before the diagnosis of TC) (0: no affection, 10: major impact on 
daily functioning).
100
This study (to be answered at the end of the evaluation)
How has participation in this study been for you?
To be rated by the interviewer after the evaluation
Perceived satisfaction by the patient concerning information about TC at the local hospital 
Satisfied Not satisfied
Patient generally well informed about TC 
Yes No
Follow-up interview
Demography
Change in civil status or fathered children since the baseline evaluation?
Completed more years of education since the baseline evaluation?
Current occupation working student not working
Health and lifestyle after TC
Somatic health problems after TC?
Mental health problems after TC?
Current sleeping problems?
Change in smoking / alcohol / drugs behavior after TC?
Current medications?
Self-reported cognitive complaints after TC
How is your concentration?
Very good Good Not so good Poor
How is your memory function?
Very good Good Not so good Poor
Have you experienced any concentration or memory problems after the TC-diagnosis?
If yes, when did you experience such problems, how where they, and are they still present?
101
Please indicate with a number on a scale from 0 to 10 if any cognitive problems affect your 
current daily functioning (0: no affection, 10: major impact on daily functioning).
This study (to be answered at the end of the evaluation)
How has participating in this study been for you?
10
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APPENDIX D - Questionnaires used in the Oslo-study
Questionnaires Baseline
evaluation
Follow-up
evaluation
Used in 
paper
Impact of Event Scale (IES) x x II, III, IV
Hospital Anxiety and Depression Scale (HADS) x x II
Fatigue Questionnaire (FQ) x x III, IV
Positive and Negative Affect Schedule (PANAS), 
state version x x II
Scale for Chemotherapy-Induced Neurotoxicity (SCIN) x x III, IV
Short Eysenck Personality Questionnaire, 
Neuroticism scale x - II, III, IV
CAGE questionnaire (alcohol problems) x - II, III, IV
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2ABSTRACT
Background:
Cognitive complaints are frequent among cancer patients, and both oncologists and patients 
have become concerned if systemic chemotherapy may have cognitive side-effects (“chemo 
brain”). After this concern became public there is a risk of expectation bias in future studies 
of cognitive complaints. Therefore, we prospectively explored cognitive complaints in 
testicular cancer patients (TCPs) treated with chemotherapy or radiotherapy during the 
1990-ies, before today’s increased awareness of this possible side-effect.
Materials and methods:
The EORTC QLQ-C30 and a testicular cancer module were completed before treatment
(baseline), at 3-months, and at 12-months by 276 chemotherapy and 71 radiotherapy
patients enrolled in three EORTC-studies. Cognitive complaints were studied as 
concentration problems, memory problems and cognitive function (CF) problems based on 
the QLQ-C30 ratings. Other QLQ-C30 functions and symptoms represented adjustment 
variables.
Results:
The chemotherapy group showed a significant increase in prevalence of concentration 
problems and CF problems from pre-treatment to 3-months. At 12-months these rates were 
back at baseline levels. The radiotherapy patients showed no significant change over time in 
prevalence of cognitive complaints. Significant differences between the two treatment 
groups were observed only at 3-months and concerned concentration problems and CF 
problems. In multivariate analyses, treatment modalities did not show significant 
associations with any of the cognitive complaint measures at any time-point, while current 
fatigue showed significant associations at all time points. Among pre-treatment variables, 
3reduced emotional function (i.e. anxiety and depression) and fatigue were significantly 
associated with cognitive complaints at 12-months in bivariate analyses.
Conclusions:
In this study from the era before the risk of “chemo brain” was known to the public, we 
found that the increased rate of cognitive complaints shortly after chemotherapy was back at 
baseline level at 12-month follow-up. In multivariate analyses chemotherapy versus 
radiotherapy was not significantly associated with cognitive complaints at any time point.
Keywords:
Cognitive complaints, Testicular cancer patients, Prospective study, Chemotherapy,
Expectation bias
4INTRODUCTION 
Since the 1990-ies oncologists and cancer patients have been concerned that systemic 
chemotherapy may have a negative effect on cognitive function [1], a phenomenon 
popularly called “chemo brain” [2,3]. According to the Mayo Clinic: “Chemo brain is a 
common term used by cancer survivors to describe thinking and memory problems that can 
occur after cancer treatment. Chemo brain can also be called chemo fog, cognitive changes 
or cognitive dysfunction.” (ref. http://www.mayoclinic.com/health/chemo-brain, retrieved 
August 26, 2010). “Chemo brain” is by now a well-established adverse effect after 
chemotherapy for cancer with 30%-80% of the patients reporting cognitive complaints 
(problems with concentration or memory) [4-6]. Both major oncology clinics and cancer 
societies in the Western world mention chemo brain or cognitive complaints in their 
reviews of adverse effects after cancer treatment.
Since the term chemo brain and the potential risk of such an adverse effect have 
been introduced to the oncological communities, many new cancer patients will be 
acquainted with the symptoms through various sources of information. For example, recent 
Googling of “chemo brain” gave 290.000 hits (http://www.google.no/search, retrieved 
August 26, 2010). The spread of knowledge about chemo brain leads to a considerable risk 
for information and expectation biases in new studies, since today’s patients asked about 
cognitive complaints may be primed for them. Consequently, they may report falsely high 
levels of cognitive complaints in relation to chemotherapy. Schagen et al [7] recently 
documented such biases in a sample of breast cancer patients who randomly got information 
about ‘cognitive problems’ versus ‘neutral’ information. The primed patients showed 
significantly higher levels of cognitive complaints. In their study of cognitive complaints in 
breast cancer patients, Shilling & Jenkins [5] stated: “Self-report (of cognitive complaints) 
5may be high, simply because we asked patients to take part in a study investigating the 
potential effects of treatment on their memory.” 
Based on this knowledge, particular interest should be paid to studies of cognitive 
complaints in historical samples of cancer patients, from time periods when chemo brain 
was unknown to the public. Cognitive complaints can be clinically assessed by the 
oncologists by asking about memory and concentration problems in the clinical 
examination. These functions can also be explored by patient-completed questionnaires like 
the European Organization of Research and Treatment of Cancer cancer-specific quality of 
life (QoL) instrument (EORTC QLQ-C30) [8], which defines cognitive function based one 
question concerning memory and another on concentration problems during the past week.
The present study is based on the QLQ-C30 datasets from testicular cancer patients 
(TCPs) enrolled in three studies performed by the EORTC group during the 1990-ies, and 
treated with either chemotherapy or radiotherapy. With prospective data on cognitive 
complaints in TCPs treated before the “chemo brain” era, this study had the following aims: 
1) To study the prevalence of self-reported cognitive complaints and its changes from before 
treatment (baseline) to 3 and 12-month follow-up among TCPs treated with either 
chemotherapy or radiotherapy, and to identify variables associated with such cognitive 
complaints; and 2) To identify self-reported QoL dimensions before treatment that were 
predictive for cognitive complaints at 12-month follow-up.
MATERIALS AND METHODS 
Patients
The patients in this study were identified from the electronic records of three randomized 
treatment-studies on orchidectomized TCPs organized by the EORTC / MRC (Figure 1). 
Our chemotherapy group consisted of TCPs with metastatic non-seminoma or seminoma 
6included in trial 30941/ TE20 [9,10] (study start 1995) which evaluated treatment with four 
different schedules of bleomycin, etoposide and cisplatin (BEP) chemotherapy (3 or 4 
cycles given over 5 or 3 days). Our radiotherapy group consisted of irradiated non-
metastatic seminoma patients included in trial 30942 /TE18 [11] (study start 1995) and trial 
30982 /TE19 [12] (study start 1996). The TE18 study compared the effects of 20 Gy versus 
30 Gy abdominal radiotherapy, while the TE19 study evaluated radiotherapy (20 or 30 Gy) 
versus a single-dose of carboplatin chemotherapy. From the TE18/TE19 studies we only had 
access to the data on the Norwegian patients (n=126). 
According to the protocols, the QLQ-C30 and a TC-module [10,13] should be 
completed before treatment (baseline), and then again approximately 3 months and 12 
months later. In the TE20 study the 3 months assessment was done shortly after the end of 
chemotherapy. The time-windows for valid questionnaire responses in our study were: 
TE20: baseline: +/-30 days from randomization, 3 months: 9-20 weeks after baseline, and 12 
months: 9-18 months after baseline. For TE18/TE19: baseline: 0-28 days before treatment 
start, 3 months: 9-18 weeks after baseline, and 12 months: 9-15 months after baseline.
We only included TCPs who were tumor-free at 12 months, had delivered 
questionnaires within the defined time windows, had filled in both cognitive items of the 
QLQ-C30 before treatment and at 3 and 12 months follow-up, and who were in the age 
range from 15 to 59 years at baseline. The final sample thereby consisted of 347 TCPs with 
valid cognitive data (Figure 1), 276 treated with chemotherapy (CHEM group) and 71 with 
radiotherapy (RAD group).
Cognitive complaints (outcome measures)
Cognitive complaints were assessed by responses to the two cognitive questions of the 
QLQ-C30 [8]: “Have you had difficulty in concentrating on things, like reading a 
7newspaper or watching television?” (item #20) and “Have you had difficulty remembering 
things?” (item #25). There were four response-alternatives: “not at all” (1), “a little” (2), 
“quite a bit” (3) and “very much” (4), and the time frame were the past week. 
We defined threes separate outcome measures: the scores of item #20 
(concentration),  the scores of item #25 (memory) and the cognitive function (CF) scores 
defined according to the QLQ-C30 [8] as a combination of the memory and concentration 
scores and transformed by the formula: CF-score = (1 – [(mean score of items #20 and #25 
– 1)/3]*100). This transformation gives seven steps on a scale from 0 (worst) to 100 (best),
with intervals of 16.67 points.
Cognitive complaints in this study were defined by the scores on either memory, 
concentration or CF. A representative sample of Norwegian men aged 20 to 59 years had 
mean CF scores between 86.5 and 91.6 according to 10 year age groups [14]. On this 
background cognitive complaints were defined by three outcomes as follows: concentration 
and memory problems absent (“not at all”) or present (“a little”/”quite a bit”/”very much”), 
and CF problems absent (score 100) or present (score '&$&&%$
Independent variables
EORTC Quality-of-Life Questionnaire (QLQ-C30)
In addition to CF, the QLQ-C30 [8] assessed physical function, emotional function (EF), 
social function (SF) and role function (RF), as well as global QoL, and nine symptom scales
including fatigue, pain and insomnia. By established algorithms the QLQ-C30 items were 
transformed to function scales with scores from 0 (worst) to 100 (best), and fatigue, pain 
and insomnia from 0 (no symptoms) to 100 (worst symptoms) [8]. For our regression 
analyses we selected the functions and symptoms which from a clinician’s point of view 
were most likely to be associated with cognitive complaints: EF, RF, SF, fatigue, and 
8insomnia. Pain was excluded due to high correlation with fatigue before treatment. Since we 
expected the diagnosis of testicular cancer to affect these functions and also considering the 
mean scores in the population sample [14], we defined the cut-off for good function at a 
score of  		$1y of reasoning, the symptoms of 
fatigue and insomnia were defined as absent by scores "#$#
		2"#$#$
TC-module questionnaire
From the TC-module [10,13] we used the items covering peripheral neuropathy, Raynaud’s 
phenomenon and reduced hearing/tinnitus, for simplicity summarized as neurotoxic 
symptoms, and linearly transformed to a summary score from 0 (no symptoms) to 100 
(worst symptoms) [8,10]. Since neurotoxic symptoms also exists in the general population 
[15], we dichotomized the transformed score into symptom absent (score"#$#%	
	
(score >16.67).
Age at baseline was also registered.
Statistical analyses
Data were analyzed by the SPSS program for PC version 16.0 (SPSS Inc, Chicago IL), 
using standard descriptive measures. The distribution of scores on the three outcome 
measures concentration, memory and CF at baseline, 3 and 12 months are presented. The 
selected functions and symptoms of the QLQ-C30 and of the TC-module as well as age and 
cancer-related variables were considered as independent variables. Changes over time in the 
proportions of patients with cognitive complaints were analyzed with 2x2 contingency 
tables and Fisher’s exact test.
At each time-point, bivariate and multivariate logistic regression analyses examined 
the association between cognitive complaints (dependent variable) and independent 
variables (treatment group [RAD group as reference] and the self-reported QoL 
9function/symptoms). The strength of the associations was expressed as odds ratios (ORs) 
with 95% confidence intervals (95%CI). Age was not entered as independent variable in the 
multivariate analyses since it did not show significant bivariate associations with the 
outcome variables at any time point. 
With bivariate and multivariate logistic regression analyses we then explored if any 
of the pre-treatment independent variables were predictors of cognitive complaints at 12 
months. All tests were two-sided, and p-values<0.01 were considered to be statistical 
significant due to multiple testing.
Ethics
The TE18, TE19 and TE20 trials were approved by the local research ethical committees of 
each participating center. All patients provided written informed consent. 
RESULTS
Attrition analysis 
Attrition analyses showed no significant differences in age or in proportions of patients with 
concentration or memory problems before treatment between the examined sample of 347 
TCPs fulfilling the selection criteria and the 404 TCPs with valid baseline data but excluded 
due to missing data at 3 or 12 months (Figure 1). However, a larger proportion of the 
excluded patients had non-seminoma compared to the included patients (70% vs. 61%, 
p=0.005).
Characteristics of the CHEM and RAD groups 
Among the 347 included TCPs, the mean age of patients at baseline was significantly lower 
in the CHEM group (33.0 years ±8.8) compared to the RAD group (38.2 years ±8.0). The 
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distribution of the four different BEP-regimens in the CHEM group was as follows: 3 cycles 
over 5 days: 23%, 3 cycles over 3 days: 27%, 4 cycles over 5 days: 21% and 4 cycles over 3 
days: 29%.
At baseline, in the CHEM group 23% had concentration problems, 23% had memory 
problems, and 37% had CF-problems. The corresponding proportions in the RAD group 
were 21%, 20% and 27%. No statistically significant inter-group differences in the
distributions of the scores for concentration, memory and CF were observed at any of the 
time points (Table 1). 
In the total sample 23% had concentration problems, 23% had memory problems, 
and 35% had CF-problems before treatment. At 12 month follow-up the corresponding 
proportions were 15%, 28% and 33%.
At 3 month follow-up, the CHEM group had significantly higher proportions with 
reduced function on EF, RF and SF compared to the RAD group (Table 2). At that time-
point, fatigue and neurotoxic symptoms were also significantly more prevalent in the 
CHEM group than in the RAD group. Except for neurotoxic symptoms at 12 months, none 
of these functions or symptoms showed significant inter-group difference before treatment 
or at 12 month follow-up.
Changes in cognitive complaints over time and intergroup differences 
The changes over time and the inter-group differences in the dichotomized cognitive 
complaints are depicted in Figures 2A-2C which also includes legends concerning statistical 
significance.
Significantly more patients in the CHEM group had concentrations problems at 3 
months compared to baseline and 12 months. The proportion of patients with concentration 
problems at 3 months was also significantly higher in the CHEM than in the RAD group. In 
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contrast, the proportions with concentration problems at baseline and 12 month follow-up
did not significantly differ between the CHEM and the RAD group (Figure 2A).
As for memory problems no significant changes over time were found for any of the 
treatment groups and no significant inter-group differences were observed at any time point.
(Figure 2B).
The proportion with CF-problems in the CHEM group at 3 months was significantly 
higher compared to the proportions at baseline and 12 months. At 3 months, the CHEM
group also had significant higher proportion of patients with CF-problems than the RAD 
group. No significant inter-group differences concerning proportions of patients with CF-
problems at baseline and 12 month follow-up were observed (Figure 2C).
Associations between independent variables and cognitive complaints at each time-
point
Bivariate analyses
At 3 month follow-up, belonging to the CHEM rather than the RAD group was significantly 
associated with concentration problems and CF-problems in bivariate analyses, while this 
was not the case before treatment or at 12 month follow-up (Table 3).
Multivariate analyses
In multivariate analyses no significant associations were observed between treatment type
and cognitive complaints at any time point (Table 3).
However, concentration problems before treatment were significantly associated 
with reduced EF and fatigue. These associations held up at 3 month follow-up, but in 
addition reduced SF and insomnia also showed significant associations with concentration 
problems. At 12 month follow-up, none of the independent variables were significantly 
associated with concentration problems.
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As for memory problems, no independent variables showed significant associations 
before treatment. At 3 months insomnia and at 12 months reduced SF and fatigue were 
significantly associated with memory problems.
Fatigue was significantly associated with CF-problems at all time points. In addition 
reduced SF and insomnia were significantly associated with such problems at 3 and 12 
month follow-up.
Focusing on the independent variables, fatigue was significantly associated with 
cognitive complaints in 6 out of 9 analyses (Table 3). Correspondingly, insomnia and 
reduced SF were associated in 4, and reduced EF in 3 analyses. Reduced RF and neurotoxic 
symptoms showed no significant association with cognitive complaints at any time points.
Baseline predictors of cognitive complaints at 12 month follow-up
In bivariate analyses reduced EF and SF, fatigue and neurotoxic symptoms before treatment 
were significant predictors of concentration problems at 12 month follow-up (Table 4). For 
memory problems no significant predictors before treatment were observed, and for CF-
problems only reduced EF was significant in bivariate analyses.
In multivariate logistic regression analyses no significant associations were observed 
between the independent variables before treatment and concentration problems, memory 
problems or CF-problems at 12 month follow-up (Table 4).
DISCUSSION
Based on our definitions between 23% and 35% of the TCPs reported cognitive complaints
(defined by the presence of memory, concentration or CF-problems) before treatment, and 
15% to 35% had such complaints at 12 months follow-up. The proportions of patients with 
either one of the three cognitive complaints did not differ significantly between baseline and
13
12 months, and no significant differences between the CHEM and RAD groups were 
observed at these two time points. In contrast, at 3 month follow-up, the proportion of 
patients in the CHEM group with concentration problems and CF-problems were 
significantly higher than both before and after. In bivariate analyses, the CHEM group had a 
doubled risk for concentration and CF problems at 3-months (OR 2.6 and 2.1 respectively) 
compared to the RAD group. However, in multivariate analyses these associations were not 
significant. Current fatigue was significantly associated with one or more of the cognitive 
complaints in multivariate analyses at all three time points. In bivariate analyses we
identified some significant self-reported QoL predictors before treatment for concentration 
problems at 12 months, while that hardly was the case for memory problems and CF-
problems. However, in multivariate analyses none of these baseline variables remained 
statistically significant predictors.
Kohli et al [4] described the course of self-reported cognitive complaints (trouble 
with concentration or memory) from before treatment to 6 months after in a mixed cancer 
sample of 595 patients (34% men). A peak prevalence of cognitive complaints was found 
shortly after termination of chemotherapy. For patients treated with radiotherapy no 
significant change over time in prevalence of cognitive complaints was observed. These 
results are in agreement with ours. However, Kohli et al observed overall higher prevalence 
rates than ours, which may be due to the different methods of assessment or to different 
groups of cancer patients. 
At 12-months, one-third of our TCPs had CF-problems, and this proportion was 
similar to the findings by Schagen et al [6] in TCPs at an average of 3 years after treatment. 
However, we assessed CF-problems by a questionnaire (the QLQ-C30) while Schagen et al 
assessed cognitive complaints by an interview.
14
Our prevalence rates of cognitive complaints at 12 month follow-up in TCPs are 
lower than the rate found in breast cancer patients interviewed by Shilling et al one year 
after treatment [5] since approximately 60% of their patients had memory complaints and 40 
% had concentration complaints at follow-up. Härtl et al [16] prospectively examined breast 
cancer patients with QLQ-C30 before start of adjuvant treatment (mixed group of 
radiotherapy, chemotherapy and/or endocrine therapy) and then at every six months for two 
years. Most of the QLQ C-30 function scores improved over time, but the mean CF scores 
in these patients remained stable around a score of 79 points from baseline and during the 
whole observation period. The comparable mean CF scores in our TCPs were at all times 
better (range 84-92 points, data not shown) than those found by Härtl et al. In sum, TCPs 
seem to report less CF-problems than breast cancer patients 12 months post-treatment.
We found that the prevalence of concentration problems and CF-problems was 
significantly higher at 3 month follow-up in the CHEM versus RAD group compared to 
before treatment, while the comparable prevalence was similar in both groups at 12 month 
follow-up and had almost reached the baseline levels. This result indicates that the increase 
in cognitive complaints is limited to the time period shortly after the end of chemotherapy, 
and is not a long-term feature. Our results are in some contrast to the findings of the original 
publication from the EORTC group [10] reporting that 19% of the patients had a worsening 
of CF-scores from baseline to 2-years follow-up. However, their selection of patients and 
the study design differed considerably from the current study. 
As to the “chemo brain” debate, our probably most important clinical result is the 
non-significant difference between the CHEM and RAD groups in proportions of patients 
with existing cognitive complaints at 12-months. Hence, chemotherapy does not seem to 
exert a long-term negative effect on subjectively experienced cognitive function in TCPs. 
However, due to previous findings of a low correlation between subjectively and objectively 
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assessed cognitive function [6;17], prospective studies with objective cognitive 
measurements are needed to further explore any possible relation between chemotherapy 
and cognitive function in TCPs.
In multivariate analyses, the treatment modality of our TCPs was not associated with 
cognitive complaints at any of the 3 time points. Significant pre-treatment predictors for 
cognitive complaints at 12-months mainly concerned concentration problems and included 
pre-treatment reduced EF and SF as well as fatigue and neurotoxic symptoms. Among these 
variables, reduced EF (i.e. anxiety and depression) and fatigue are established [6,17-19],
while reduced SF and neurotoxic symptoms represent new findings. The two latter variables 
could be operating independently, and considering the known peripheral neurotoxic effect 
of cisplatin in TCPs [20-22] the association with neurotoxic symptoms is an interesting 
finding which warrants further evaluation in subsequent studies. However, reduced SF and 
slight neurotoxic symptoms as defined in our study may also reflect a more general 
personality factor like increased neuroticism [23].
The strength of our study is that we, by our design and selection of patients, could 
prospectively study the prevalence of cognitive complaints in the same 347 TCPs through 
the whole observation period. Our results are valid for today’s patients as the treatment 
modalities investigated in these EORTC-trials are still in use. Even though self-reported 
cognitive complaints may not be a sufficient measure to capture “objective” cognitive 
adverse effect of chemotherapy, knowledge about prevalence and associated factors of self-
reported cognitive complaints are important for intervention strategies towards cognitive 
problems in TCPs. Further, the choice of our patient sample from the 1990-ies minimizes 
the risk of expectation bias possibly valid in current studies of cognitive complaints after 
chemotherapy [7,24]. Our TCPs were treated 10-15 years ago, before “chemo brain” was 
publicly known, and our unbiased results may add some valuable information to the field. 
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Our study also has several limitations. Firstly, responses to the two cognitive items 
of the QLQ-C30 represent a very rough measurement of self-experienced cognitive 
function. Further, by defining the presence of cognitive complaints as a transformed CF-
score <100 we might have over-estimated the prevalence of existing cognitive complaints. 
On the other hand, a main focus was on the differences between the CHEM and the RAD 
groups which we consider less dependent on our cut-off definitions. Also more important 
than the prevalence rates are probably the course of these rates over time. We find it 
reassuring that the 12-months prevalence of cognitive complaints almost had returned to 
baseline levels in both treatment groups. 
We have not included the extent of metastases as an independent variable, but all 
patients in the CHEMO group belonged to the “good prognosis groups” as defined by the 
International Germ Cell Cancer Collaborative Group [25]. We lacked demographic 
variables such as level of basic education that has shown a significant association with 
cognitive function [26]. Our RAD group consisted only of Norwegian patients, while 
CHEM group also included patients from other European countries mainly from England.
Lastly, our sample of 347 TCPs represents only 46% of the patients with valid cognitive 
data at baseline. However, since cognitive function in the QLQ-C30 is assessed by two 
questions only, we regarded that imputation was contraindicated in this study.
CONCLUSIONS
For TCPs treated with today’s standard chemotherapy during the 1990-ies, the prevalence 
of self-reported cognitive complaints increased significantly shortly after treatment, and 
then returned almost to the pre-treatment levels at 12 month follow-up. In multivariate 
analyses considering important QoL domains such as emotional and social function, fatigue 
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and insomnia, treatment modality was not significantly associated with cognitive 
complaints at any time point.
Regardless of their etiology, cognitive complaints in TCSs may have considerable 
consequences for the QoL and functioning in education and work life. In order to reduce 
distress related to cognitive complaints, the evaluation and treatment of emotional distress 
and fatigue seem particularly relevant. 
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Figure 1. Patients in the study 
Norwegian testicular 
cancer patients
TE18: N=81    TE19: N=45
Total N = 126
Valid data at baseline, 
3 and 12 months 
N = 276 Final sample of patients 
<60 years with
valid data at baseline,
3 and 12 months
Chemotherapy: N = 276
Radiotherapy: N = 71
Total: N = 347
Chemotherapy group Radiotherapy group
TE20 study TE18 study TE19 study radiotherapy arm
Valid data at baseline and 
12 months
N = 417
Patients in TE20 trial
N = 812
N = 625 N = 885
Valid data at baseline and 
age <60 years
N = 636
Testicular cancer patients
N = 791
Extragonadal germ cell 
malignancy, N=21
Valid data at baseline and
age <60 years
N = 115 
Valid data at baseline 
and 12 months
N = 96
Valid data at baseline, 
3 and 12 months 
N = 71
Valid data
at baseline and
age <60 years
N = 751 
Valid data: Patients who delivered questionnaire in defined time-window and had filled in 
both cognitive items (#20 and #25) of the EORTC QLQ-C30
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Figure 2A. Proportions with concentration problems
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Figure 2B. Proportions with memory problems
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Figure 2C. Proportions with cognitive function 
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2A. Statistical significance legend:
At 3 months the proportion with 
concentration problems in the CHEM 
group was significantly higher than in 
the RAD group.
The proportion of the CHEM group 
with concentration problems at 3 
months was significantly higher than at 
baseline and 12 months.
2B. Statistical significance legend:
At 3 months the proportion with 
memory problems in the CHEM and 
RAD groups did not differ 
significantly.
The proportion of the CHEM group 
with concentration problems at 3
months did not significantly differ 
from baseline or 12 months.
2C. Statistical significance legend:
At 3 months the proportion with 
cognitive function problems was 
significantly higher in the CHEM 
compared to the RAD group.
The proportion of the CHEM group 
with cognitive function problems was 
significantly higher at 3 months than 
at baseline and 12 months.
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Table 1. Distributions of scores on the outcome measures (cognitive complaints) in the chemotherapy 
group (CHEM, n=276) and in radiotherapy group (RAD, n=71) at the tree time points.
Before treatment 3 months 12 months
Outcome measures CHEM RAD CHEM RAD CHEM RAD
N    (%) N    (%) N    (%) N   (%) N    (%) N   (%)
Concentration problems
Not at all
A little
Quite a bit
Very much
213 (77)
52  (19)
7   (3)
4   (1)
56 (79)
11  (16)
4   (5)
0   (0)
169 (61)
85  (31)
16    (6)
6    (2)
57 (80)
12  (17)
2   (3)
0   (0)
234  (85)
32  (12)
10   (3)
0   (0)
60 (85)
10  (14)
1   (1)
0   (0)
Memory problems 
Not at all
A little
Quite a bit
Very much
211 (76)
52  (19)
7   (3)
4   (1)
57 (80)
12  (17)
2   (3)
0   (0)
170 (62)
81  (29)
21   (8)
4   (1)
49 (69)
18  (25)
4   (6)
0   (0)
197 (71)
65  (24)
13   (5)
1   (0)
50 (70)
17  (24)
3   (4)
1   (2)
Cognitive function
100.00 (best)
83.33
66.67
50.00
33.33
16.67
0.00 (worst)
174  (63)
62  (23)
30  (11)
5   (2)
3   (1)
1   (0)
1   (0)
52  (73)
7  (10)
8  (11)
4   (6)
0   (0)
0   (0)
0   (0)
132  (48)
66  (24)
49  (18)
16   (6)
8   (3)
4   (1)
0   (0)
47  (66)
12  (17)
8  (11)
2   (3)
2   (3)
0   (0)
0   (0)
184  (67)
58  (21)
20   (7)
9   (3)
4   (2)
1   (0)
0   (0)
48  (67)
14  (20)
5   (7)
2   (3)
2   (3)
0   (0)
0   (0)
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Table 2. Self-reported quality of life functions and symptoms before treatment and at 3 and 12 
months in the chemotherapy group (CHEM, n=276) and the radiotherapy group (RAD, n=71)
Independent variables Before treatment 3 months 12 months
CHEM RAD CHEM RAD CHEM RAD
N    (%) N    (%) N    (%) N   (%) N    (%) N   (%)
EORTC QLQ-C30 functions
Reduced emotional function
Reduced role function
Reduced social function
114  (41)
95  (34)
91  (33)
24  (34)
26  (37)
30  (42)
103  (37)*
178  (65)
144  (52)
12 (12)
15  (21)
15  (21)
53  (19)
50  (18)
39  (14)
10  (14)
8  (11)
13  (18)
EORTC QLQ-C30 symptoms
Presence of fatigue 
Presence of insomnia 
128  (46)
125  (45)
39  (55)
26  (36)
217  (79)
103  (37)
37  (52)
17  (24)
101  (37)
83  (30)
33  (47)
23  (32)
TC module symptoms
Neurotoxic symptoms 14  (5) 4  (6) 115  (42) 9  (13) 63  (22) 6  (9)
*Statistical significant differences (p<0.01) on an item between the CHEM and the RAD group at that time point 
in bold fonts
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2SUMMARY
BACKGROUND: Whether systemic chemotherapy has a negative effect on cognitive 
function in patients, concern oncologists. In testicular cancer patients (TCPs) treated with 
cisplatin-based chemotherapy, only few cross-sectional studies have addressed this concern.
We prospectively studied neuropsychological functioning in TCPs.
PATIENTS AND METHODS: In a consecutive sampling, 122 TCPs were examined at 
baseline (after orchidectomy, before any additional treatment) and then at follow-up a 
median of 12 months after end of treatment. The examinations included a 
neuropsychological test battery, interview on background variables, and questionnaires on 
mental distress, fatigue and neurotoxic symptoms. Changes in neuropsychological 
functioning from baseline to follow-up were compared between three treatments groups: no 
chemotherapy (N=31), one cycle of chemotherapy (N=38), and two or more cycles of 
chemotherapy (N=53). Variables associated with a decline in neuropsychological test 
performance from baseline to follow-up were explored.
RESULTS: No statistically significant differences in proportions of TCPs with a decline in 
neuropsychological test performance were observed between the three treatment groups. 
Decline in neuropsychological test performance was not associated with demographic 
variables, distress, fatigue, or with chemotherapy.
CONCLUSION: No negative effect of systemic chemotherapy on neuropsychological test 
performance in TCPs at one-year follow-up was found in this study.
Key words: chemotherapy, cognitive function, neuropsychological functioning,
neurotoxicity, prospective study, testicular cancer patients
3INTRODUCTION
Eventual negative effects of systemic chemotherapy on cognitive function (CF) in cancer 
patients have been investigated during the last decades [1,2]. Most studies concern breast 
cancer patients [2-8] and have shown divergent results regarding the association between 
systemic chemotherapy and reduced neuropsychological test performance. However, subtle 
post-treatment neuropsychological reduction has been observed in a small subgroup of 
breast cancer patients, possibly related to chemotherapy and/or hormonal factors [1,2].
More prospective neuropsychological studies of CF after different regimens of 
chemotherapy have been requested [1,9]. Neuropsychological function in testicular cancer 
patients (TCPs) several years after cisplatin-based chemotherapy has so far been examined 
in two cross-sectional studies [10,11]. Schagen et al. [10] found that significantly more 
TCPs treated with chemotherapy showed reduced neuropsychological test performance 
compared with those with no treatment after orchidectomy. No significant difference in 
proportions with reduced test performance was observed between TCPs treated with 
chemotherapy or with radiotherapy. In contrast, Pedersen et al. [11] observed no difference 
in neuropsychological test performance between TCPs treated with chemotherapy or not.
We conducted a prospective study of neuropsychological functioning in a 
consecutive Norwegian sample of TCPs. Evaluation of CF was done after orchidectomy 
prior to any additional treatment (baseline) and then at one year after end of treatment 
(follow-up). The aims of the study were: 1) To compare changes from baseline to follow-up
of neuropsychological test performance in TCPs exposed to three different treatment 
modalities: no chemotherapy, one cycle of chemotherapy, and multiple cycles of 
chemotherapy; 2) To study variables associated with a decline in neuropsychological test 
performance from baseline to follow-up.
4PATIENTS AND METHODS
Patients and treatment
Newly orchidectomized TCPs aged 18 to 60 years evaluated at two university hospital (the 
Norwegian Radium Hospital and Ullevål Hospital) between 2006 and 2008 were invited to 
participate in this prospective study. Exclusion criteria were: 1) Severe mental disorders like 
psychoses or substance dependence disorders; 2) Degenerative brain disease or previous 
severe brain trauma; 3) Brain metastases or severe somatic dysfunction; or 4) Lacking 
proficiency of Norwegian language. 
Information about histology, stage of testicular cancer (TC) [12], risk-adapted
treatment and follow-up time (months from end of treatment to follow-up evaluation) was 
obtained from the medical records. 
Data collection
At both time points TCPs had neuropsychological testing, questionnaires and a semi-
structured interview on background and self-reported CF (separate paper). The evaluations 
took 90-120 minutes and were performed by the first author. The baseline evaluation was 
done prior to any additional treatment, and the follow-up evaluation was scheduled to a
regular out-patient visit approximately 12 months after end of chemotherapy or start of 
surveillance (or radiotherapy).
Neuropsychological test battery Verbal learning and memory, motor function, 
psychomotor speed and executive functions were assessed with traditional 
neuropsychological tests [13-16].Visual learning and memory, attention and working 
memory were assessed with computer tests from the Cambridge Neuropsychological Test 
Automated Battery (CANTAB) [17-19]. The basic test battery consisted of 8 tests yielding 
15 sub-test measures (Table 1). 
5At baseline if time allowed and the patients were motivated, the basic test battery 
was supplemented with two more CANTAB-tests of executive function [18,19], which
yielded additional three sub-test measures. Hence, the total test battery included 18 
measures: 15 basic and three supplementary ones (Table 1). The same tests were given both 
at baseline and follow-up. To minimize practice effects from repeated testing, alternate test 
versions were used if available and employed on the two learning/memory-tests and one of 
the executive tests.
Intellectual functioning was estimated at baseline by the Norwegian version of the 
National Adult Reading Test (NART) [20,21], where a lower score indicates better 
intellectual functioning (range 0-50).
The psychological response to the trauma of getting TC was assessed with the 
Impact of Event Scale (IES) [22] which covered intrusion [7 items; Cronbach’s 
3($4((baseline)/0.86 (follow-up)] and avoidance -'!3($'5($'%

week. Each item was rated from 0 (not at all) to 5 (often), with higher scores denoting more 
distress. An IES-total score of >26 was the cut-off for clinically significant distress [23], and 
changes in dichotomized IES-total score from baseline to follow-up was noted.
The Fatigue Questionnaire [24] provided scores for physical and mental fatigue 
items that are summed up as total fatigue with Cron6=0.82(baseline)/0.88(follow-
up). Each of the 11 items was rated from 0 (less) to 3 (much more), so total fatigue ranged
from 0 (low) to 33 (high). Increase of total fatigue was defined if total score was  3 points 
higher at follow-up compared to baseline (7"()%$
Scale for Chemotherapy-Induced Neurotoxicity [25] assessed symptoms of 
peripheral neuropathy, Raynaud’s phenomenon and ototoxicity on 4-point scales from 1 (no 
symptoms) to 4 (much symptoms). Item-scores were dichotomized into symptoms (score 3 
6or 4) vs. no symptoms (score 1 or 2). Increase of neurotoxic symptoms was defined as a 
change from no symptoms to symptoms from baseline to follow-up.
Neuroticism is a basic personality trait covering the tendency to be nervous and was 
rated at baseline with 6 items of an 18-items version of the Eysenck Personality 
Questionnaire [26,27]. The sum-scores ranged from 0 (low) to 6 (high), and 8	6
was 0.54.
Alcohol use at baseline was assessed with a 4-items version the of the CAGE 
questionnaire [28], with sum-scores ranging from 0 (low) to 4 (high). A sum-score of 
defined a possibly hazardous alcohol use.
Other variables: The level of education was dichotomized into "	2"
years of completed basic education. Paired relation consisted of those being married or 
cohabiting. Employment status was categorized as working, being full-time student, or not 
working (long-term sickness leave, disability pension or unemployed). Mental problems
before TC were defined as requiring help from medical professionals or the use of 
psychotropic medication at least once.
Data management and statistics
General
Data were analyzed with the SPSS PC version 16.0 (SPSS Inc, Chicago IL), using standard 
descriptive measures, parametric and non-parametric tests as appropriate. Pearson’s chi-
square and Fisher’s exact tests were used to compare categorical variables between groups. 
Cronbach’s coefficient  described internal consistency. Bivariate correlations were 
examined with Pearson’s coefficient r. Due to the explorative nature of this study, the 
significance level was not corrected for multiple testing, and p-values<0.05 indicated 
statistical significance. All tests were two-sided.
7Neuropsychological test scores
Raw-scores on the neuropsychological tests at baseline and follow-up were compared across 
treatment groups with the Kruskall-Wallis test. Changes in raw-scores (follow-up score 
subtracted from baseline score) were compared with analyses of covariance (ANCOVAs) 
with age at baseline and follow-up time as covariates.
In addition to analyses on the group level, we performed analyses of changes in the 
individual patients [9] using a standardized regression-based model (SRB) [29,30], which 
allowed adjustment of the neuropsychological test findings for relevant covariates. The 
SRB-model utilizes the baseline and follow-up scores of the control group (no 
chemotherapy group in our study) to derive regression equations that predict an individual’s 
follow-up score on a test-measure based on his baseline-score and selected covariates. Due 
to limited group sizes, only age and estimated intelligence (NART-score) were used as 
covariates. Some neuropsychological test-scores were logarithmic or square-root 
transformed to achieve a better model fit.
Applying SRB, a predicted follow-up score on each test-measure for each individual 
was obtained. An individual z-score of change was then obtained for each test-measure by 
subtracting the person’s actual follow-up score from the predicted score and dividing the 
difference by the standard error of estimate (derived from the control group). The obtained 
z-score represented the standardized magnitude and direction of the difference between the 
expected and the actual follow-up score. A z-score outside ±1.64 was defined as a reliable 
decline or improvement from baseline to follow-up on the reported test-measure.
Cognitive domain z-scores of change were computed by averaging the z-scores of 
change for all test-measures of a given cognitive domain in each individual (see Table 1 for 
8test-measures in each cognitive domain). These domain z-scores of change were compared 
across treatment group using analyses of variance (ANOVAs).
Definition of individual change
There are no established cut-off values in the literature concerning the proportion of 
declined or improved test-measures needed in order to define a relevant individual change
in neuropsychological performance over time. Studies inclusive like those by Jenkins et al.
[6] and Stewart et al. [7] have defined decline/improvement when reliable change appeared 
on two or more test-measures. However, since the number of measures varied from 14 to 23 
in these studies, that definition imply variable proportions (15% and 8%, respectively) of the 
number of test-measures.
We defined that individual decline had occurred with reliable decline on "()
our test-measures, and individual improvement correspondingly. We also assessed 
individual changes using 15% as a cut-off to examine the consequences of our chosen 
proportion. Finally, we explored the relationship between the proportion of test-measures 
with decline and improvement for each individual. If the proportion of test-measures with
decline was "()		
	
	
	!
as showing overall decline in neuropsychological test performance. 
The proportions of patients with individual decline, improvement and overall decline
with the various definitions described above were compared across the treatment groups. All 
analyses were performed both on the total test battery (18 test-measures), and on the basic 
test battery (15 test-measures).
9Ethics
The study was approved by the Ethical Committee of the Southern Health Region of 
Norway and the National Data Inspectorate. All patients delivered a written informed 
consent. 
RESULTS 
Patients
Among 202 eligible TCPs, 129 (64%) were recruited at baseline. Non-inclusion was due to 
administrative reasons or declination by the patients. Attrition analyses showed no 
significant differences between included and non-included patients concerning age or stage 
of TC at diagnosis. 
At follow-up examination (median 12 months, range 8-23 months after end of 
chemotherapy/start of surveillance), 122 disease-free TCPs (95% follow-up rate) were re-
evaluated. Seven patients were lost to follow-up: three patients denied re-evaluation, one 
had moved abroad and three were excluded due to development of mental disorders or 
somatic diseases. The sizes of the treatment groups at follow-up were: NO-CHEMO group 
(N=31) (including one patient with radiotherapy only); ONE-CHEMO group (N=38) and
MULTIPLE-CHEMO group (N=53), with 33 patients having 3 or 4 cycles with bleomycin, 
etoposide and cisplatin (BEP, Table 2). Among 122 TCPs, 89 (73%) were tested with 
supplementary neuropsychological tests. 
Age at baseline was significantly higher in the ONE-CHEMO group compared to the 
NO-CHEMO and the MULTIPLE-CHEMO group (Table 2). No statistically significant 
group differences were found for follow-up time, NART-score, level of education or other 
demographic variables (Table 2).
10
The two chemotherapy groups had significantly higher total-fatigue score than the 
NO-CHEMO group both at baseline and follow-up. Presence of neurotoxic symptoms did 
not differ significantly across treatment groups at baseline, while at follow-up a larger 
proportion of the MULTIPLE-CHEMO group had Raynaud-like symptoms compared to the 
other groups (Table 2).
Changes in neuropsychological test performance
Group analyses
There were no significant group differences on raw-scores at baseline or follow-up on any 
of the 18 test-measures (Table 3), except that the NO-CHEMO group had significantly 
fewer errors on the Spatial Working Memory test at baseline compared with the two other 
groups. Further, no significant group differences were found for change in raw-scores 
(adjusted for age and follow-up time) of any of the 18 test-measures (Table 3). 
Individual analyses
In the control (NO-CHEMO) group, the correlation coefficients between baseline and 
follow-up test scores used for deriving the SRB-models ranged between r=0.48 and r=0.90 
(Table 4). The proportions of patients that exhibited reliable decline on any of the 18 test-
measures ranged from 0% to 23%, whereas the proportions of patients that exhibited 
reliable improvement ranged from 0% to 39% (Table 4). The proportions of TCPs in all 
treatment groups (inclusive the subgroup with 3 or 4 BEP) showing reliable 
decline/improvement on each of the test-measures are listed in Table 4.
No significant group differences in cognitive domain z-scores of change were found 
for any of the five cognitive domains studied (data not shown).
11
No statistically significant group differences were observed in proportions with 
individual decline on "()-measures or overall decline (Table 5). However, 
significantly larger proportions in the ONE and the MULTIPLE-groups showed 
improvement on "()
	*+-CHEMO group. Employing the 
15% cut-off did not significantly change these results, except no significant difference was 
found between the NO- and the ONE-CHEMO groups concerning proportions with 
improvement (Table 5). When the above analyses were performed on the dataset from the 
basic test battery only (15 measures), no substantial different results were observed. 
Sub-analyses showed no significant differences between the group of TCPs with 3-4
BEP and the NO-CHEMO group in proportions with individual decline and overall decline,
while the 3-4 BEP group had significantly larger proportions with individual improvement
than the NO-CHEMO group (Table 5).
Variables associated with a decline in neuropsychological test performance
A significantly larger proportion of the 42 TCPs that exhibited decline on "()
neuropsychological test-measures reported worsening of tinnitus/hearing loss compared 
with those without such decline, while no such association was found for peripheral 
neuropathic or Raynaud-like symptoms (Table 6). None of the demographic variables (age, 
education or NART-score) or cancer-related variables (given chemotherapy, metastatic 
disease or follow-up time) were significantly associated with a decline in 
neuropsychological test performance, neither were scores (or change-scores) of mental 
distress or fatigue (Table 6).
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DISCUSSION
In this prospective study, we found no statistically significant difference across treatment 
groups in proportions of TCPs with a decline in neuropsychological test performance from 
baseline to median one-year follow-up after end of treatment. Decline in neuropsychological 
test performance was not significantly associated with chemotherapy. Hence, we did not 
find any evidence that BEP-chemotherapy has a detrimental effect on neuropsychological 
functioning one year after treatment.
Cisplatin has a known peripheral neurotoxic effect [25,31], and it has also been 
detected in the central nervous system (CNS) after systemic administration [32]. Therefore 
our result of no significant association between multiple chemotherapy cycles and decline in 
neuropsychological test performance seems reassuring for the patients. Our results are in 
concordance with the cross-sectional findings by Pedersen et al. [11]. However, presuming 
any transitory effect of cisplatin on the CNS, our results could have been different if 
cognitive testing had been performed closer to the end of treatment. Long-term functioning 
is, though, of larger clinical importance for the patients than short-term. Further, our group 
sizes were relatively small, so we could have missed small statistically significant group
differences concerning decline of performance due to type II errors. However, such 
differences regularly have little clinical significance. Counter-intuitively, we did find that 
the two chemotherapy groups had significant larger proportions with improvement; but we 
hardly believe that chemotherapy has a positive effect on cognitive function. As shown in 
table 3, there were no significant group differences for raw-scores of tests neither at baseline 
(except one), at follow-up, or for change-scores between baseline and follow-up.
Research on CF after breast cancer has observed reduced functioning on several 
cognitive domains including attention, memory and processing speed [2]. This contrasts 
13
with our findings since we did not identify any specific cognitive domain affected by 
chemotherapy in TCPs.
None of the chosen demographic or cancer-related variables, except from increase in 
self-reported ototoxic symptoms, were significantly associated with a decline in 
neuropsychological test performance. Ototoxic symptoms (tinnitus / hearing loss) are well-
known neurotoxic effects of cisplatin-based chemotherapy [31], but most probably this is a
spurious finding due to multiple testing that eventually should be explored in future studies.
It would also be of clinical importance to further elaborate if a decline in 
neuropsychological test performance corresponded to the patients’ own report of change in 
CF.
Current level of mental distress may interfere with neuropsychological test
performance [33]. Hence, a change in distress-level from baseline to follow-up could 
possibly imply changes in neuropsychological performance between the two time points 
[30]. In spite of this, we chose not to include distress-score as a covariate in the SRB-
models due to relatively small group sizes implying allowance for few covariates. The 
relation between a change in distress-score and decline in neuropsychological test 
performance was explored separately, and no significant association was found.
A small subset of TCPs may have reduced testosterone level [34], and testosterone 
deficiency is associated with reduced cognitive function in older men [35]. Hence, the 
possible impact of testosterone level on neuropsychological functioning in TCPs warrants 
investigation in future studies.
Our study has several strengths. We included a consecutive sample of TCPs and 
evaluated CF prospectively. TCPs without any chemotherapy constituted a suitable control 
group, and the drop-out rate from baseline to follow-up was low. The prospective design 
14
enabled us to apply recommended statistical methods for assessing individual changes in 
neuropsychological test performance [9,30].
There are some limitations, however. After initiation we realized that the total test-
battery was too comprehensive for some patients. We therefore defined a basic test-battery 
and made two relatively time-consuming tests of executive function supplementary. We also 
had some missing data on some of the other tests. Altogether this complicated the analyses; 
however by defining individual decline and improvement with proportions instead of with 
absolute number of test-measures, this problem was mostly overcome. Since a portion of 
patients of the MULTIPLE-CHEMO group received only two cycles of chemotherapy or 
had additional chemotherapy (14 had 2 x BEP, three had no bleomycin, and three additional 
chemotherapy to BEP), we performed a sub-analysis comparing proportions with a decline 
in test performance between the group with 3 or 4 BEP and the NO-CHEMO group. No
significant difference emerged. Lastly, the SRB method is based on the assumption that the 
control group is representative. However, the size of our control group was limited which 
may have influenced our results. 
CONCLUSIONS
Results from this prospective study indicate that systemic chemotherapy does not have a 
negative effect on neuropsychological test performance in TCPs one year after end of 
treatment. These findings should be replicated in larger studies before a final conclusion can 
be made. However, our results seem reassuring for TCPs awaiting cisplatin-based 
chemotherapy.
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Table 6. Description of TCPs with a decline from baseline to follow-up on 	

neuropsychological test-measures 
* T-test and Mann Whitney Wilcoxon test used for continuous independent variables with normal and 
skewed distributions respectively, and Pearson chi-square or Fisher’s exact tests used for categorical 
independent variables
Independent variables p-value* Decline (N=42) vs. not (N=80)
Age at baseline (median years) 0.11 34 vs. 31.5
NART (mean score) 0.56 17.3 vs. 18.2
High level of education (baseline) 0.70 45% vs. 50%
Metastatic disease (TC stage II-IV) 0.65 24% vs. 20%
Any chemotherapy ("% 0.13 83% vs. 70%
Follow-up time (median months) 0.85 12 vs. 12
Neuroticism (mean score) 0.49 1.5 vs. 1.7
Possibly hazardous alcohol use at baseline 0.25 29% vs. 19%
Mental problems before TC 0.66 21% vs. 26%
Impact of Event Scale (IES) (mean total-score)
Baseline
Follow-up
Change in dichotomized IES total-score
Most distress at baseline
No change in distress-level
Most distress at follow-up
0.97
0.32
0.64
17.6 vs. 18.0
14.8 vs. 13.6
14% vs. 9%
81% vs. 86%
5% vs. 5%
Fatigue Questionnaire (mean total-score) 
Baseline
Follow-up
Worsening of total fatigue-score
0.55
0.47
0.53
13.5 vs. 13.8
14.0 vs. 13.1
31% vs. 25%
Worsening of neurotoxic symptoms 
Peripheral neuropathy
Raynaud-like symptoms
Tinnitus or hearing loss
0.57
1.00
0.03
17% vs. 12%
21% vs. 21%
21% vs. 6%
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2ABSTRACT
OBJECTIVE: There is a concern about negative cognitive effects of systemic 
chemotherapy. We prospectively explored self-reported cognitive problems in testicular 
cancer patients (TCPs) treated with and without chemotherapy.
METHODS: One hundred and twenty-two TCPs were interviewed about self-reported 
cognitive problems shortly after orchidectomy but before any additional treatment 
(baseline), and then at a median of one year after end of treatment (follow-up). Symptoms of 
mental distress, fatigue and peripheral neurotoxicity were assessed by questionnaires, and 
patients also underwent neuropsychological testing. Self-reported cognitive problems were 
compared between three treatments groups: no chemotherapy, one cycle of chemotherapy, 
and multiple cycles of chemotherapy. Variables associated with an increase of self-reported 
cognitive problems from baseline to follow-up were explored.
RESULTS: Significantly larger proportions of TCPs in the two chemotherapy groups had 
an increase of self-reported cognitive problems from baseline to follow-up compared to the 
no-chemotherapy group. Increase of self-reported cognitive problems was significantly 
associated with mental distress, fatigue, lower level of education and Raynaud-like 
symptoms, but not with a decline in neuropsychological test-performance.
CONCLUSION: In TCPs, an increase of self-reported cognitive problems from baseline to 
one-year follow-up was associated with chemotherapy treatment, fatigue and mental 
distress, but not with a decline in neuropsychological test-performance.
Keywords: adverse effects, chemotherapy, prospective study, self-reported cognitive 
problems, testicular cancer patients
3INTRODUCTION
Cognitive problems are frequently reported by cancer patients [1-3]. This has led to an 
increasing scientific focus on cognitive function (CF) after cancer treatment. There is a 
concern that systemic chemotherapy may have a negative effect on CF in cancer patients, 
but this association is still not well documented [4-6]. Most studies in this field have 
explored CF in breast cancer patients, and the prevalence of self-reported cognitive 
problems is high in this group of cancer patients [7,8]. However, a low concordance 
between self-reported cognitive problems and objectively assessed neuropsychological 
functioning has been observed repeatedly [6,9-11]. Self-reported cognitive problems, but 
not reduced neuropsychological test performance, have been found significantly associated 
with emotional distress and fatigue [6,10,12]. Regardless of etiology, cognitive problems 
may have negative consequences for patients’ daily functioning and well-being. More 
systematic knowledge of self-reported CF in several groups of cancer patients of both sexes 
are needed [2,13].
Two studies have investigated self-reported CF in testicular cancer patients (TCPs). 
Fosså et al. [14] prospectively studied CF as a dimension of quality of life in 666 TCPs 
treated with cisplatin-based chemotherapy. They found that 19% of the patients reported 
worsening of CF two years after chemotherapy compared to the pre-treatment level; 
however, a comparison with patients not treated with chemotherapy was not available. In a 
cross-sectional study of 182 TCPs assessed at a median of 3 years after end of treatment,
Schagen et al. [15] observed that approximately one-third of the TCPs in all treatment 
groups (chemotherapy, radiotherapy and surveillance) reported some cognitive problems. 
As for breast cancer patients, self-reported cognitive problems were associated with 
emotional distress and fatigue, but not with reduced neuropsychological test performance.
4As part of a Norwegian study of CF in TCPs, we prospectively explored self-
reported cognitive problems in patients treated with and without chemotherapy. Evaluations 
were performed after orchidectomy (surgery) but prior to any additional treatment 
(baseline), and at one year after end of treatment (follow-up). To our knowledge, this is the 
first prospective study of self-reported CF in TCPs, and the aims of the study were: 1) to 
compare proportions of TCPs with an increase of self-reported cognitive problems from
baseline to one-year follow-up among patients treated with different treatment modalities 
(no chemotherapy, one cycle of chemotherapy or multiple cycles of chemotherapy); and 2) 
To study variables associated with an increase of self-reported cognitive problems from 
baseline to one-year follow-up.
METHODS
Patients and procedures
Between August 2006 and September 2008, recently orchidectomized TCPs aged 18-60
were invited to participate in the present prospective study. Exclusion criteria were: 1) 
Severe mental disorders like psychoses or substance dependence disorders; 2) Degenerative 
brain disease or previous severe brain trauma; 3) Brain metastases or severe somatic 
dysfunction, or 4) Lacking proficiency of Norwegian language.
Evaluations consisted of a semi-structured interview on self-reported CF and 
background variables, some questionnaires and a neuropsychological assessment (complete 
neuropsychological results presented in a separate paper accepted for publication in Annals 
of Oncology). The baseline evaluation was done prior to start of any additional treatment, 
and the follow-up evaluation was scheduled approximately 12 months after end of 
chemotherapy or start of surveillance/radiotherapy. All evaluations were performed by the 
5first author. Information about stage of testicular cancer (TC) [16] and treatment was 
obtained from the medical records.
Among 202 eligible TCPs, 129 (64%) were recruited at baseline. Attrition analyses 
showed no significant differences between included and non-included patients in age or 
stage of TC. From 129 patients examined at baseline, 122 disease-free TCPs (95% follow-
up rate) were re-evaluated at follow-up at a median of 12 months (range 8-23 months) after 
end of chemotherapy/start of surveillance (or radiotherapy). Seven patients were lost to 
follow-up: three denied re-evaluation, one had moved abroad and three had developed 
severe mental disorders or somatic disease.
Among the 122 TCPs re-evaluated at follow-up, 31 TCPs had received no 
chemotherapy (inclusive one patient with radiotherapy only; NO-CHEMO group), 38 TCPs
had received one cycle with chemotherapy (ONE-CHEMO group), and 53 TCPs had 
received two or more cycles with chemotherapy (MULTIPLE-CHEMO group). The 
chemotherapy regimens consisted of one treatment with carboplatin or of cycle(s) with
bleomycin, etoposide and cisplatin (BEP-chemotherapy).
Data collection 
Self-reported cognitive problems
In semi-structured interviews at baseline and follow-up, the TCPs were asked to describe 
their general concentration and memory function with the response alternatives very good, 
good, not so good, or poor. The responses to both concentration and memory function were 
then dichotomized into no problems (very good/good) and problems (not so good/poor). A 
change of category in the dichotomized function-scores from baseline to follow-up was 
noted. If a patient changed category from no problems to problems in either the 
6dichotomized concentration and/or the memory score, he was defined as reporting an 
increase of self-reported cognitive problems from baseline to follow-up.
At baseline, the patients were additionally asked if they had experienced any long-
term (>3 months) cognitive problems before their TC-diagnosis, eventually when these 
problems started, and finally to indicate on an 11-point Likert scale if these cognitive 
problems affected habitual daily functioning before the TC-diagnosis (0: no affection, 10: 
major impact on daily functioning). At follow-up, the patients were asked if they had 
noticed any cognitive problems after the TC-diagnosis, and eventually to rate them on the 
same 11-point scale described above. Responses on the 11-point scales were dichotomized 
using the median value (which was 0 both at baseline and follow-up) as a cut-off into no
cognitive problems affecting daily functioning (rating 0) and at least some cognitive 
problems affecting daily functioning (rating 1-10). An increase of cognitive problems 
affecting daily functioning was defined when a patient changed category from no to at least 
some cognitive problems affecting daily functioning from baseline to follow-up.
Background variables from interviews
The level of education was dichotomized into "	2"	

education. Paired relation was defined as being married or cohabiting. Employment status
was categorized as working, being full-time student, or not working. Mental problems
before TC were defined as requiring help from medical professionals or the use of 
psychotropic medication at least once.
Questionnaires 
The Impact of Event Scale (IES) assessed the psychological response to the trauma of 
getting TC [17;18]. The IES measures symptoms of intrusion (7 items) and avoidance (8 
7items) during the past week, and each item is scored from 0 (not at all) to 5 (often) with 
higher scores denoting more distress. We used IES total score >26 as cut-off score for 
clinical significant distress [19]. A change in dichotomized distress status from baseline to 
follow-up was noted.
The Fatigue Questionnaire assessed total fatigue symptoms with 7 items on physical 
fatigue and 4 items on mental fatigue [20]. Items are rated from 0 to 3 with the total fatigue 
score ranging from to 0 (low) to 33 (high). Worsening of fatigue symptoms was defined if
follow-up score of total fatigue was at least 3 points higher than the baseline score (7"()
change on scale). 
Scale for Chemotherapy-Induced Neurotoxicity (SCIN) assessed symptoms of 
peripheral neuropathy (paresthesias in hands or feet), Raynaud’s phenomenon (white fingers 
or cold feet), and ototoxic symptoms (tinnitus or hearing loss) [21]. Items are rated on 4-
point scales ranging from 1 (no symptoms) to 4 (much symptoms), and the scores were 
dichotomized into symptoms (score 3 or 4) vs. no symptoms (score 1 or 2). Worsening of 
neurotoxic symptoms was defined as a change in category from no symptoms to symptoms
from baseline to follow-up. 
Neuroticism, a basic personality trait covering the tendency to be nervous, was rated 
at baseline by 6 items of an 18-items version of the Eysenck Personality Questionnaire
(EPQ-18) [22,23]. Sum-scores range from 0 (low) to 6 (high).
Alcohol use at baseline was assessed with a 4-items version the of the CAGE 
questionnaire [24,25], with sum-scores ranging from 0 (low) to 4 (high). A sum-score of 
defined a possibly hazardous alcohol use.
8Neuropsychological assessment
A neuropsychological test battery assessing the main cognitive domains was used, and is 
described in the neuropsychological paper (ref). Through a standardized regression model 
(SRB) [26], individual decline in neuropsychological test performance was defined when a
patient exhibited decline on at least 10% of the neuropsychological test-measures from 
baseline to the follow-up evaluation.
An estimate of intellectual functioning was measured at baseline by the Norwegian 
version of the National Adult Reading Test (NART) [27,28]. Scores range from 0 to 50 and 
lower scores represent better functioning.
Data management and statistics
Data were analyzed with the SPSS program for PC version 16.0 (SPSS Inc, Chicago IL), 
using standard descriptive measures, parametric and non-parametric tests as appropriate. 
Pearson’s chi-square and Fisher’s exact tests were used to compare categorical variables 
across groups. P-values<0.05 were considered as statistically significant, and all tests were 
two-sided.
Ethics
The study was approved by the Ethical Committee of the Southern Health Region of 
Norway and the National Data Inspectorate. All patients delivered written informed consent. 
RESULTS 
Patients
As expected, significantly larger proportion of TCPs in the MULTIPLE-CHEMO group had 
metastatic disease compared to the NO-CHEMO and the ONE-CHEMO groups (Table 1).
9Age at baseline was significantly higher in the ONE-CHEMO group compared to the two 
other groups. The two chemotherapy groups had significantly higher total-fatigue score than 
the NO-CHEMO group both at baseline and at follow-up. At follow-up, a larger proportion 
in the MULTIPLE-CHEMO group reported Raynaud-like symptoms compared to the two 
other groups. No significant group differences were found for other demographic variables, 
follow-up time, decline in neuropsychological test performance, alcohol-use, mental 
problems before the TC-diagnosis, neuroticism or level of mental distress (IES total score)
(Table 1).
Self-reported cognitive problems 
Twenty-five TCPs (20%) had an increase of self-reported cognitive problems from baseline 
to follow-up. There was a significant (p=0.02) difference across the treatment groups in 
proportions of TCPs with an increase of self-reported cognitive problems: larger proportions
in the ONE-CHEMO group (29%) and the MULTIPLE-CHEMO group (25%) had an 
increase of problems compared to the NO-CHEMO group (3%, Table 2). However, no 
significant difference appeared between the ONE- and the MULTIPLE-CHEMO group 
(p=0.64).
Thirteen patients (11%) had an increase of cognitive problems affecting daily 
functioning from baseline to follow-up. No statistically significant group difference was 
observed for this variable (p=0.08, Table 2). 
Variables associated with an increase of self-reported cognitive problems
Among the 25 TCPs with an increase of self-reported cognitive problems, a significantly 
larger proportion had received chemotherapy (96% vs.69%), had worsening of fatigue score 
(50% vs.22%) and of Raynaud-like symptoms (42% vs.16%), had lower education level 
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(68% vs.44%) and had mental problems before TC (48% vs.19%) compared with those 
without an increase of self-reported cognitive problems (Table 3). Further, the TCPs with an 
increase of cognitive problems had significantly higher follow-up scores of mental distress 
(median score 15.5 vs.10) and fatigue (median score 16 vs.11) compared with those with no 
increase of cognitive problems (Table 3).
No statistically significant association was found between an increase of self-
reported cognitive problems and a decline in neuropsychological test performance from 
baseline to follow-up (p=0.82, Table 3). Eight patients were classified with both an increase 
of self-reported cognitive problems and a decline in neuropsychological test performance 
(Table 4). Among these eight patients, three had received one cycle of carboplatin and five
had received 3 cycles of BEP-chemotherapy.
DISCUSSION
In this prospective study we found that significantly larger proportions of TCPs treated with 
one or more cycles of chemotherapy had an increase of self-reported cognitive problems 
from baseline to one-year follow-up compared with patients who did not receive 
chemotherapy. Increase of self-reported cognitive problems from baseline to follow-up was 
significantly associated with higher levels of mental distress and fatigue, lower level of 
education and worsening of Raynaud-like symptoms, but not with a decline in 
neuropsychological test performance.
We observed that TCPs treated with chemotherapy were more likely to report an 
increase of cognitive problems compared with those not treated with chemotherapy. A 
plausible explanation for this finding is that chemotherapy may have a toxic effect on CF in 
some TCPs. However, no significant association between an increase of self-reported 
cognitive problems and a decline in neuropsychological test performance appeared in our 
11
sample (and no significant group difference in proportions of TCPs with a decline in 
neuropsychological test performance was observed). Hence, the decline in self-reported CF 
was not mirrored by a decline in neuropsychological performance. Despite the non-
significant association between “subjective” and “objective” CF-decline in this study, eight 
of our TCPs had both an increase of self-reported cognitive problems and a decline in 
neuropsychological test performance. Five out of these patients had received 3 cycles of 
BEP-chemotherapy. Larger studies are needed in order to identify if there are any subgroups 
of TCPs that may be susceptible for negative cognitive effects of cisplatin-based 
chemotherapy.
Another explanation for the observed group difference could be that some patients 
gave biased report about CF after being “primed” about negative cognitive effects of 
chemotherapy when entering the study. In a study of breast cancer patients, Schagen et al.
[29] observed that patients who had pre-existing knowledge about a possible risk of reduced 
CF after chemotherapy reported significantly more cognitive problems compared with 
patients who did not have such pre-existing knowledge.
As reported in several studies [12,15], we found that an increase of self-reported 
cognitive problems in the TCPs was associated with increased levels of mental distress and 
fatigue symptoms, but not with a decline in neuropsychological test performance. Self-
reported cognitive problems in TCPs may possibly reflect emotional status rather than 
actual neurocognitive functioning. Numerous studies of cancer patients have demonstrated a 
high concordance between self-reported cognitive problems and emotional distress/fatigue 
as well as a low concordance between “subjective” and “objective” CF. It is debated if self-
reported cognitive problems and reduced neuropsychological functioning largely represent 
different constructs in cancer patients [12], and our results might support such a notion.
12
After TC, 11% of the patients in our sample reported an increase of cognitive 
problems that had at least some impact on their daily functioning. To date, no single causal 
factor of such cognitive problems in TCPs has been identified. The etiology is probably 
multi-factorial, and mental distress, fatigue, side-effects of treatment and other factors like 
hormonal changes [30] could play a role. However, self-reported cognitive problems in 
TCPs warrant clinical attention since such problems may indicate current mental distress or 
fatigue with a need for intervention. 
A strength of our study is that we could prospectively explore individual change in 
self-reported cognitive problems from baseline to one-year follow-up in TCPs treated with 
chemotherapy and not. Also, the follow-up rate was high. However, some limitations of our 
study should be mentioned. Self-reported CF was assessed with semi-structured interviews 
rather than with a validated questionnaire. Because of this, comparisons of the prevalence of 
cognitive problems with other samples of cancer patients should be done with caution. 
Dichotomizing the responses on CF from the interviews reduced the variability in the data, 
and this may have influenced the results. As the same person conducted both the interviews 
and the neuropsychological testing there was a risk of interpretation bias.
CONCLUSIONS
In this prospective study of TCPs, increase of self-reported cognitive problems from 
baseline to a median of one-year follow-up was significantly associated with chemotherapy 
treatment and symptoms of mental distress and fatigue, but not with a decline in 
neuropsychological test performance. Self-reported cognitive problems in TCPs probably 
have a multi-factorial etiology, and current emotional distress and fatigue seem to be 
important factors.
13
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Table 2. Self-reported cognitive problems (dichotomized responses from interviews)
N (%)
TOTAL
N=122
NO-
CHEMO
N=31
ONE-
CHEMO
N=38
MULTIPLE-
CHEMO
N=53 p-
value*
Concentration problems Baseline 8  (7) 1  (3) 4  (11) 3  (6) 0.45
Follow-up 16  (13) 1  (3) 8  (21) 7  (13) 0.09
Change: More problems 12  (10) 1  (3) 6  (16) 5  (9)
Concentration problems Stable 106  (87) 29  (94) 30  (79) 47  (89)
Less problems 4  (3) 1  (3) 2  (5) 1  (2)
Memory problems Baseline 13  (11) 4  (13) 4  (11) 5  (9) 0.88
Follow-up 25  (20) 2  (7) 10  (26) 13  (25) 0.08
Change: More problems 17  (14) 0  (0) 7  (18) 10  (19)
Memory problems Stable 100  (82) 29  (94) 30  (79) 41  (77)
Less problems 5  (4) 2  (6) 1  (3) 2  (4)
Increase of self-reported cognitive 
(concentration and/or memory) problems 
from baseline to follow-up
25  (20) 1  (3) 11  (29) 13  (25) 0.02
At least some cognitive 
problems
Before TC 20  (16) 4  (13) 8  (21) 8  (15) 0.62
affecting daily functioning At follow-up 29  (24) 3  (10) 11 (29) 15  (29) 0.10
Increase of cognitive problems affecting 
daily functioning 13  (11) 0  (0) 5  (13) 8  (15) 0.08
* Pearson’s chi-square test 
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Table 3. Description of TCPs with an increase of self-reported cognitive problem from baseline to 
follow-up
Increase of self-reported cognitive 
problems (N=25) vs. not (N=97) p-value*
Metastatic disease (TC stage II-IV) 24% vs. 21% 0.79
Follow-up time (median months) 13 vs. 12 0.13
Chemotherapy ("% 96% vs. 69% 0.004
Age at baseline (median years) 31 vs. 33 0.59
Paired relation (at follow-up) 68% vs. 71% 0.81
High level of education (at follow-up) 32% vs. 56% 0.04
NART (mean score) 20.6 vs. 17.2 0.06
Mental problems before TC 48% vs. 19% 0.004
Possibly hazardous alcohol use (baseline) 20% vs. 23% 1.00
Neuroticism (mean score) 1.8 vs. 1.6 0.56
Impact of Event Scale (IES) mean total-score
Baseline
Follow-up
Change in dichotomized IES-score:
Most distress at baseline
No change in distress level
Most distress at follow-up
20.6 vs. 17.1
18.5 vs. 12.9
8% vs. 11%
84% vs. 85%
8% vs. 4%
0.21
0.03
0.67
Fatigue Questionnaire mean total-score 
Baseline
Follow-up
Worsening of total fatigue score
14.7 vs. 13.4
17.2 vs. 12.5
50% vs. 22%
0.12
<0.001
0.009
Worsening of neurotoxic symptoms 
Peripheral neuropathy
Raynaud-like symptoms
Tinnitus or hearing loss
21% vs. 12%
42% vs. 16%
17% vs. 10%
0.31
0.01
0.48
Decline in neuropsychological test 
performance from baseline to follow-up 32% vs. 35% 0.82
* T-test and Mann Whitney test used for continuous independent variables with normal and skewed 
distribution respectively, and Pearson’s chi-square or Fisher’s exact test used for categorical 
independent variables; statistically significant differences (p<0.05) marked in bold fonts 
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Table 4. Cross-tabulation between increase / no increase of self-reported cognitive problems and 
decline / no decline in neuropsychological test performance from baseline to follow-up
N (% of total sample)
Increase of self-reported 
cognitive problems
No increase of  self-reported 
cognitive problems Total
Decline in neuropsychological test 
performance 8  (6) 34  (28) 42  (34)
No decline in neuropsychological test 
performance 17  (14) 63  (52) 80  (66)
Total 25  (20) 97  (80) 122  (100)
18
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